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ABSTRACT 
 
Background 
Congenital Hyperinsulinism (CHI) is characterized by unregulated secretion of insulin in the presence 
of hypoglycaemia. Mutations in eleven different genes ABCC8, KCNJ11, GLUD1, GCK, HADH, UCP2, 
HNF4A, HNF1A, MCT1, HK1 and PGM1 have been associated with genetic forms of CHI. However, 
the genetic cause for many CHI patients (nearly 50%) remains elusive. Mutations in transcription factors 
such as HESX1, PROP1, POU1F1, LHX3, LHX4, PITX1, PITX2, OTX2, SOX2 and SOX3 have been 
associated with congenital hypopituitarism(CH) in mouse and humans. However, these mutations 
account only for a small proportion with the majority of patients having an unknown genetic cause for 
their symptoms. The use of next generation sequencing in children with undiagnosed or unidentified 
syndromic disorders is becoming more popular in recent years, increasing the diagnostic ability and 
discovery of novel genes and mutations contributing to novel clinical phenotypes. 
 
Aims 
1. To identify novel genetic mechanisms in patients with rare endocrine disorders.  
2. To functionally characterize a transcription factor associated with pituitary and pancreatic 
development and to characterize a novel gene associated with CHI. 
 
Patients  
Six patients with varied phenotypes such as CHI and CH(n=1), CHI(n=1), primary IGF1 deficiency 
with dysmorphic features (n=1), severe short stature with dysmorphic features(n=1), severe short 
stature(n=1), hypercalcemia and glomerular disease(n=1) were recruited into this study. 
 
Methods  
Whole exome sequencing(WES) was performed on the genomic DNA in trios (patient and the biological 
parents) for 5 patients. In one of the patients where the DNA sample was not possible to obtain from 
the biological father, WES was performed on the genomic DNA from the patient and the biological 
mother. mRNA expression during murine embryogenesis was studied using in situ hybridization and 
the protein expression in human embryos was demonstrated by immunohistochemistry. The pathogenic 
effect of the variant on protein function was further demonstrated by transcriptional activation assays 
using luciferase and quantification of protein expression using western blot.  
 
Results  
1. WES identified a de novo heterozygous mutation in FOXA2 (c.505T>C, p.S169P) in a highly 
conserved residue within the DNA binding domain in a patient with CHI and CH. A 
strong expression of Foxa2 mRNA was found in the developing hypothalamus, pituitary, 
pancreas, lungs and oesophagus of mouse embryos using in situ hybridization. Expression 
profiling on human embryos by immunohistochemistry showed strong expression of hFOXA2 
in the neural tube, third ventricle, diencephalon and in the pancreas. Transient transfection of 
HEK293T cells with Wt (Wild type) hFOXA2 or mutant hFOXA2 showed an impairment in 
transcriptional reporter activity by the mutant hFOXA2. Further analyses using western blot 
assays showed that the FOXA2 p.(S169P) variant is pathogenic resulting in lower expression 
levels when compared with Wt hFOXA2. 
	 v	
2. A novel compound heterozygous mutation (p.R989G, p.K1026N) in ASXL3 contributing to 
Bainbridge Ropers syndrome in association with primary IGF1 deficiency was found in a patient 
with severe short stature with dysmorphism.  
3. A de novo heterozygous frameshift mutation (p.G539fs*4) was found in CaMKK2 isoform-7 in 
a patient with persistent CHI, negative for mutations in known genes. On expressing the 
pG539fs*4 mutant in COS7 cells a significantly higher basal and Ca2+-CaM dependent kinase 
activity was noted when compared with WT (Wild Type) isoform-7.  Both isoform-7 and the 
pG539fs*4 mutant have elevated basal kinase activity compared with isoform-1, the major 
CaMKK2 isoform expressed in most tissues.  
4. A heterozygous splicing mutation in B3GAT3 was found in a patient with short stature, 
congenital heart defects, facial dysmorphism and skeletal abnormalities.  
5. A homozygous mutation in the promoter region of GH1 was identified in a patient with severe 
short stature and low IGF1. 
In one patient, no relevant genetic variant segregating with the phenotype was identified. 
 
 
Conclusions 
FOXA2 mutation can cause a complex congenital syndrome with hypopituitarism, and hyperinsulinism. 
Frameshift mutation in CaMKK2 is a potential novel cause of persistent CHI.WES has helped to identify 
the underlying genetic etiology in 5 out of 6 families recruited in the study. 
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1.1 SUMMARY OF CHAPTER 1 
 
Chapter 1 provides an introduction to Whole Exome Sequencing (WES). This chapter 
begins with a brief description of WES in medicine followed by the usefulness of WES 
in diagnosing various conditions in paediatric endocrinology. 
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1.2 WHOLE EXOME SEQUENCING 
1.2.1 Introduction 
The sequencing technologies have been constantly evolving over the last decade 
since the completion of Human Genome Project (1). They include individual gene 
based approach (Sanger sequencing), large scale genome wide analysis to determine 
genetic determinants of disease, whole exome and whole genome sequencing (2). 
Whole exome sequencing is one such major advancement in the field of genomic 
medicine (3) and is a highly effective form of genetic analysis as this allows the 
sequencing of the majority (>90%) of the protein coding portion of an individual’s DNA 
(4).  
1.2.2 Exome Sequencing  
The human genome is vast and comprises of 3 billion base pairs that contains both 
the coding and the non-coding regions (5). Approximately 1% of the entire human 
genome constitute the protein coding region or exomes that harbours about 85% of 
the disease causing mutations (5). Therefore, sequencing of exomes has the potential 
to discover the underlying genetic causes of not only rare diseases but also in 
determining predisposing variants in cancers and common diseases (4). The cost to 
sequence the whole exome is about six fold less when compared to the cost involved 
to sequence the whole genome and therefore WES is a cost-effective method to 
identify the disease causing mutations (6), especially in rare diseases. WES is 
performed after the exomes or the coding part are captured from the genomes using 
specific probes and by high-throughput technologies (2). The sequence is then 
compared with human reference sequence, where by the use of computer tools, the 
differences in alignment are identified to determine the potential genetic variants (4). 
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Some of the limitations of WES include its inability to assess the non-coding alleles, 
the limitations in coverage of the regulatory regions of the genome and limitations in 
capturing the entire exome (2). WES has been promising in identifying novel genes 
and underlying genetic pathways of diseases despite the above limitations.  
1.2.3 WES in Medicine 
WES as a research tool has facilitated the understanding of the molecular basis of 
genetic diseases. The earliest report of the utility of WES was published in 2009 (7) 
when MYH3 was identified as a disease causing gene in individuals with Freeman-
Sheldon syndrome (FSS; OMIM193700). Another example is the exome sequencing 
studies in individuals with Kabuki syndrome where the sequencing identified KMT2D 
(formally known as MLL2) in >50% of patients in this syndrome, characterized by wide 
phenotypic variability and multiple congenital malformations (8). These kind of studies 
uncover the genetic basis of the rare disorders and help in the management of the 
patients. 
In addition to identifying genetic causes for rare diseases, WES can serve as a 
potentially useful tool in screening, prenatal diagnosis and disease treatment (5). The 
applicability of WES in prenatal diagnosis was demonstrated using fetal DNA in 
maternal serum in finding aneuploidies (9). These methods are non-invasive when 
compared with other methods such as amniocentesis or chorionic villi biopsy (10, 11).  
The underlying molecular basis is known only in two-thirds of the described monogenic 
disorders (5). The discovery of the causative gene contributes massively to the 
understanding of the pathogenesis of the disease process. The identification of a novel 
genetic cause for a rare disease depends on a number of factors such as identification 
of similar variant in the gene in other patients with similar clinical phenotype and 
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absence or rarity of the variant present in control population. In rare diseases, where 
the finding of similar affected phenotypes can be difficult, functional experiments on 
the identified variant to determine the pathological impact of the variant on protein 
function is crucial to understand the biological pathways associated with the disease 
and to validate the variant as pathogenic. WES can therefore be a powerful tool in 
finding the genetic etiology for Mendelian disorders (12).  
Besides monogenic disorders, WES can identify common genetic variants associated 
with complex and common diseases with multigenic traits (13). With the emerging rare 
variants-common disease hypothesis, WES will have a bigger role in common 
diseases along with the main driving force, genome-wide association studies (GWAS) 
(14). WES has made promising advances in common diseases such as cardiovascular 
disease, hypertension, obesity, diabetes and also has massively aided in detailed 
understanding of molecular mechanisms and pathways in cancer (5). 
 
For genetically heterogeneous disorders, the use of targeted exome sequencing, 
which involves sequencing of many known disease associated genes rather than the 
whole exome can be sufficient (15). This also confers other advantages such as 
reduced cost, better depth of sequencing and reduced diagnostic time. For example 
there are a number of genes associated with heterogeneous conditions such as 
learning difficulties and congenital hearing loss in which targeted sequencing of the 
implied genes has better diagnostic abilities with reduced cost (5). 
 
 
 
 
 
6 
Figure 1.1: WES and its impact on health improvement. In both research and clinical 
settings, WES is used in common diseases, cancer and rare diseases. This potentially 
leads to the establishment of gene networks, new Single nucleotide 
polymorphisms(SNPs), new mutation detection and discovery of new genes (5). 
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1.2.4 WES in Paediatric Endocrinology 
Paediatric endocrinology consists of many rare diseases. Although the clinical 
phenotype and management has been established in many of these conditions, the 
underlying genetic etiology remains unidentified. WES has enabled to uncover the 
molecular diagnosis and shed valuable insights in understanding the novel genetic 
pathways in many disorders involving growth, puberty, adrenal gland, type 2 diabetes 
mellitus and a variety of genetic syndromes with predominant endocrine involvement 
(2). Besides, WES based studies have opened up new insights in understanding the 
pathogenesis of neuroendocrine tumours (2). Clinical endocrinologists often treat 
children with multitude of endocrine related problems that have a suspected 
underlying genetic etiology. The large number of potentially relevant genes in many of 
these conditions makes candidate gene sequencing difficult. WES in such patients is 
helpful in identifying the underlying genetic cause. The unbiased approach of 
sequencing the coding regions of approximately 20,000 genes simultaneously confers 
the major benefit to WES (3).  
1.2.4.1 WES in Disorders Involving Growth and Puberty 
Although common genetic variants associated with height have been found in more 
than 400 genomic loci in GWAS population studies, many of these variants do not 
directly account for short stature (16, 17). However, they highlight the fact that there 
are multiple potentially novel pathways that govern growth. WES in individuals from 
the same family with idiopathic short stature can be a helpful tool in identifying the 
potential genetic cause. For example, a WES based study, identified novel 
heterozygous mutations in ACAN, in individuals with idiopathic short stature from three 
affected families. ACAN encodes aggrecan which is a proteoglycan in the extracellular 
matrix of the growth plate with a role in the linear growth (18).   
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Puberty is a complex process which is initiated by the release of gonadotropins from 
the pituitary gland which is under the control of the hypothalamic gonadotrophin 
releasing hormone that functions as a pulse generator. The biological and genetic 
mechanisms that govern this process and the timing of puberty have not been clearly 
understood (19). WES based studies in individuals with familial central precocious 
puberty have identified a loss-of-function mutation in MKRN3, an imprinted gene that 
encodes for probable E3 ubiquitin-protein-ligase makorin-3 (20). Expression studies 
on murine embryos demonstrated the reduced MKRN3 mRNA expression in the 
hypothalamus before the pubertal onset (20). Thus by WES, the novel genetic 
pathway underlying MKRN3, a repressor of pubertal onset was identified and the 
finding of similar mutations in further studies have not only confirmed the important 
findings but also brings a question if differential expression of MKRN3 can explain the 
variability in pubertal onset in children (21). WES has also been useful in 
understanding some of the genetic mechanisms underlying Kallmann syndrome, 
characterised by hypogonadotropic hypogonadism with or without anosmia, where 
homozygous loss of function mutations in FEZF1, a gene involved in the migration of 
the olfactory receptor neurons in mice was found in four individuals with Kallmann 
syndrome from two independent families (22, 23). Novel mutations in genes involved 
in ubiquitination pathway such as RNF216, OTUD4 and STUB1 have been identified 
to cause Gordon Holmes syndrome, a neurodegenerative disorder characterised by 
ataxia and hypogonadism (24, 25). Moreover, WES based studies have identified 
novel genes such as STAG3, PSMC3IP, EIF4ENIF1 and SYCE1, associated with 
familial premature ovarian failure and gonadal dysgenesis (26-29). 
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1.2.4.2 WES in Disorders of Adrenal gland and Endocrine Neoplasia 
Various WES based studies in patients with adrenal hypercortisolism due to adrenal 
tumour have significantly advanced the understanding of the adrenocortical disease. 
Somatic mutation(p.Leu206Arg)  in PRKACA, the cAMP dependent protein kinase A 
catalytic subunit causes an increase in cAMP signalling and has been identified in 
adrenal tumours by WES based studies on adrenal tumour-blood pairs in patients with 
adrenal Cushing syndrome (30-33). Similarly, mutations in DOTIL and CLASP2 have 
been found to be involved in macronodular hyperplasia and adrenocortical 
oncocytomas (31). Inactivating mutations in ARMC5, have been reported in majority 
of patients (both familial and isolated) with bilateral macro nodular hyperplasia (34). 
ARMC5 has a potential role in steroidogenesis, gene transcription, cell growth and 
survival as demonstrated by in-vitro studies (35). 
The role of WES in endocrine neoplasia has enabled the identification of novel 
germline mutations, such as DICER1, which predisposes an individual to an increased 
risk of endocrine tumour in later life and also somatic mutations (36). In many cases, 
WES is performed in pairs where the sequencing of tumour cells and normal biopsy 
tissue (or unaffected lymphocytes) is done simultaneously to identify the tumour 
initiating mutation (2). When such paired sequencing is performed in cohort of patients 
with similar type of tumour, the common genetic etiology governing the 
pathophysiology of the tumour is likely to be identified (2). 
1.2.4.3 WES in Familial Glucocorticoid Deficiency 
Familial Glucocorticoid Deficiency (FGD) is an autosomal recessive disease 
characterised by glucocorticoid deficiency due to the hereditary unresponsiveness to 
adrenocorticotropic hormone (ACTH) (37). The underlying genetic mechanisms of 
FGD is not completely understood as mutations in ACTH receptor, MC2R constitute 
 
 
 
10 
only 25% of cases and mutations in its accessory protein MRAP, accounts for a further 
15-20% of cases with FGD (37). With the advent of WES, novel pathways involved in 
the mitochondrial detoxification of reactive oxygen species have been identified to 
cause FGD(38). Homozygous mutations in TXNRD2, encoding thioredoxin reductase 
2 have been found to cause FGD in seven individuals from a consanguineous family 
(39). An increase in susceptibility to oxidative stress due to a significant increase in 
reactive oxygen species production was demonstrated in the TXNRD2 knock-down 
adrenocortical cell line when compared with the controls (39). Mutations in 
nicotinamide nucleotide transhydrogenase (NNT) gene have been found to reduce the 
amount of NADPH production, required for p450 related oxidative-reductive reactions 
in the adrenal cortex, thereby leading to FGD (40). Mutations in MCM4, encoding 
minichromosome maintenance deficient 4, that has a role in DNA replication and cell 
cycle regulation have been associated with adrenal insufficiency, natural killer cell 
deficiency and short stature (41). Homozygosity mapping in recessive conditions can 
help in the localisation of the candidate region of the genome in genetically isolated 
populations that harbour the causal mutations. This was used by the investigators in 
genetically isolated populations with FGD and enabled identification of the target 
candidate regions, sequencing of which identified NNT and MCM4 mutations (40, 41). 
1.2.4.4 WES in Thyroid Disorders  
Mutations in IGSF1, encoding the immunoglobulin superfamily member 1 protein, 
were identified by WES studies to cause a novel X-linked disease causing central 
hypothyroidism, macro-orchidism and short stature (42). The IGSF1 plasma 
membrane glycoprotein is expressed in the anterior pituitary gland and plays a vital 
role in trafficking of the protein to the cell surface (43). WES also identified a 
homozygous missense mutation in SLC26A4 (also associated with thyroid 
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dyshormonogenesis), in a consanguineous family with thyroid dysgenesis, thereby 
expanding the clinical spectrum (44). 
1.2.4.5 WES in Juvenile Osteoporosis 
Mutations in PLS3, encoding plastin-3, a protein involved in the formation of 
filamentous actin bundles were identified by WES in a study involving five families with 
X-linked osteoporosis and fractures (45). Although the underlying biological 
mechanism for osteoporosis and increased fracture risk is unknown, it has been 
proposed that PLS3 mutation can cause altered mechanosensing by the osteocytes 
leading to the effects on bone remodelling (45).  
1.2.4.6 WES in 46 XY Disorders of Sex Development 
The formation of bipotential gonad is followed by a series of complex and coordinated 
genetic programmes and signals that determine the formation of either the testis or 
the ovary (46). Once the sex determination occurs, the circulating sex hormones along 
with genetic mechanisms act together in the differentiation of internal and external 
genitalia. Disorders of sex development (DSD) occurs as a result of disruption in the 
process of sex determination or differentiation which can cause a discrepancy 
between the phenotypic sex and chromosomal sex (47). However, many patients with 
DSD do not receive a genetic diagnosis. In particular, in some individuals with 46XY 
DSD, loss of function in SRY or NR5A1 results in disruption of the process of testis 
determination and can result in gonadal dysgenesis (48, 49). However, mutations in 
SRY or NR5A1 account for only 10-15% cases of 46XY DSD (46). Likewise, 46XY 
DSD due to disruption in the process of testis differentiation is not always explained 
by mutations in the gene encoding the androgen receptor (50). Hence in majority of 
patients with 46XY DSD, the diagnosis is not reached at the genetic level. WES in this 
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group of patients has the potential to uncover the underlying genetic etiology. In a 
study, the investigators adopted WES based approach in 46XY DSD individuals 
without genetic diagnosis and found that a genetic diagnosis was found in 35% of 
cases (14 of 40 cases) and six patients had variants of unknown significance who may 
be reclassified in the future as the literature evolves (46). 
Table 1.1: Summary of genes found by WES in some endocrine disorders 
Endocrine disorder Gene 
Central precocious puberty MKRN3 
Hypogonadotropic 
hypogonadism(Kallmann syndrome) 
FEZF1 
Hypogonadotropic hypogonadism & 
ataxia 
RNF216/OTUD4 
Premature ovarian failure STAG3, PSMC3IP, EIF4ENIF1 and SYCE1 
Familial glucocorticoid deficiency TXNRD2, NNT 
Central hypothyroidism, testicular 
enlargement 
IGSF1 
Juvenile osteoporosis PLS3 
46XY disorder of sexual development FOG2 
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1.2.4.7 WES in Clinical Endocrinology 
Overall, WES has the potential to change and enhance the diagnostic approach in 
patients with rare endocrine diseases with a suspected genetic etiology. The use of 
WES has been very promising in the field of endocrinology but has a widespread use 
in the field of neurology, particularly for children with neurodevelopmental issues and 
congenital anomalies (51). It has been reported that almost quarter of the patient 
population within the field of neurology with neurodevelopmental issues can be 
diagnosed by using WES (52).  
Among the large number of variants identified in WES, a majority of them are common 
in the general population and unlikely to have a causative role in the disease. The 
frequency of occurrence of any variant can be found in the publicly available data 
bases such as the 1000 Genomes Project, the National Heart, Lung, and Blood 
Institute Exome Variant Server and the Exome Aggregation Consortium browser 
(ExAC). 
Trio sequencing, which involves sequencing of the patient sample along with the 
biological parents optimises interpretation (4). Trio sequencing helps in the 
identification of de novo, heterozygous, homozygous and compound heterozygous 
variants and also in the identification of variant with autosomal recessive and dominant 
modes of inheritance (2).  
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1.2.5 Disadvantages in WES 
The use of WES in the diagnosis of rare diseases is based on the assumption that 
these patients have highly penetrant genetic variants and follow a classic Mendelian 
pattern of inheritance (53). Although this approach has several advantages and is 
currently the most tractable approach for the analysis of exome sequencing data, there 
are some limitations in this approach. The possibility of genetic mutations in multiple 
genes contributing to short stature is overlooked by this approach. Only the rare 
variants with population minor allele frequency of <1%are analysed by this approach. 
Although it is unlikely that common variants (minor allele frequency>1% in reference 
databases) will have a large effect on the linear growth, their analysis does not form a 
part in this approach. The synonymous variants are ignored in this approach and only 
the non-synonymous variants are analysed. It is possible that synonymous changes 
also perturb the gene function or expression. WES has disadvantages of not be able 
to analyse the noncoding regions of the genome(introns), somatic or non-germline 
changes, epigenetic changes and copy number variations. WES, in addition to 
identifying the disease causing variants, can also identify incidental findings, such as   
BRCA1 or BRCA2 have the predisposition to cancer. The American College of Medical 
Genetics has published guidelines and includes a list of 57 genes that is 
recommended by the clinical laboratories to report on incidental findings (54). 
However, this recommendation is a subject of controversy as the true clinical impact 
of finding novel or rare variants is not known and identifying these variants may not 
necessarily have a positive effect on the health (2). 
Despite these limitation, in the current setting, WES has been successfully used in 
establishing genetic diagnosis in children with undiagnosed rare diseases. With time, 
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WES will be used more by the clinicians which will help in the identification of 
increasing number of pathogenic variants with a wealth of molecular database (2). 
1.2.6 WES, GWAS and Whole Genome Sequencing (WGS) 
GWAS searches for SNPs that are more prevalent in population with particular disease 
than those without it. GWAS study looks at many loci at the same time. GWAS is used 
to pinpoint genes that may contribute to the development of a common disease. WES 
is however used to identify the underlying genetic etiology in rare diseases. WES, 
although a cost-effective way to identify disease-related variants, it has its limitations 
as described above. With the decreasing sequencing cost and accumulating 
knowledge of the human genome, whole genome sequencing has the potential to 
identify important variants in regulatory regions typically inaccessible for exome 
sequencing. 
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2.1 SUMMARY OF CHAPTER 2 
Chapter 2 provides an introduction to the embryological development of pituitary 
gland, role of transcription factors and mutations in congenital hypopituitarism. This 
chapter opens with a brief description on the embryology and genes involved in the 
pituitary gland development. This then leads into detailed description of the clinical 
condition “congenital hypopituitarism”, its genetic causes, clinical presentation, 
diagnosis, and management. 
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2.2 PITUITARY GLAND 
The pituitary gland, located within the sella turcica at the base of the brain is the master 
regulator of growth, puberty, metabolism, response to stress, reproduction and 
lactation (55). The pituitary gland consists of three lobes: the anterior, the intermediate 
and the posterior lobes. The anterior and the intermediate lobe (involutes in the adult) 
comprise the adenohypophysis and the posterior lobe comprises the neurohypophysis 
(56). The adenohypophysis or the anterior part of the pituitary gland secrete six 
different hormones produced from five different cell types: growth hormone (GH) from 
somatotrophs, thyroid stimulating hormone (TSH) or thyrotrophin from the thyrotrophs, 
adrenocorticotropic hormone (ACTH) from corticotrophs, prolactin (PRL) from 
lactotrophs, follicular stimulating hormone (FSH) and luteinizing hormone (LH) from 
gonadotrophs (57). The intermediate lobe consists of melanotrophs that secrete pro-
opiomelanocortin (POMC), which is a precursor to melanocyte-stimulating hormone 
(MSH) and endorphins (57). Within the posterior lobe, arginine vasopressin (AVP) and 
oxytocin are secreted which are synthesised magnocellular neurones of the 
paraventricular and supra-optic nuclei within the hypothalamus (57). Secretory and 
inhibitory peptides that regulate the secretion of hormones from the anterior pituitary 
gland are produced from the hypothalamus. The infundibulum or the pituitary stalk not 
only carries the neural tracts from the hypothalamus to the posterior pituitary gland but 
also carries the portal blood delivering the hypothalamic regulating hormones to the 
anterior pituitary gland (57). 
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2.2.1 Embryology and Development of Pituitary Gland 
The oral ectoderm gives rise to the formation of the anterior and intermediate lobes of 
the pituitary while the posterior pituitary is derived from the neural ectoderm (57). The 
development of the pituitary gland has been extensively studied in mouse which 
occurs in a sequential, well defined and coordinated manner that involves the 
formation of the pituitary placode, rudimentary Rathke’s pouch, definitive Rathke’s 
pouch and the mature pituitary gland (58). The developmental cascade of murine 
pituitary gland reflects that of humans (58). At embryonic stage, E7.5 in the mouse, 
the roof of the oral ectoderm thickens and gives rise to the pituitary placode, which by 
E9.0, invaginates to form the rudimentary Rathke’s pouch that then forms into the 
definitive Rathke’s pouch by E10.5 (59). The Rathke’s pouch then gives rise to the 
anterior and the intermediate lobes of the pituitary gland (55). The neural ectoderm 
evaginates at the base of the ventral diencephalon to give rise to the infundibulum and 
the posterior pituitary (55). At E12.5, there is separation of Rathke’s pouch from the 
oral ectoderm (55). The various stages of pituitary gland development in the rodent 
are depicted in figure 2.1 (55). The hormone-secreting progenitor cells proliferate 
between E12.5 and E15.5 followed by spatial and temporal differentiation of the 
various cell types (55), starting from the thyrotrophs and corticotrophs, followed by the 
somatotrophs, gonadotrophs and lactotrophs that each secrete their respective 
hormones (60, 61). 
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Figure 2.1: Stages in mouse pituitary gland development. (a) Oral ectoderm. (b) 
Rudimentary pouch. (c) Definitive pouch. (d) Adult pituitary gland. I-Infundibulum; NP-
neural plate; N-notochord; PP-pituitary placode; OM-oral membrane; H-heart; F-
Forebrain; MB-midbrain; HB-hindbrain; RP-Rathke’s pouch; AN-anterior neural pore; 
O-oral cavity; PL-posterior lobe; OC-optic chiasm; P-pontine flexure; PO-pons; IL-
intermediate lobe; AL-anterior lobe; DI-diencephalon; SC-sphenoid cartilage (56). 
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2.2.1.1 Early Developmental Genes and Signals in Pituitary   Development 
The development of the pituitary gland is orchestrated by a series of well-co-ordinated 
cascade of morphogenetic signalling molecules and transcription factors that play a 
vital role in the process of organ commitment, cell proliferation, patterning and 
differentiation (56). The formation of the rudimentary Rathke’s pouch(RP), is initiated 
by the signalling molecules such as Bone Morphogenetic Protein 4(Bmp4) and thyroid 
transcription factor (Ttf1) from the ventral diencephalon combined with the Sonic 
Hedgehog (Shh) from the oral ectoderm (62). The invagination of the RP and further 
pituitary progenitor cell proliferation is directed by the co-ordination of Fibroblast 
growth factor signalling (Fgf8 and Fgf10) and Wnt5a along with early transcription 
factors such as Gli1, Gli2, Lhx3, Ptx1 and Ptx2 (62).The expression of Hesx1 and 
Prop1(prophet of Pit-1) in RP leads to differentiation of specific pituitary cell 
types.Prop1 in-turn induces the expression of Pou1f1, leading to the terminal 
differentiation of somatotrophs, lactotrophs and thyrotrophs (63). The gonadotrophs 
differentiation is induced by the expression of Gata2 and steroidogenic factor 1(sf1) 
(63). The differentiation of corticotrophs is regulated by the expression of Tbx19 from 
the POMC-producing cells (63). 
The development of pituitary is a carefully co-ordinated complex process which 
requires the expression of the signalling molecules during critical periods of 
development. The genes that are expressed early are not only involved in the organ 
commitment but also play an important role in the activation and expression of 
downstream signalling molecules that have a specific role in the differentiation of 
progenitor cells (56).The differentiation of various pituitary cell types from the various 
transcription factors is shown in  figure 2.2 (55). 
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Figure 2.2: Schematic representation of pituitary developmental cascade with 
sequential expression of pituitary transcription factors and genes (56). A cascade of 
signalling molecules and transcription factors such as Bmp4, Sf1, Lhx4, Prop1, Pitx1, 
Pit1 play a crucial role in organ commitment, cell proliferation, patterning, and terminal 
differentiation of the cells that secrete hypothalamic regulatory peptides (GHRH, TRH, 
GnRH) and the pituitary hormones (ACTH, PRL, GH, TSH, LH and FSH). 
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The understanding of human pituitary disease has been significantly enhanced by 
studying the effects of induced mutations and gene knock outs in the murine models. 
This has led to the identification of mutations in a number of genes that give rise to the 
phenotype of hypopituitarism in humans. Mutations in transcription factors such as 
Hesx1, Lhx3, Lhx4, Prop1, Pou1f1, Pitx2 and Tbx19 have been implicated to cause 
hypopituitarism in both the mice and the humans (57). Hypopituitarism is the deficiency 
of one or more hormones secreted by the pituitary gland.  Congenital hypopituitarism 
comprises of a spectrum of disorders with variable phenotypes that can range in 
severity, from isolated hormone deficiency [IGHD being the most common] to 
combined pituitary hormone deficiency (CPHD) when two or more pituitary hormones 
are deficient (57). Congenital hypopituitarism may present as part of a syndrome with 
abnormalities in structures that share a common embryological origin with the pituitary 
gland (57).  
The mutations in the known transcription factors implicated in the etiology of syndromic 
and non-syndromic hypopituitarism are described below: 
2.3 SYNDROMIC FORMS OF HYPOPITUITARISM 
2.3.1 Septo-Optic Dysplasia 
 
De Morsier syndrome or septo-optic dysplasia(SOD) is a rare condition with a reported 
incidence of 1 in 10,000 newborns and is equally prevalent in both sexes (64). SOD is 
heterogeneous congenital anomaly and is characterised by the presence of at least 
two of the three features: hypopituitarism (one or more pituitary hormone deficiency), 
hypoplasia of the optic nerve and defects of the midline structures of the forebrain 
such as absent septum pellucidum or agenesis of corpus callosum (64). While the 
presence of all the three features occurs only in about 30% of the patients, 
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hypopituitarism and midline brain abnormalities can be a feature in 62% and 60% of 
the patients respectively (55). SOD has multifactorial etiologies such as genetic, viral 
infections, alcohol, drugs, vascular and environmental teratogens. Mutations in 
HESX1, SOX2 and SOX3 have been implicated in SOD (65, 66). However, the 
proportion of patients with SOD having mutations in these genes is very small, 
implying that there may be other unidentified genetic factors that may account for SOD 
(65, 66).  
Any disruption occurring during the development of forebrain and the pituitary between 
3-6 weeks of gestation can account for SOD (55). Disturbances in visual axis, squint 
or nystagmus secondary to unilateral or bilateral (majority) optic nerve hypoplasia can 
be the presenting feature of SOD (66). The pituitary hormone deficiencies may not be 
always present in patients with SOD but may evolve later in life, thus requiring life-
long follow-up. The commonest pituitary hormone deficiency is GH followed by TSH, 
ACTH and gonadotropins (66). Posterior pituitary involvement and diabetes insipidus 
are rare. There also may be associated neurological manifestations such as cerebellar 
hypoplasia, schizencephaly, seizures and global developmental delay (67). 
2.3.2 HESX1 mutations and SOD 
HESX1 is critical transcription factor that has a central role in the early differentiation 
and determination of the forebrain and the pituitary gland (55). Expression studies 
during mouse embryogenesis show that Hesx1 is one of the earliest markers of the 
pituitary primordium, first expressed in the anterior midline visceral endoderm and its 
continued expression in this area plays a vital role in the development of the forebrain, 
ventral diencephalon, anterior pituitary and the presumptive hypothalamus (55). 
Evidence from murine studies show that targeted disruption of Hesx1 causes forebrain 
abnormalities, micropthalmia and absent optic vesicles, the features which are in line 
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with SOD in humans (68). The first homozygous missense mutation (Arg160Cys) was 
found in the homeobox of HESX1 in two siblings with SOD with  optic nerve 
hypoplasia, absent corpus callosum and septum pellucidum, an ectopic/undescended 
posterior pituitary and anterior pituitary hypoplasia with hypopituitarism (68). 
Subsequently homozygous and heterozygous mutations have been reported to cause 
variable phenotype ranging from IGHD to SOD. Only minority of patients with SOD 
(<1%) have HESX1 mutations, implying that there are potential unidentified genes 
contributing to this complex disorder (69, 70). 
2.3.3 SOX2 and SOX3 Mutations 
The expression of SOX2 and SOX3 are important for the differentiation of progenitor 
stem cells and pituitary development (71, 72). SOX2 mutations have been described 
in association with anterior pituitary hypoplasia, hypogonadotropic hypogonadism, 
hippocampal and corpus callosum abnormalities (73, 74).  SOX3 causes X linked 
hypopituitarism in males and may consist of abnormalities of corpus callosum, 
hypoplasia of the infundibulum, isolated or combined hormonal deficiencies (75, 76). 
The phenotype may be associated with learning difficulties (77). 
 
2.3.4 Holoprosencephaly (HPE) 
HPE is a heterogeneous condition with multifactorial etiology resulting from the 
abnormal cleavage of the forebrain and may be associated with pituitary, corpus 
callosum, nasal and ocular abnormalities (78). The most common endocrine 
manifestation in HPE is cranial diabetes insipidus (55). The transcription factor GLI2 
mediates the signal from the Sonic Hedgehog(SHH) signalling pathway, the mutation 
of which has been implicated in the development of HPE sequence (79). GLI2 
 
 
 
26 
mutations have been associated with hypopituitarism, partial agenesis of corpus 
callosum, single central maxillary incisor, post axial polydactyly and single nares (55). 
2.3.5 LHX3 mutations: Hypopitutarism with Spine Abnormalities 
Lhx3 or the LIM homeobox is an important early development gene detected in the 
Rathke’s pouch and the developing nervous system, the continuous expression of 
which helps in the proliferation of gonadotrophs, thyrotrophs, somatotrophs and 
lactotrophs (80). Homozygous targeted disruption of this gene from mouse causes 
pituitary aplasia and results in their death, shortly after birth (81). Patients with 
homozygous LHX3 mutations have deficiencies of GH, PRL, TSH, LH,FSH and also 
sometimes ACTH deficiencies with small to an enlarged anterior pituitary with a lesion 
suggestive of microadenoma (82, 83). There also can be an association of short rigid 
cervical spine with limitation of neck movement and sensorineural hearing loss (83-
85). 
 
2.3.6 LHX4 mutations 
The expression of Lhx4 is closely related to that of Lhx3 (86). The expression pattern 
of Lhx4 is found throughout the invaginating Rathke’s pouch at very early mouse 
embryonic stage but by E15.5 its expression is predominantly found in the anterior 
lobe of the pituitary (55). Targeted Lhx4 deletion in mice results in hypoplastic pituitary 
due to reduction in cell numbers (58). Experiments involving Lhx3 and Lhx4 gene 
dosage in murine models demonstrate that a single allele of Lhx3 or Lhx4 is sufficient 
for the formation of definitive Rathke’s Pouch (58). With targeted deletion of Lhx3 and 
Lhx4 in mouse, the progression from rudimentary to definitive Rathke’s pouch does 
not occur (58). Variable degrees of hypopituitarism involving GH, ACTH, TSH and 
gonadotropin deficiencies with ectopic posterior pituitary, hypoplastic sella, cerebellar 
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abnormalities and Chiari malformation have been reported in patients with 
heterozygous LHX4 mutations (83, 87, 88). LHX4 is required for the activation and 
expression of GH1, therefore LHX4 mutations result in short stature due to GH 
deficiency (89). 
2.3.7 OTX2 mutations 
OTX2 is another important transcription factor required for the formation of forebrain 
and its maintenance (90, 91). In humans, mutations in OTX2 have been described in 
patients with hypopituitarism and bilateral anophthalmia with a normal or small anterior 
pituitary and an ectopic posterior pituitary. OTX2 mutations can also cause 
hypopituitarism without associated ocular abnormalities (92). Among the 
anophthalmia/micropthalmia syndromes, 2-3% of the underlying genetic aetiology is 
due to a mutation in OTX2 (93, 94). 
 
2.3.8 Axenfield-Rieger syndrome (PITX2 mutations) 
In the mouse, Pitx2 is initially expressed in the oral ectoderm and then in the Rathke’s 
pouch. It is also expressed in the mesenchyme near the optic eminence, forelimbs 
and the domains of the abdominal cavity (57). It is required at multiple stages of the 
pituitary development after the commitment of the definitive Rathke’s pouch. Targeted 
Pitx2 mutations in mice causes hypopituitarism with hypoplastic anterior pituitary (95). 
Heterozygous mutations in PITX2 (OMIM 601542 also known as RIEG1) are 
implicated in Axenfield-Rieger syndrome, an autosomal dominant condition that 
comprises of malformation of the anterior segment of eye, dental hypoplasia, 
protuberant umbilicus and brain abnormalities (96, 97). Pituitary abnormalities due to 
PITX2 mutation in humans are yet to be described. 
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2.4 NON-SYNDROMIC FORMS OF HYPOPITUITARISM 
2.4.1 PROP1 Mutations 
In the mouse embryo, the transcription factor Prop1 is expressed within the Rathke’s 
pouch from E10, in a region overlapping the Hesx1 expression domain (55). The 
expression of Prop1 starts to decrease after E12 and disappears at E15.5 (98). This 
decline in Prop1 expression is important as overexpression can result in delay in the 
differentiation of gonadotrophs leading to transient gonadotrophin deficiency and 
delayed puberty (55). Prop1 regulates the expression of Hesx1 and Pou1f1 by acting 
as transcriptional repressor of the former and transcriptional activator for the latter 
(99). Therefore the appropriate and timely suppression of Prop1 is important for 
Pou1f1 determination and in the establishment of other cell lineages (100). Naturally 
occurring Prop1 mutations in Ames dwarf mice cause GH,PRL,TSH and 
gonadotrophin deficiencies due to failure in determination of Pou1f1 lineage which 
determines the differentiation of somatotrophs, lactotrophs and thyrotrophs (55). In 
humans, PROP1 is located at chromosome 5q and consists of three exons and a 
protein product of 226 amino acids (56). The most common mutations in PROP1 are 
recessive mutations associated with GH, TSH, PRL and gonadotropin deficiencies 
(101). ACTH deficiency is uncommon but has been reported in patients with PROP1 
mutations (102). The degree of TSH and gonadotropin deficiencies is variable. The 
gonadotropin deficiency may range from micropenis, undescended testes, delayed 
puberty and infertility (101).  
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2.4.2 POU1F1(PIT1) Mutations 
POUIFI (previously PIT-1), is a transcription factor that is expressed at E14.5 during 
the mouse pituitary development and persists throughout the postnatal period and in 
the adult pituitary (55). The differentiation of somatotrophs, lactotrophs and 
thyrotrophs depends on the Pou1f1 expression (55). POU1F1 mutations in humans 
are mostly autosomal recessive but dominant mutations have been described (103). 
The phenotype consists of GH and PRL deficiencies in early life and TSH deficiency 
occurring in late childhood with normal sized or small anterior pituitary and a normal 
posterior pituitary with no midline abnormalities (104). 
 
2.4.3 TBX19 mutations (OMIM 604614. Previously known as TPIT) 
TBX19 belongs to T-box family of transcription factors and is expressed from E11.5 
within the developing anterior pituitary and the ventral diencephalon in mouse 
embryos (105).  In the adult mouse pituitary, TBX19 expression is detected in 
corticotrophs in anterior lobe that express POMC and in the melanotrophs forming the 
intermediate lobe (106). TBX19 mutations are thus associated with isolated ACTH 
deficiency (107). Homozygous and compound heterozygous mutations in TBX19 have 
been described implying a recessive mode of inheritance (107). ACTH deficiency can 
present in the neonatal period with severe hypoglycaemia, jaundice or seizures (108). 
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2.5 ISOLATED HORMONE DEFICIENCY DUE TO MUTATION IN SPECIFIC  
      CELL TYPE: GH1 MUTATIONS 
In addition to mutations in the developmental genes, causing combined pituitary 
hormonal deficiencies, there are genetic mutations that contribute to isolated hormone 
deficiencies. An example is mutations in GH1. 
Growth hormone is encoded by GH1 gene, the mutations of which are estimated in up 
to 12.5% of patients with isolated GH deficiency although the true incidence is difficult 
to ascertain owing to geographical and ethnic differences (109). Isolated GH 
deficiency(IGHD) due to GH1 mutations consists of three types: Type 1a is the 
severest form due to the deletion of GH1 gene in which patients will not have any 
detectable serum GH and respond well to recombinant GH, although some patients 
develop anti-GH neutralizing antibodies (110). Type 1b IGHD is due to homozygous 
splice site mutation in GH1 and is characterized by low but detectable GH after 
provocative stimulation (110). Type 2 IGHD is the common form and is due to splice 
site and missense mutations in GH1 and is an autosomal dominant condition. Type 3 
IGHD, an X-linked recessive disorder is associated with X-linked 
agammaglobulinemia (110). 
A mutation leading to the absence of a disulphide bridge in GH1 results in the 
decreased binding of GH to its receptor and subsequent downstream signalling, 
causing a high serum GH levels with low serum IGF-1 concentration leading to short 
stature (111).Patients with IGHD can also develop additional pituitary hormonal 
deficiencies later in life and therefore require life-long monitoring. In addition to GH1 
mutations, several other mutations in genes encoding GHRHR, TSH, LH and FSH 
have been known to cause specific hormonal deficiencies (112-114). 
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2.6 CLINICAL MANIFESTATIONS OF HYPOPITUITARISM 
Establishing the diagnosis of congenital hypopituitarism is important as untreated 
hypopituitarism can result in serious morbidities such as global developmental delay 
due to prolonged undetected hypoglycaemia and untreated hypothyroidism, significant 
reduction in final height and morbidities related to water and electrolyte imbalance. 
The clinical spectrum of hypopituitarism is dependent on the combination of hormonal 
deficits. The clinical manifestations may be non-specific in the neonatal period such 
as poor feeding, temperature instability, jitteriness, poor weight gain and prolonged 
jaundice (115). Early diagnosis in this age group can be challenging due to factors 
such as prematurity, associated neonatal comorbidities, lack of data appropriate for 
gestation and immaturity of hypothalamic-pituitary axis (55). Neonates can also 
present with associated developmental defects such as ocular, midline, genital 
abnormalities or syndromes associated with hypopituitarism. Presence of fixed squint, 
nystagmus in a neonate can be due to underlying optic nerve hypoplasia which can 
be isolated or a part of the spectrum of septo optic dysplasia. Such patients will need 
life- long follow up and assessment of endocrine function, even if their initial endocrine 
investigations are normal (116). Congenital hypopituitarism can be life threatening in 
neonates due to an underlying ACTH deficiency and may present as sepsis, seizures 
or conjugated hyperbilirubinaemia (117). 
Growth failure can occur in infancy in severe GHD (118). Male neonates may present 
with micropenis or undescended testes as the penile growth is dependent on normal 
LH secretion during the second and third trimester (56). Diabetes insipidus can present 
as polyuria, polydipsia but may be masked in patients with ACTH deficiency as cortisol 
is essential to excrete the water load. Hydrocortisone replacement may unmask 
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diabetes insipidus and hence vigilance is essential in patients with suspected 
hypopituitarism with or without midline defects when being treated with hydrocortisone 
therapy for cortisol deficiency. 
2.7 INVESTIGATIONS IN HYPOPITUITARISM 
The investigations of hypopituitarism comprise of stimulation or provocative tests to 
check the adequacy of the hypothalamic-pituitary axis (HPA) and neuroradiology. 
2.7.1 ACTH Deficiency 
In neonates, ACTH deficiency can be life threatening. It is however challenging to 
assess the intactness of the hypothalamic-pituitary-adrenal axis as the circadian 
rhythm of cortisol is not well established during the first six months of life (119). The 
usefulness of baseline serum cortisol samples in the morning or evening are limited in 
this age group. Multiple cortisol measurements during the various points during the 
day and night can be challenging and may not reveal definitive information on the 
integrity of the axis. Hypoglycaemia induced cortisol stimulation is contraindicated in 
the age group but standard synacthen test is safe and easy to perform in this age 
group. However the standard synacthen test is limited by sensitivity of 80% and 
therefore false negative results are a possibility despite ACTH deficiency (117). In 
older children, after the establishment of circadian rhythm , 08:00 am cortisol of 
175nmol/L or more combined with a 30 minute stimulated level of more than 
540nmol/L on a standard synacthen test has a sensitivity of 69% and specificity of 
100% in  excluding ACTH deficiency (117). 
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2.7.2 TSH Deficiency 
TSH deficiency is normally characterised by a low or inappropriately normal TSH 
combined with a low serum free thyroxine. Isolated TSH deficiency is rare but can 
occur in combination of other pituitary hormone deficiencies (120). Provocative test 
such as thyrotropin releasing hormone(TRH) test is generally not required to establish 
the diagnosis of central hypothyroidism (121). 
2.7.3 GH Deficiency 
Severe GH deficiency can present in the neonatal period as hypoglycaemia. The 
provocative tests to assess the hypothalamic-pituitary-growth axis are contraindicated 
in children less than one year of age. The diagnosis of GH deficiency in this age group 
is normally suggested by low plasma GH concentration in response to spontaneous 
hypoglycaemia, low plasma IGF-1 and/or the presence of additional hormonal 
deficiencies (122).In older age groups the diagnosis is based on the faltering growth 
velocity, low IGF1, suboptimal GH response to GH provocation test and/or the 
presence of a structural anomaly in the pituitary gland detected on MRI. 
2.7.4 Gonadotropin Deficiency 
Males with gonadotropin deficiency can present with micropenis with or without 
undescended testes. The physiological postnatal surge in LH, FSH and testosterone 
is detected up to 6 months in males and about 2 years in females (123). A combination 
of GnRH (gonadotropin releasing hormone) and hCG (human chorionic gonadotropin) 
stimulation tests are useful in the earlier detection of hypogonadotropic hypogonadism 
(HH) in infants where a low baseline gonadotropin concentrations (LH & FSH) and 
blunted response to stimulation with GnRH are found (124). 
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2.7.5 ADH Deficiency (Diabetes Insipidus(DI)) 
Early morning paired serum and urine osmolality, hypernatraemia along with 
symptoms such as polyuria, weight loss may be helpful in the diagnosis as water 
deprivation test can be dangerous in this age group. The symptoms of DI can be 
masked in patients with ACTH deficiency as cortisol is important for water excretion 
from the kidneys. 
 
2.7.6 The Role of Neuroradiology 
In infants with suspected or diagnosed hypopituitarism, MRI of the pituitary and brain 
can help to assess the size of anterior pituitary, the location of posterior pituitary, the 
morphologies of infundibulum, corpus callosum, septum pellucidum, optic nerves, 
optic chiasma and associated brain abnormalities (125). The neuro radiological 
abnormalities are usually related to the severity or the evolution of hypopituitarism 
(126). In patients with ectopic posterior pituitary, the risk of hypopituitarism is much 
greater than patients with normally positioned pituitary. Neonates with optic nerve 
hypoplasia and small anterior pituitary will require a lifelong follow-up despite their 
initial normal endocrine function as hypopituitarism may evolve over a period of time 
(126).  
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2.8 MANAGEMENT OF CONGENITAL HYPOPITUITARISM 
The management of congenital hypopituitarism is multidisciplinary and requires a 
lifelong follow-up. The management should not only focus on optimizing the hormone 
replacement but also to monitor carefully for the evolvement of potential hormonal 
deficiencies in the future. In syndromic forms of hypopituitarism, it is also vital to 
address the wider issues such as visual and neuro-developmental issues and offer 
appropriate genetic counselling (55).  
While replacing hormones in suspected combined pituitary hormone deficiency, it is 
important to assess the adequacy of cortisol secretion and replacing with 
hydrocortisone when the cortisol secretion is suboptimal before commencing on 
thyroxine (55). As mentioned above, patients on cortisol replacement should be 
carefully monitored for symptoms of DI.   
Overall, the mainstay of treatment of congenital hypopituitarism is to identify the 
existing and evolving hormonal deficits optimizing their replacement. 
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CHAPTER 3 
 
 
 
 
CONGENITAL HYPERINSULINSIM-
MOLECULAR MECHANISMS, DIAGNOSIS 
AND MANAGEMENT 
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3.1 SUMMARY OF CHAPTER 3 
Chapter 3 provides an introduction to glucose physiology, regulation of insulin 
secretion, ATP-sensitive potassium channels (KATP), and congenital 
hyperinsulinism(CHI). This chapter opens with a brief description on insulin secretion 
and pancreatic β-cell physiology, followed by introduction to KATP channels. This then 
leads into detailed description of the clinical condition “congenital hyperinsulinism”, its 
causes, clinical presentation, diagnosis, histological subtypes and management. 
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3.2 CONGENITAL HYPERINSULINISM (CHI) 
Congenital hyperinsulinism (CHI) is a condition in which  there is an unregulated 
insulin secretion from the β-cells of the pancreas (127). This unregulated insulin 
secretion suppresses the production of glucose by inhibiting gluconeogenesis and 
glycogenolysis leading to severe and persistent hypoglycaemia (128). In the absence 
of glucose, the brain normally utilises the ketone bodies as an alternative source of 
energy. However, in CHI, the metabolic actions of the excess insulin inhibit 
ketogenesis and lipolysis depriving the brain of both glucose and ketones as energy 
source leading to hypoglycaemic brain injury. During the neonatal, infancy and 
childhood periods, CHI is an important cause of hyperinsulinaemic hypoglycaemia and 
requires early recognition, diagnosis and immediate and appropriate management to 
prevent or reduce the neurological injury (129).  
 
3.3 INSULIN SECRETION AND PANCREATIC β-CELL PHYSIOLOGY 
Insulin is the key regulator of blood glucose concentration and its secretion is tightly 
linked to the metabolism of glucose, intricately translated into signals in pancreatic β-
cells (130). Glucose enters the pancreatic β-cells mainly via glucose transporter 2 
(GLUT 2) situated in the cell membrane. The transport of glucose across the 
pancreatic β-cell membrane in proportion to the blood glucose concentration is 
facilitated by the high affinity(Km) for glucose with GLUT2 (131). Once transported, the 
glucose is converted to glucose-6-phosphate by an islet specific enzyme, glucokinase. 
Glucokinase acts like a sensor to the β-cell, increasing its activity during high blood 
glucose concentration and reducing its activity when the blood glucose concentration 
falls low (132). These activities in-turn guide the signals regulating the insulin 
production in the pancreatic β-cells.  
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The β-cell membrane has ATP-sensitive K+ channel (KATP channel) that plays a 
fundamental role in maintaining the glucose homeostasis (133). These channels 
couple the glucose metabolism to β-cell’s electrical excitability and insulin secretion 
(133).  
3.3.1 Structure of KATP Channel 
The KATP channel is a hetero-octameric complex arranged in a 4:4 stoichiometry. 
This model was first suggested by Inagaki and colleagues on the basis of optimum 
activity of KATP channels when SUR1 and Kir6.2 subunits were co expressed with a 
molar ratio of 1:1 (134). The channel comprises of two types of subunits consisting of 
four inward rectifying potassium channel pore forming (Kir6.2) subunits and four high 
affinity sulfonylurea receptor 1 (SUR 1) subunits (an ATP binding cassette transporter) 
(134). The Kir6.x subunits belong to the superfamily of weak inwardly rectifying, 
voltage independent potassium (K+) channels that allow a large influx of K+ flux at 
negative potentials (135). The channel is arranged in such a way that the Kir6.2 
subunit forms the inner core and the SUR1 is a regulatory subunit and forms the outer 
part (134). This assembly is unique and the correct assembly is vital for the transport 
and subsequent expression of the channel on the surface of the cell membrane.   
 
The Kir6.2 forms the core of the channel whilst the SUR1 (an ATP binding cassette 
transporter) acts as a regulatory subunit. KATP channels can only function if they are 
assembled and correctly transported to the cell membrane surface (trafficking) (136). 
The assembly and trafficking of KATP channels are intricately linked processes (136). 
Each Kir6.2 subunit consists of two transmembrane domains (TM1 and TM2) linked 
by an extracellular pore-forming region H5 that serves as a potassium selectivity filter 
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(137). The TM2 domains from all the four Kir6.2 subunits form the pore of the channel. 
Both the aminoacid and carboxyl terminals are found in the cytoplasm and are 
responsible for ATP binding and channel gating (137). 
Each SUR1 subunit consists of 17 transmembrane regions organized into three 
domains (137). The TMD1 and TMD2 comprise of the transmembrane regions from 
TM6-11 and TM12-17 respectively. The TMD0 that comprises of the regions from 
TM1-5 plays an important role in trafficking the Kir subunit to the surface of the cell 
membrane (137). The subunit also comprises of two nucleotide binding folds (NBFs) 
on the cytoplasmic side (138). The NBF-1 is found between TMD1 and TMD2 and 
NBF-2 is present after TMD2 (139). 
Both the subunits (Kir6.2 and SUR1) have to be co-expressed on the surface of the 
cell membrane in order to function. The trafficking of either subunit in the absence of 
other is prevented by the presence of an endoplasmic reticulum (ER) retention signal 
in the C terminal region of Kir6.2 and between TM11 and NBF-1 in SUR1 (136). 
Mutations causing the truncation of the Kir6.2 C-terminus results in deletion of the 
retention signal and causes its expression in the absence of SUR1 (140). 
When blood glucose level is low, the KATP channels in pancreatic β-cell remain open 
to allow the diffusion of potassium that maintains the resting membrane potential at a 
hyperpolarized state and keeps the voltage gated calcium channels closed. With an 
increase in the blood glucose concentration, the production of ATP increases and 
raises the intracytosolic ATP/ADP ratio which inhibits the SUR1. This results in the 
closure of the KATP channels leading to membrane depolarization. This in-turn 
causes Ca2+ influx into the pancreatic β-cell via the voltage gated Ca2+ channels. 
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The increase in the intracellular calcium concentration triggers the exocytosis and the 
release of insulin(141). The mechanism of insulin release is depicted in the figure 3.1. 
 
Figure 3.1: Mechanism of release of insulin from the pancreatic β-cell:The glucose 
enters via GLUT2 (Glucose Transporter 2) is phosphorylated. This increases the 
ATP/ADP ratio which causes the closure of the KATP   channel resulting in the 
membrane depolarisation, resulting in the opening of the voltage gated calcium 
channels. The entry of calcium results in exocytosis and subsequent insulin release. 
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3.3.2 KATP  Channel Independent Insulin Secretion 
 
The key mechanism of insulin release from the pancreatic β-cell is the glucose 
stimulated insulin secretion by triggering the KATP channel dependent signals. 
However, there are evidences to suggest that the insulin release from the pancreatic 
β-cell can occur independent of the KATP channels (142-144).Gembal et al. 
demonstrated that the depolarisation of the β-cell membrane on the mouse islets, by 
increasing the extracellular potassium concentration triggered calcium influx and the 
resultant insulin release  despite diazoxide (143). They also demonstrated that the 
insulin secretion proportionately increased by increasing glucose concentration.   This 
is suggestive of potential KATP channel independent mechanism that operates in 
glucose mediated insulin secretion. Straub et al. demonstrated glucose stimulated 
insulin secretion  without an increase in the intracellular free calcium on islets on a 
patient with mutation in the KATP channel (144).The insulinotropic action of glucose 
in Ca2+ depleted rat pancreatic islets occurred in the presence of a phorbol ester 
(phorbol 12-myristate 13-acetate; PMA) and forskolin (adenylate cyclase activator) 
(145). 
 
3.4 ETIOLOGY OF CHI 
Hyperinsulinaemic hypoglycaemia can have an underlying monogenic etiology or can 
be transient secondary to intra-uterine growth retardation (IUGR) and maternal 
diabetes mellitus (gestational or insulin dependent), birth asphyxia and can be 
associated with several developmental syndromes (such as Beckwith-Wiedemann, 
Kabuki and Turner syndromes) and rare metabolic conditions such as congenital 
disorders of glycosylation (CDG) syndromes (146).  
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Mutations in 11 genes are associated with genetic forms of CHI (ABCC8, KCNJ11, 
GLUD1, GCK, HADH1, UCP2, MCT1, HNF4A, HNF1A, HK1, PGM1) (147). ABCC8 
or KCNJ11 mutations constitute the majority of causes of monogenic CHI (147).  
3.4.1 CHI due to Defects in Pancreatic β-cell KATP Channels 
 
The Kir6.2 and SUR1 subunits are encoded by the genes KCNJ11 and ABCC8 
respectively. The first link between CHI and KATP channels was suggested with the 
help of linkage analysis in 15 families (12 Ashkenazi Jewish, 2 consanguineous Arab 
and 1 non-Jewish Caucasian) where the region responsible to cause CHI was mapped 
to 11p14-15.1 (148). By fluorescence in situ hybridization (FISH), Thomas et al. 
mapped the gene encoding SUR to this region and identified splice site mutations in 
individuals from nine different families (149). Subsequently, a homozygous missense 
mutation (L147P) in Kir6.2 was reported in a child with CHI (150). 
The most common causes of CHI are recessive mutations involving ABCC8 or 
KCNJ11, that diminish or completely abolish the activity of KATP channel which results 
in constant membrane depolarization and an unregulated release of insulin despite 
the presence of hypoglycaemia (151). In about half of the patients with CHI, germline 
mutations are found in ABCC8 or KCNJ11 (152). The majority of the reported 
mutations are in ABCC8 (about 150 homozygous, compound heterozygous and 
inactivating heterozygous) and in KCNJ11, about 24 mutations have been reported 
(152). 
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3.4.1.1 Molecular Basis of ABCC8 and KCNJ11 Recessive Mutations 
 
The mutations involving the genes encoding KATP channels can cause defects in the 
biogenesis and turnover of the channel, defects in the trafficking of the channel from 
the endoplasmic reticulum and Golgi apparatus to the plasma membrane or defects 
causing altered response to nucleotide activation and open state (153-155). The loss 
of function mutations contributing to these defects are of two types: class I mutations 
are those that cause defects in trafficking and class II mutations result in reduced 
KATP channel response to nucleotide activation or reduced intrinsic channel open 
probability (130). 
The recessive homozygous mutations abolish the activity of KATP channel completely 
resulting in severe CHI, unresponsive to diazoxide treatment. Recessive compound 
heterozygous mutations can cause a milder phenotype that can respond to treatment 
with diazoxide (156). 
3.4.2 Defect in Biogenesis and Turnover  
The biogenesis and turnover of SUR1 and KiR6.2 were studied with pulse-labelling 
methods by Crane et al. and it was found that SUR1, when expressed alone had a 
half-life of approximately 25.5 hours. On the other hand, Kir6.2 had biphasic turnover 
with a half-life of 36 minutes for the first 60% and 26 hours for the remaining (157). 
The co-expression of SUR1 and Kir6.2 prevented the fast degradation of Kir6.2 and 
the combined estimated half-life was about 7.3 hours. Mutations involving the 
channels such as Kir6.2 W91R and SUR1∆F1388 result in rapid degradation and 
affect the biogenesis and turnover (157).  
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3.4.3 Trafficking Defects 
The masking of the endoplasmic retention signal is an important requirement to allow 
correct trafficking and co-expression of the KATP  channels on the surface of the β-
cell membrane. The endoplasmic retention signal comprises of a three peptide 
sequence (RKR; Arg-Lys-Arg), present in both the SUR1 and Kir6.2 (136, 140). 
Mutations affecting the trafficking can cause CHI.The phenyl alanine at the position 
1388 in SUR1 is critical for normal trafficking, and SUR1∆F1388 causes CHI (153). 
The other mutations that have been demonstrated to affect trafficking include SUR1 
L1544P and SUR1 R1394H (154, 158). 
3.4.4 Defects in Channel Regulation 
The nucleotide binding folds (NBF-1 and NBF-2) of SUR1 regulate the conductance 
of Kir6.2 and several mutations (R1420C, T1139M and R1215Q) can alter the 
sensitivity to changes in ATP/ADP ratio and can result in loss of ADP dependent KATP 
channel function and constitutive release of insulin (139, 155).  
3.4.5 Dominant Activating KATP Channel Mutations 
Dominant KATP channel mutations can cause CHI which may either be diazoxide 
responsive or unresponsive depending on the response of Kir 6.2 and SUR1 to the 
ADP or diazoxide. Dominant KATP mutations do not affect the trafficking of the 
channels. Huopio et al. identified diazoxide responsive heterozygous mutations in 
seven patients and their mothers (159). Pinney et al. described dominantly inherited 
KATP mutations in 14 patients (11 ABCC8 and 3 KCNJ11 mutations) (160).The 
functional studies indicated that the mutations had significantly decreased channel 
opening probability and also reduced response to MgADP and diazoxide (160). The 
presence of WT ABCC8 or KCNJ11 allele in heterozygous conditions resulted in 
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partial response to alterations in ATP/ADP ratio suggesting that the dominant 
mutations result in milder phenotype compared to the recessive ones (160). Flanagan 
et al. reported diazoxide unresponsive dominant mutations in ABCC8 either as de 
novo or inherited from one of the parents (161). MacMullen et al. reported 13 missense 
ABCC8 heterozygous mutations associated with diazoxide-unresponsive disease 
(162). Expression of these mutations in COSm6 cells revealed normal trafficking of 
channels but severely impaired responses to MgADP or diazoxide (162).  
3.4.6 CHI due to Gain of Function Mutations in GLUD 1  
Gain of function mutations in GLUD1 causes hyperinsulinism-hyperammonemia 
(HI/HA) syndrome, which is the second most common cause of monogenic CHI after 
KATP channel mutations (127). GLUD1 is mapped to chromosome 10q23.3 and 
encodes a mitochondrial matrix enzyme, glutamate dehydrogenase (GDH). This 
enzyme catalyses the oxidative deamination of glutamate to alpha-ketoglutarate and 
ammonia, resulting in ATP production. GDH is allosterically inhibited by GTP and 
activated by leucine (163). Mutations in GLUD1 reduce the allosteric inhibition of GDH 
by ATP and GTP, resulting in the increase in the enzyme activity. The increased 
enzyme activity in the pancreatic β-cells, causes an increase in the  ATP/ADP ratio 
which consequently activates KATP channels, resulting in cell depolarization and 
insulin release (164). In addition to pancreatic β-cells, GDH is also expressed in other 
organs such as pancreas, liver, brain, kidney, heart and lungs (165). 
The first reports of patients with HI/HA syndrome were identified by Zammarchi et al. 
and Weinzimer et al. in a group of patients who were noted to have an increased GDH 
activity in their lymphoblasts derived from peripheral blood lymphocytes (166, 167). 
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The phenotype of patients with GLUD1 mutations is milder compared to other forms 
of CHI and is characterised by fasting hypoglycaemia and hypoglycaemia following 
protein rich meals (165). The patients also have asymptomatic hyperammonemia. The 
hyperammonemia is mild to moderate and is resistant to  treatment with detoxification 
agents and protein restriction diet (168). A small percentage of patients with GLUD1 
mutations have been reported to have normal serum ammonia level but still 
demonstrate leucine hypersensitivity(165). Using animal models, the source of high 
ammonia production in majority of GLUD1 mutations have been shown to be from 
kidneys due to the increased renal GDH activity (169). 
The patients with HI/HA syndrome have greater incidence of epilepsy when compared 
with the other forms of CHI (165). GLUD 1 mutations occurring in the GTP binding site 
have been found to have increased frequency of epilepsy (165). The reason for the 
increased frequency of neurological complications in these patients in unclear but 
various potential mechanisms such as recurrent hypoglycaemia, chronic elevated high 
ammonia causing brain injury have been suggested (164). The elevated GDH activity 
in the brain reduces the availability of glutamate for the glutamate decarboxylase and 
GABA synthesis, resulting in decreased GABA concentration (170). Although this is 
an interesting potential mechanism, the measurement of GABA and other 
neurotransmitters in the CSF of these patients have been normal (170). 
3.4.7 CHI due to mutations in HADH 
Mutations in HADH are responsible for recessive form of CHI (171). HADH is a 
mitochondrial gene encoding the enzyme 3-hydroxyacyl-coenzyme A dehydrogenase 
that catalyses the penultimate reaction in the beta oxidation of fatty acids and converts 
L3-hydroxyacyl CoAs of variable chain length to their corresponding 3- ketoacyl CoAs 
 
 
 
48 
(172). Although HADH is expressed in many tissues, the highest level of expression 
is found in the islets of Langerhans (172). The patients with HADH mutation are protein 
sensitive. Protein sensitivity had been demonstrated in HADH knock out mice 
(173).These findings suggest that an amino acid triggered pathway of insulin release 
might be a potential underlying cause (174). It is also hypothesised that HADH 
mutations may cause a loss of inhibitory regulation of GDH by HADH and leading to 
increased GDH activity and CHI (173, 175). Most of the reported patients to date are 
from consanguineous families. The biochemistry profile of these patients may show 
an increased level of plasma hydroxyl-butyryl- carnitine and urinary 3-hydroxyglutarate 
levels (174). The patients with HADH mutations are diazoxide responsive and hence 
it is recommended to test for this gene mutation in those diazoxide responsive patients 
from consanguineous families with negative KATP gene mutations (176). 
 
3.4.8 CHI due to Gain of Function Mutations in GCK  
GCK encodes the glycolytic enzyme, glucokinase which acts like a pancreatic β-cell 
sensor and has a key role as a rate limiting enzyme in the metabolism of glucose 
(177). It converts the transported glucose into glucose-6-phosphate. Glucokinase has 
low affinity for glucose, a key property that helps in maintaining the plasma glucose at 
physiological concentrations by governing the glucose stimulated insulin secretion 
(178). 
Activating or gain of function GCK mutations increase the affinity of glucokinase for 
glucose which lowers the threshold for glucose stimulated insulin secretion. The 
increased affinity results in an increased ATP/ADP ration within the pancreatic β-cell, 
causing the closure of KATP channel, depolarization and consequent insulin release 
(178). The phenotype of GCK activating mutations are variable ranging from 
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asymptomatic hypoglycaemia, medically unresponsive CHI and CHI with some 
variable responses to diazoxide (178-180). 
3.4.9 CHI due to Mutations in Transcription Factors-HNF4A and HNF 1A 
HNF4A belongs to the nuclear hormone receptor superfamily and codes for 
hepatocyte nuclear factor 4α. It is a transcription factor that plays an important role in 
regulating the expression of genes involved in glucose stimulated insulin secretion 
(181). While the heterozygous inactivating mutations in HNF4A and HNF1A is 
associated with maturity-onset diabetes of the young (MODY 1 & MODY 3 
respectively), heterozygous mutations in these transcription factor have also been 
implicated in CHI (182). The mechanism of causation of CHI by HNF4A mutation is 
not precisely known. One of the proposed mechanisms is: HNF4A reduces the levels 
of PPARα (peroxisomal proliferator-activated receptor alpha) (181, 183).  The 
transcription factor PPARα is known to control the expression of genes involved in the 
beta oxidation of fatty acids and PPARα null mice develop fasting hypoglycaemia. 
HNF4A, by reducing the levels of PPARα, reduces the beta-oxidation of fatty acids 
(183). This reduction in beta-oxidation of fatty acids results in lipid accumulation in the 
cytoplasm. Malonyl-CoA is one such lipid, the accumulation of which potentially 
inhibits the enzyme carnitine-palmitoyltransferase I which then causes an increase in 
the long-chain-acyl-CoA in the cytoplasm which in turn signals the release of insulin 
(181, 184).  
The other possible mechanism by which HNF4A mutation causes CHI is that it may 
potentially cause a reduction in the expression of Kir 6.2 subunits. HNF4A knockout 
mouse had 60% reduction in the expression of KiR6.2 subunit (181). Patients with 
HNF4A mutations developing CHI are characterised by large birth weight (185, 186). 
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The severity of hyperinsulinism may vary from transient form to persistent form 
requiring diazoxide treatment (187). The mutations in these transcription factors 
(HNF4A and HNF1A) can also affect the function and development of other organs 
and may result in extra pancreatic manifestations (147). Renal fanconi syndrome and 
hepatic glycogen storage disorders have been associated with HNF4A mutation in 
addition to CHI (188). The affected children are at increased risk of developing 
monogenic diabetes, responsive to oral sulfonylureas later in life. The underlying 
mechanisms responsible for the early unregulated excess insulin secretion which later 
switches to a state of insulin deficiency is unclear. 
3.4.10 Exercise-induced Hyperinsulinism(EIHI) 
Exercise-induced hyperinsulinism (EIHI) is inherited in an autosomal dominant fashion 
and is characterised by inappropriate insulin secretion following or during anaerobic 
exercise leading to hypoglycaemia. Heterozygous activating mutations in SLC16A1 
(solute carrier family 16, member 1) encoding monocarboxylate transporter (MCT1) 
have been implicated in EIHI (189-191). Strenuous exercise causes a build-up of 
lactate and pyruvate which under normal physiological conditions, are not transported 
across the pancreatic β-cells since the pyruvate transporter (MCT1) is not expressed 
in β-cells (190). However, a gain of mutation in the promoter region of SLC16A1, 
causes an increased expression of MCT1 in the β-cells, rendering the plasma 
membrane permeable to pyruvate and lactate (190). The increased uptake of lactate 
and pyruvate by the β-cells in these patients during exercise, stimulates the release 
of insulin despite low blood glucose levels. The affected patients do not experience 
fasting hypoglycaemia. Avoidance of strenuous exercise in these patients usually 
prevents the hypoglycaemic episodes. 
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3.4.11 CHI due to Uncoupling Protein 2 (UCP2) Mutations 
UCP2 is implicated to downregulate the insulin secretion from the pancreatic β-cells 
and is expressed in many tissues. UCP2 knock out mice has been shown to develop 
hyperinsulinism (192). UCP2 also has a role in the metabolism of fatty acids and 
protection against oxidative stress. Vozza et al. demonstrated that UCP2 suppresses 
the glucose oxidation and stimulates glutamine oxidation in the mitochondrial matrix 
(193). Dominant loss of function mutation in UCP2 have been reported to cause 
diazoxide responsive CHI, presumably by enhancing the glucose oxidation, facilitating 
pyruvate entry and triggering the insulin release (193). 
3.4.12 CHI due to Mutations in Hexokinase 1(HK1) 
HK1 encodes for the enzyme hexokinase 1 which has high affinity for glucose (low-
Km) and in normal individuals there is a very little or no expression in the pancreatic β-
cells. HK1 is mapped to a region in the chromosome 10q (194). Henquin et al. 
demonstrated the presence of low-Km hexokinase-I in β-cells of hyper functional islets 
in 5 patients with CHI who were negative for KATP channel mutations (195). The 
authors proposed that the inappropriate insulin secretion to hypoglycaemia can be due 
to HK-1 substituting glucokinase for the phosphorylation of glucose (194). Although 
the precise mechanism that allows the expression of HK1 in the β-cells is not known, 
it is hypothesised that a somatic genetic event during the pancreas development could 
have affected the factor or the mechanism responsible for the normal repression of 
HK1 in the β-cells. Mice lacking PKC-λ in their β-cells demonstrated increased 
expression of HK-I and excessive insulin secretion at low glucose levels, which was 
reversed by re-expression of the simultaneously decreased Foxa2, implying that the 
transcription factor Foxa2 has a role in regulating HK1 expression (196). 
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3.4.13 CHI due to Phosphoglucomutase 1(PGM1) Mutations 
Phosphoglucomutase 1 (PGM1) is essential for glycogen degradation as it converts 
glucose-6-phosphate to glucose-1-phosphate. Inactivating mutations in PGM1 have 
been reported in children with abnormal glycosylation and hypoglycaemia (197). The 
phenotype consisted of fasting ketotic hypoglycaemia, postprandial hyperinsulinaemic 
hypoglycaemia, short stature, cleft lip and palate (197). 
 
The various genetic mechanisms controlling the release of insulin from the pancreatic 
β-cell is shown in figure 3.2.  
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Figure 3.2: Role of different genes in enhancing the insulin secretion from pancreatic 
β-cell: Kir6.2 & SUR-1(encoded by KCNJ11 & ABCC8) regulate the KATP channel. 
Mutations in these channels can diminish their opening or cause complete closure 
resulting in constant depolarisation of the cell membrane and constant insulin release 
despite hypoglycaemia. Mutations in genes such as GCK, MCT1, HADH (encoding 
SCHAD), UCP2 cause an increase in the ATP/ADP ratio by different mechanisms 
which causes closure of the KATP channel resulting in membrane depolarisation. 
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3.5 CHI-HISTOLOGICAL SUBTYPES 
The two main types of CHI in relation to the histopathology are diffuse and focal. 
Diffuse form of CHI is characterised by the presence of hyperfunctioning islets that 
secrete excess insulin in the whole of the pancreas (198). The most common genetic 
etiologies for diffuse CHI are mutations in ABCC8 and KCNJ11. Diffuse CHI due to 
the inactivating mutations in ABCC8 or KCNJ11 do not respond to diazoxide (Figure 
3.3). 
Focal form of CHI is characterised by nodular hyperplasia involving small localized 
regions of the pancreas measuring 2-10 mm in diameter. The areas of nodular 
hyperplasia in the islets consist of ductoinsular complexes and giant β-cell nuclei 
surrounded by normal pancreatic tissue (197). The focal disease is sporadic in origin. 
Two independent genetic events contribute to the etiology. The first event involves a 
mutation in paternally inherited ABCC8 or KCNJ11 genes. The second event involves 
a loss of heterozygosity, where there is a somatic loss of the maternal 11p allele 
involving the ABCC8 and KCNJ11 region (11p15.1 to 11p15.5) within the focal 
lesion(199). The resultant uniparental isodisomy causes the paternally inherited 
ABCC8 or KCNJ11 mutation to be fully expressed contributing to increased insulin 
secretion. There is also altered expression of the adjacent Beckwith-Wiedemann 
syndrome(BWS) locus containing imprinted genes-IGF2, H19 and CDKN1C that lead 
to increased proliferation of β-cells evolving into focal adenomatous hyperplasia(200). 
The focal forms of CHI usually do not respond to diazoxide.  
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3.5.1 Differentiation between Diffuse and Focal forms of Hyperinsulinism 
Focal form of CHI is curable by surgery by excising the lesion of adenomatous 
hyperplasia. However, medically unresponsive diffuse form of CHI will require a near 
total pancreatectomy. A non-invasive technique to differentiate between the diffuse 
and the focal lesion was first described by Otonkoski et al in 2006, where the use of 
18F-fluro-L-dihydroxyphenylalanine Positron Emission Tomography (18F-DOPA PET) 
has proved to be beneficial in locating the small focal lesions of adenomatous 
hyperplasia (201). This technique is based on the principle of measuring the DOPA 
decarboxylase activity, which is expressed in islet cells. When the pancreatic islets 
take up L-DOPA, it is converted into dopamine by DOPA decarboxylase (201). The 
diffuse and focal lesions have high DOPA decarboxylase activity. The focal and diffuse 
uptake of DOPA on PET CT scan is depicted in figure 3.3. 
 
Figure 3.3: Focal and Diffuse forms of CHI. A-Focal CHI; B-diffuse CHI [adapted from 
Arya, VB; (2015) Understanding the novel genetic mechanisms of congenital 
hyperinsulinaemic hypoglycaemia. Doctoral thesis, UCL (University College London] 
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3.6 CLINICAL PRESENTATION OF CHI 
Hyperinsulinaemic hypoglycaemia (HH) usually presents during the neonatal period 
and can be severe. The symptoms may be non-specific such as poor feeding, 
jitteriness, lethargy and in severe cases may involve seizures. HH during the neonatal 
period can be transient in infants who had intra uterine growth restriction(IUGR) or 
those who sustained perinatal asphyxia. Transient HH is also observed in babies born 
to diabetic mothers (insulin dependent or gestational). These infants typically have a 
large birth weight.  The transient form of HH can take many weeks and months to 
resolve and may require treatment with diazoxide. 
HH is an associated feature in some of the syndromes such as Kabuki syndrome, 
Soto’s syndrome, Turner syndrome, Beckwith-Wiedemann syndrome(BWS) and also 
in metabolic conditions such as congenital disorder of glycosylation (127). BWS is an 
overgrowth syndrome characterised by prenatal and/or postnatal overgrowth, 
organomegaly, macroglossia, anterior abdominal wall defects, hemihypertrophy, ear 
lobe creases and helical pits (202). BWS is the commonest developmental syndrome 
associated with HH. HH in BWS is usually transient but may require treatment.  
CHI can be a late presenting feature, especially in patients with GLUD1 mutations 
(HI/HA syndrome) as the hypoglycaemia in these patients is not as severe as seen in 
patient with KATP channel mutations. These patients have asymptomatic mild to 
moderate hyperammonaemia and develop symptoms of hypoglycaemia following a 
protein-rich meal (167). In patients with a history of intestinal surgery or bowel 
resection, hyperinsulinaemic hypoglycaemia develops as a part of the dumping 
syndrome. Patients with SLC1A1 mutations develop exercise induced hypoglycaemia 
after 30 minutes of anaerobic exercise (189). 
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3.7 DIAGNOSIS OF CHI 
The early diagnosis of CHI is important in order to reduce or prevent hypoglycaemia 
induced brain injury. Since the symptoms of hypoglycaemia can often be subtle and 
non-specific in the neonatal period, it is important to have a low threshold in order to 
investigate these patients. Persistence of hypoglycaemia despite intravenous glucose 
administration and an intravenous glucose load of >8mg/kg/min (normal range:4-
6mg/kg/min) is highly suggestive of CHI (128). The characteristic plasma biochemistry 
profile in CHI is that of hypoketonaemic, hypofattyacidaemic hypoglycaemia with a 
detectable insulin concentration. The severity of hypoglycaemia has no correlation 
with the level of serum insulin concentration (127). A high c-peptide concentration may 
also help to establish the diagnosis. Other investigations that can support the 
diagnosis of CHI include an elevation of blood glucose concentration>1.5mmol/L 
following an intramuscular/intravenous dose of glucagon (127). A positive glycaemic 
response to subcutaneous dose of octreotide with decreased plasma concentration of 
insulin-like growth factor-binding protein 1(IGFBP-1) may also aid diagnosis in some 
cases as the high concentration of circulating insulin suppresses the transcription of 
IGFBP-1 gene (203-205). 
Elevated plasma ammonia concentration in a patient with hyperinsulinism may 
suggest the possibility of HI/HA syndrome. However, some patients with HI/HA 
syndrome can have normal plasma ammonia concentration (164). Provocative testing 
using a protein/leucine load may be helpful to establish a diagnosis in patients with 
suspected HI/HA syndrome (164). 
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Elevated plasma hydroxybutyrylcarnitine and urinary 3-hydroxyglutarate in a patient 
with CHI may be suggestive of HADH deficiency (173). Patients with exercise induced 
hyperinsulinism will require a formal exercise or a pyruvate loading test to demonstrate 
hypoglycaemia. 
3.8 MEDICAL MANAGEMENT OF CHI 
The aim of treatment is to achieve and sustain normoglycaemia (blood glucose level 
of 3.5-6mmol/L). In neonates with CHI, a central venous access is often required to 
deliver a high concentration of intravenous glucose infusion. It is important to maintain 
orality with some oral feeds(alone or in combination with glucose polymer-Maxijul or 
Polycal) to avoid a disturbed feeding pattern that may develop as feed aversion in 
these babies (128). 
 
3.8.1 Glucagon 
Infants with CHI can have extremely difficult venous access. In such situations, 
administration of intramuscular glucagon(0.5-1mg) can be a temporary measure to 
improve the blood glucose levels. This is followed by intravenous glucose infusion to 
prevent rebound hypoglycaemia. During the acute management of CHI, glucagon can 
be given either intravenously or by subcutaneous infusion to improve the blood 
glucose levels. Glucagon acts by promoting glycogenolysis and gluconeogenesis. It 
also has effect on ketogenesis and lipolysis.  
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3.8.2 Diazoxide 
Diazoxide is the mainstay of medical treatment in hyperinsulinism and is usually 
effective in all forms of CHI except those caused by inactivating mutations in ABCC8 
and KCNJ11 (129). Patients with activating mutations in GCK demonstrate a variable 
response to diazoxide (180). Patients with focal forms of hyperinsulinism do not 
generally respond to diazoxide treatment. Diazoxide is a KATP channel agonist that 
binds and opens the intact KATP channels and reduces the insulin secretion. It is 
administered orally (5-15mg/kg/day) and the responsiveness is noted by 
normoglycaemia, age appropriate fasting tolerance with undetectable insulin at the 
end of the fast and feeding with normal volume and frequency (129). The main side 
effects are that of hypertrichosis and fluid retention, especially in the newborns. The 
use of diazoxide in conjunction with thiazide diuretic chlorothiazide (5-10mg/kg/day) 
reduces the side effect of fluid retention. The other side effects include leukopenia, 
hyperuricaemia, tachycardia and feeding problems. 
Genetic analysis on patients who do not respond to the maximum dose of diazoxide, 
helps in the identification of those who may need 18F-DOPA-PET CT scan to search 
for a focal lesion. Patients with paternally inherited mutation in ABCC8 and KCNJ11 
(or those with no mutations in these genes) potentially have focal disease (206).  
Patients with homozygous or compound heterozygous mutations in ABCC8 and 
KCNJ11 will have a diffuse disease and will need alternative treatment options (206).  
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3.8.3 Octreotide 
Octreotide is a somatostatin that is used as a second line medical therapy in the 
management of CHI. It acts by activating the somatostatin receptor-2 and -5 and also 
by restricting the movement of calcium in the pancreatic β-cells. It is administered as 
a subcutaneous injection every 6-8 hours(5-30µg/kg/day). The use of octreotide is 
associated with tachyphylaxis requiring higher doses(desensitisation occurring after 
2-3 doses) (207). Octreotide is used cautiously in neonates as life threatening 
necrotising enterocolitis can occur as an adverse side effect (208). 
3.8.4 Newer Medical Therapies for CHI 
The long acting somatostatin preparation, lanreotide has been reported to be 
successful in patients with CHI (209). Lanreotide is given subcutaneously as once 
monthly injection (210).  
Exendin-(9-39) is a GLP-1 receptor(glucagon like peptide-1) anatagonist and has 
been shown to treat hypoglycaemia and improve the fasting glucose in mouse model 
of KATP HI(SUR-1
-/-) when administered by chronic subcutaneous infusion(211). In a 
randomized, open-labelled pilot study involving human subjects, it was demonstrated 
that administration of exendin-(9-39) resulted in significantly higher blood glucose 
nadir levels when compared to placebo (212). 
Recently, the use of immunosuppressive mammalian target of rapamycin 
inhibitor(mTOR), sirolimus, in four consecutive infants with diazoxide unresponsive HI 
resulted in improved glycaemia (213). However, long-term safety of sirolimus, in young 
infants with CHI, is not fully established.  
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3.9 SURGICAL MANAGEMENT OF CHI 
The indications for surgery in patients with CHI include severe form of diffuse CHI 
unresponsive to medical therapy and those with focal disease. The patients with 
diffuse disease require near total pancreatectomy (214). This is associated with post-
operative complications such as persisting hypoglycaemia requiring additional 
feeding, diazoxide or octreotide, high incidence of diabetes mellitus and exocrine 
pancreatic insufficiency. For the focal disease, localisation of the focal lesion by 18F-
DOPA-PET/CT helps in excision of the focal adenomatous lesion (214, 215). The 
newer approach of laparoscopic pancreatectomy is associated with lesser 
complications and a faster recovery than open laparotomy (216). 
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3.10 AIMS OF THE PROJECT 
Mutations in transcription factors such as HESX1, PROP1, POU1F1, LHX3, LHX4, 
PITX1, PITX2, OTX2, SOX2 and SOX3 have been associated with congenital 
hypopituitarism in mouse and humans. However, these mutations account only for a 
small proportion with the majority of patients having an unknown genetic cause for 
their condition.  
Mutations in genes ABCC8, KCNJ11, GLUD1, GCK, HADH, UCP2, HNF4A, HNF1A, 
MCT1, HK1 and PGM1 have been associated with genetic forms of CHI. However, 
the genetic cause for many CHI patients (nearly 50%) remains elusive (217).  
The aims of this project were: 
1. To recruit patients with complex phenotypes such as congenital 
hypopituitarism, congenital hyperinsulinism and severe short stature with or 
without dysmorphism with no identified genetic etiology for detailed clinical and 
biochemical phenotyping. 
2. To study these patients with whole-exome sequencing to identify potential 
novel genetic etiology and/or novel genetic pathways underlying their condition 
based on the available biological information. 
3. To functionally characterize the identified mutation by appropriate laboratory 
techniques. 
 
 
 
 
 
 
63 
3.11 PATIENT RECRUITMENT 
A cohort of 6 patients from 6 families were recruited into this project over a period of 
two years. All these patients were managed at Alder Hey Children’s NHS Foundation 
Trust, Liverpool. Personal data (name, date of birth, gender and ethnic background) 
and detailed phenotypic and laboratory data were collected on these patients. The 
patients were identified by experienced Consultant Endocrinologists as likely to have 
a high chance of an underlying monogenic etiology for their endocrine problems. The 
recruitment of the patients and their families into the study and obtainment of informed 
and written consents were done by me. All the six recruited patients had microarray to 
look for copy number changes. Trio sequencing was performed on the affected patient 
along with both the biological parents where possible. In one of the patients (proband 
D), where it was not possible to obtain DNA sample from the biological father, 
sequencing was performed on the patient and the biological mother. Two of the six 
patients had CHI (proband A and proband C) and had molecular genetic testing done 
for genetic mutations in known CHI genes: KCNJ11, ABCC8, GLUD1, GCK, HADH, 
HNF4A, INSR, SLC16A1, TRMT10A and HNF1A at University of Exeter Medical 
School, Exeter and were negative for mutations in these genes associated with the 
clinical phenotype. The flowchart for patient recruitment is shown below in the figure 
5.1. The summary of the clinical phenotypes of the recruited patients is shown in the 
table 5.1. 
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3.12 ETHICS 
The study was given favourable ethical opinion by the North West - Liverpool Central 
Research Ethics Committee (REC Reference: 15/NW/0758) and site study approval 
was granted by the Clinical Research Business Unit at Alder Hey Children’s NHS 
Foundation Trust, Liverpool, UK.  
 
 
 
 
 
Figure 3.4: Flowchart of Patient Recruitment 
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Table 3.1: Summary of the Recruited Patient Phenotypes 
 
 
PROBANDS PHENOTYPES 
A Persistent mutation negative congenital hyperinsulinism, hypopituitarism with 
GH,ACTH,TSH deficiency, coloboma, pulmonary stenosis and developmental delay 
B Primary IGF1 deficiency, craniosynostosis 
severe short stature, dysmorphic features, complex learning problems 
C Persistent mutation negative congenital hyperinsulinism 
D Severe short stature, recurrent hypoglycaemia ,congenital Deafness, posterior Cloaca, 
growth Hormone deficiency, cardiac defects, facial dysmorphism, hypermobile joints 
E Severe short stature, low IGF1 
F Persistent Hypercalcemia, high PTH(mutations negative for FHH and primary 
hyperparathyroidism), glomerulonephritis 
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CHAPTER 4 
 
 
 
  GENERAL METHODS 
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4.1 SUMMARY OF CHAPTER 4 
In chapter 4, various techniques used in the general methodology for this project such 
as DNA extraction and quantification, whole-exome sequencing, bioinformatics 
pipeline, and variant filtering are discussed. The DNA extraction was performed by me 
at the institute of child health laboratory in Liverpool. Whole exome sequencing and 
bioinformatics were performed at the Centre for Genomic Research, University of 
Liverpool. Analysis of the VCF (variant calling files) data, variant filtering and 
segregation of the likely pathogenic variants were performed by me by using the 
ingenuity variant analysis software (QIAGEN Bioinformatics). 
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4.2 GENOMIC DNA EXTRACTION FROM BLOOD 
 
DNA was obtained from blood samples of the child and both the biological parents 
(trio) using the QIAmp DNA blood Midi Kit (Qiagen, Hilden, Germany) as per the 
manufacturer’s instructions.  
The steps are described briefly: 
1. One ml of whole blood was added to 100µl of QIAGEN protease (proteinase K) 
and 1.2ml of Buffer AL (Lysis buffer).  
2. The mixture was mixed thoroughly to yield a homogenous solution and 
incubated at 70 degrees Celsius for 10 minutes.  
3. After 10 minutes of incubation, 1ml of 96-100% ethanol was added to the 
sample and mixed thoroughly to yield a homogeneous solution.  
4. This solution was transferred to QIAmp Midi column and centrifuged at 3000 
rpm for 3 minutes.  
5. The filtrate was discarded and 2 ml of Buffer AW1(wash buffer 1) was added to 
the QIAmp Midi column and centrifuged at 5000 rpm for 1 minute followed by 
the addition of 2 ml Buffer AW2(wash buffer 2) and centrifuging the mixture at 
5000 rpm for 15 minutes.  
6. After discarding the filtrate, the purified genomic DNA was eluted from the 
QIAmp midi spin column and 200 µl of Buffer AE (elution buffer) was added and 
centrifuged for 2 minutes at 8000 rpm. The extracted DNA was stored in Buffer 
AE at -30 degrees Celsius for long term use. 
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4.2.1 Quantification of DNA 
The quantity of the DNA was estimated by using NanoDrop Nucleic Acid Quantification 
method (Thermo Fisher Scientific). The NanoDrop instruments utilize a patented 
sample retention system that allows the quantification of nucleic acids from 1–2µL 
samples.  
Using the ‘NanoDrop’ 2000c Spectrophotometer, the DNA concentration was 
measured as follows:  
1. The NanoDrop sensor was blanked by using blanking solution-distilled water, 
1.5 µL and a routine wavelength verification check was completed with the help 
of the inbuilt computer software.  
2. Following this, 1.5 µL of the DNA sample was added onto the NanoDrop sensor 
and the concentration was analysed using the software.  
3. The 260/280 calculation ratio gives a measurement of output of wavelength vs 
absorbance. A ratio of >1.8 was generally accepted as pure for DNA. The DNA 
concentration was measured as ng/ µL. 
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4.2.2 DNA Quality Control: Bioanalyzer or Fragment analyzer  
Principle of Fragment Analyzer 
Further quality control of the extracted DNA was performed using the Fragment 
Analyzer™ system. The instrument consists of a multiplex of capillary electrophoresis 
and is used to perform high throughput, automated separation and quantification of 
nucleic acids. The separation of DNA is through the application of an electric field 
through an array of fused silica capillaries filled with conductive gel. With the 
application of high voltage, the DNA molecules migrates through the gel in relation to 
their length or size, with the smaller fragments migrating faster than the larger 
fragments (Figure 4.1). When the nucleic acid molecules migrate and reach the end 
of the capillary, detection is facilitated by fluorescence of a sensitive dye present in 
the gel matrix. The fluorescence can be monitored using the relative fluorescence unit 
(RFU) intensity as a function of time during the capillary electrophoresis separation. 
This information can be used to produce digital electropherogram traces 
representative of the DNA content of the entire samples (Figure 4.2). 
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Figure 4.1: Gel image of the DNA samples representing the relative sizes of the DNA 
molecules against the standard ladder 
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Figure 4.2: Electropherogram Traces showing the relative fluorescence unit of 
various genomic DNA samples(peaks) indicating the integrity of the samples 
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4.3 WHOLE EXOME SEQUENCING 
4.3.1 Workflow for Exome Sequencing 
The basic steps for exome sequencing include the following: 
1 Sample preparation 
2. Hybridization and capture 
3. Indexing and processing for multiplexed sequencing 
4. Sequencing 
4.3.1.1 Sample Preparation 
Samples were sheared with the Picoruptor to a size of approximately 150-200 bp and 
the samples were cleaned with 1.8x AMPure beads (Agencourt). The target size of 
the DNA fragments (150-200 bp) was confirmed using the 2100 Bioanalyzer. The ends 
of the sheared DNA were repaired with T4 DNA Polymerase and Klenow enzyme and 
further purified by using AMPure XP beads (Figure 4.3). This was followed by addition 
of ‘A’ bases to the 3´ ends of the DNA fragments and purified again by AMPure XP 
beads. The DNA fragments with 3´ overhanging ‘A’ bases were ligated by using 
T4DNA ligase buffer and SureSelect Adaptor Oligo Mix. The sample was further 
purified using AMPure XP beads. The adaptor-ligated library was amplified by 5 
rounds of PCR using Herculase II fusion DNA polymerase and again purified with 
AMPure XP beads. The libraries were checked on an Agilent HS 2100 Bioanalyser 
chip for fragment size peak of approximately 225 to 275 bp and quantified by Qubit 
assay. 750 ng of pre-capture library in a volume of 3.4µL (initial concentration of 221 
ng/ µL was used for the hybridization reaction.  
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Figure 4.3: Sample preparation for Exome sequencing showing genomic DNA 
shearing, end repair of DNA fragments, addition of 3’ A overhangs, adapter ligation 
and PCR amplification [adapted from Arya, VB; (2015) Understanding the novel 
genetic mechanisms of congenital hyperinsulinaemic hypoglycaemia. Doctoral thesis, 
UCL (University College London]. 
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4.3.1.2 Hybridization 
The pre-capture libraries (genomic DNA) obtained in the previous step were then 
mixed with SureSelect hybridisation mix (Biotinylated RNA Library Baits) along with 
hybridization buffers and incubated for 24 hours at 65°C. RNA Baits will hybridize with 
the complementary DNA fragments present in the genomic DNA sample. 
 
Following this, the samples (hybridized DNA) were mixed with washed streptavidin 
beads (Dynabeads MyOne Streptavidin T10). Streptavidin has an extraordinarily high 
affinity for biotin. The captured products were washed according to the protocol 
attached to the beads and the RNA is digested. (Figure 4.4) 
 
4.3.1.3 Indexing and Sample Processing for Multiplexed Sequencing 
The SureSelect-enriched captured DNA libraries from the previous step are PCR 
amplified in 10 cycles of PCR reactions with 8 bp indexing primers (forward and 
reverse) using Herculase II fusion DNA polymerase with Herculase II reaction buffer. 
The amplified post-capture libraries were purified using AMPure XP beads. The 
quantity and quality of the post-capture indexed libraries were assessed by Agilent 
2100 Bioanalyzer for the peak DNA fragment size positioned between 250 and 350 
bp. Following this, the quantity of each index-tagged library was assessed by qPCR 
using the Agilent QPCR NGS library quantification kit from Kapa on a Roche Light 
Cycler LC480II according to manufacturer's instructions. The template DNA was 
denatured according to the protocol described in the Illumina cBot User guide and 
loaded at 300 pM concentrations.  
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4.3.1.4 Sequencing 
The sequencing was carried out on one lane of an Illumina HiSeq4000 at 2x150 bp 
paired-end sequencing with v1 chemistry. The read files (Fastq) were generated from 
the sequencing platform via the manufacturer’s proprietary software. 
 
 
Figure 4.4: Target enrichment using SureSelect [adapted from Agilent SureSelectXT 
Target enrichment for Illumina user guide] 
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4.4 BIOINFORMATICS 
The bioinformatics pipeline briefly consists of the following steps: 
1. Processing and quality assessment of the sequence data 
2. Alignment of reads to the reference sequence 
3. Variant detection 
 
4.4.1 Processing and Quality Assessment of Sequence Data 
Initial processing and quality assessment of the sequence data was performed using 
an in-house pipeline (developed by Dr Richard Gregory). Briefly, basecalling and de-
multiplexing of indexed reads was performed by CASAVA version 1.8.2 (Illumina) to 
produce samples in FASTQ format. The raw FASTQ files were trimmed to remove 
Illumina adapter sequences using Cutadapt version 1.2.1. The reads were further 
trimmed to remove low quality bases, with a minimum window quality score of 20. 
The raw trimmed sequence data are shown in table 4.1. The reads shorter than 10 
bp were removed. The forward reads are indicated as R1, the reverse reads as R2 
and the unpaired reads as R0. Table 4.2 summarises the read counts before and 
after adapter and quality trimming. Figure 4.5 shows the read length distributions 
after adapter and quality trimming. Note that R0 (unpaired) reads are trimmed more 
than paired reads as they more often represent poor quality sequence. Later 
analysis uses only R1 and R2 reads, which show a very little adapter/quality 
trimming. 
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 All trimmed read data, as well as detailed statistics on the read trimming are 
available from the following URLs: 
http://cgr.liv.ac.uk/illum/LIMS9132_80e653e1bc84f8a9 
http://www.cgr.liv.ac.uk/illum/LIMS10697Results_8399f2b3f8c45af5/	
 
 
Table 4.1:  Summary of raw and trimmed sequence data of DNA samples  
                    
 
 
 
 
 
 
Figure 4.5: Read length distributions of samples after adapter and quality trimming 
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4.4.2 Alignment of Reads to the Reference Genome 
 
R1/R2 read pairs were aligned to the human genome reference with decoy sequences 
(ftp.broadinstitute.org/bundle/2.8/b37/human_g1k_v37_decoy.fasta). This comprises 
the GRCh37 primary assembly (chromosomal plus unlocalised and unplaced contigs), 
the rCRS mitochondrial sequence (AC:NC_012920), Human herpesvirus 4 type 
1(AC:NC_007605) and the concatenated decoy sequences. Reads were mapped to 
the reference sequences using BWA mem version 0.7.5a (218) with default 
parameters. To retain only confidently aligned reads, alignments were filtered to 
remove reads with a mapping quality lower than 10, which equates to a 10% chance 
that the read was derived from another genomic location. Misalignment caused by 
small insertions / deletions (indels) can lead to false SNP calls. To avoid this, the 
mapped reads were locally re-aligned to improve the alignments around small 
insertions/deletions (indels) using the Genome Analysis Tool Kit (GATK) version 
2.1.13 (219, 220). Duplicate reads arising from PCR amplification can bias variant 
calling. To avoid this, read duplicates were identified and filtered to retain only a single 
representative, using the Picard “MarkDuplicates” tool, version 1.85 
(http://picard.sourceforge.net/) 
The quality scores assigned to the individual base calls in each sequence read 
influence the variant calling algorithms. The scores represent the per-base estimates 
of error emitted by the sequencing machines which are subject to various sources of 
systematic technical error, leading to over- or under-estimated base quality scores in 
the data (https://gatkforums.broadinstitute.org/gatk/categories/methods). Hence, base 
quality score recalibration (BQSR) was applied for all the alignment files. BQSR is a 
module of GATK that applies machine learning to model these errors empirically and 
adjust the quality scores accordingly. BQSR firstly builds a model of covariation based 
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on the data and a set of known variants (i.e. dbSNP), then it adjusts the base quality 
scores in the data based on the model. This will create more accurate base qualities, 
which in turn improves the accuracy of our variant calls. 
 
 
 
 
Table 4.2: Summary of sequence alignments (before and after filtering to remove 
reads with low mapping quality and redundant duplicate reads) for various DNA 
samples with mean depth of coverage 
 
 
 
 
 
 
1Sum of all R1 and R2 reads used in the alignment 
2Reads that align to the reference genome, before removing low mapping quality reads and 
redundant duplicate reads (% of all reads used in alignment) 
3The size of the total capture regions is 50,390,601bp 
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4.4.3 Variant detection  
Variant detection was performed using the GATK package. Single nucleotide 
polymorphisms (SNPs) and small insertions/deletions (INDELs) were identified in the 
same analysis step. In order to carry out the variants recalibration, which assigns a 
well-calibrated probability to each variant call in a call set, the VQSR (Variant Quality 
Recalibration Score) module in GATK was calibrated by combining the variants found 
in a random selection of 22 samples from the 1000 genome UK cohort along with the 
variants from the 8 samples in this project. Variants were outputted, and annotated 
using SnpEff version 3.2a (221). Finally, the phaseByTransmission module in GATK 
package was used for the trio analyses for the samples from the same family.  
 
 
4.4.4 Identifying Causal Alleles 
 
Whole exome sequencing on an average identifies ~24,000 single nucleotide variants 
(SNVs) in African American samples and ~20,000 in European American samples, 
among which 95% are known polymorphisms in human population(3). One of the main 
challenges in whole exome sequencing is the narrowing down and filtering of disease-
related alleles from a huge background of polymorphisms that are non-pathogenic and 
errors related to sequencing. 
 
The strategies for filtering the exome sequencing data and narrowing down to identify 
the alleles segregating with the phenotype depend on a number of factors such as the 
mode of inheritance of a trait; the pedigree or population structure; whether a 
phenotype arises owing to de novo or inherited variants; and the extent of locus 
heterogeneity for a trait(3). 
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4.5 APPROACHES TOWARDS IDENTIFYING CAUSAL ALLELES  
4.5.1 Discrete Filtering: 
The variants are filtered against polymorphisms available in publicly available 
databases such as dbSNP, 1000 Genomes Project, Exome Aggregation 
Consortium(ExAC) and those found in unaffected individuals such as unaffected 
biological parents or siblings. By this approach the non-causative polymorphisms are 
eliminated and the novel candidate genes are filtered. This is especially important 
because the number of candidate genes are drastically reduced because only a small 
fraction ( 2% on average) of the single nucleotide variants (SNVs) identified in an 
individual by exome sequencing are novel(3). The assumption in this approach that 
the filter set may not contain alleles from individuals with the phenotype can be 
problematic for two reasons. First, dbSNP is ‘contaminated’ with a small but 
appreciable number of pathogenic alleles (3). Second, as the number of sequenced 
exomes and genomes increases, the filtering of observed alleles in dbSNP should 
take into account the minor allele frequency (MAF) as otherwise truly pathogenic 
alleles that are segregating in the general population at low but appreciable 
frequencies will be eliminated (3). This risk is especially relevant for recessive 
disorders, in which carrier status (heterozygous) will not result in a phenotype but will 
be present in the control population at a low frequency. Analysis of recessive disorders 
in which the maximum MAF is set at 1% is still well powered(3). 
 
A lower MAF cut-off of 0.1% is helpful for dominant disorders, as the estimated 
prevalence of the disorder (generally well below 0.1%) provides an upper bound on 
the MAF(3). Additionally, the greater the number of novel variants with lower MAFs 
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that are present in a sample population, the more difficult it will be to home in on the 
causal gene (or genes) (6).  
4.5.2 Stratifying the Candidate Genes After Discrete Filtering 
1. After filtering for polymorphisms against the public databases mentioned 
above, further stratification was done based on the predicted impact on the 
protein function. Frameshift mutations, nonsense mutations and splice-site 
mutations which disrupt the canonical splice sites are more likely to be causal 
as compared to missense variants. 
2. The stratification was further performed based on the available biological or 
functional information about a gene. This involves alleles with an existing or 
predicted role in a biological pathway or interacting with genes known to cause 
the phenotype.  
3. Assessing evolutionary conservation among different species was also used to 
stratify the candidate genes. The mutations occurring in the sequences or 
amino acid residues that show high conservation among different species are 
likely to be pathogenic. 
4. In silico tools such as SIFT, PolyPhen and Mutation Taster were used to further 
stratify the pathogenicity of the non-synonymous alleles. 
 
4.5.3 In Silico Tools: SIFT and PolyPhen 
Sorting intolerant from tolerant (SIFT) and polymorphism phenotyping (PolyPhen) are 
freely available as Web-based servers(222-224). SIFT and PolyPhen predict if the 
missense mutation is likely to be deleterious to the protein function by the use of 
sequence homology of related proteins and the degree of conservation of the affected 
base throughout evolution. PolyPhen uses annotated UniProt entries to predict 
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whether the amino acid substitution occurs within an important structural or functional 
site of the protein, for example, active or binding sites, and residues involved in 
disulphide bond formation(223). The predictive value of PolyPhen will therefore be 
reliant on the protein of interest having (i) a known, annotated crystal structure or (ii) 
the presence of a modelled protein of sufficient similarity in the UniProt database(225). 
 
4.5.4 Pedigree Information 
 
For Mendelian phenotypes, the pedigree information can be used to substantially 
narrow the genomic search space for candidate causal alleles. For identifying de 
novo coding mutations, an approach that involves sequencing of parent-child 
trios(Figure 4.6) is extremely efficient as it is highly unlikely that the proband will 
have multiple de novo events occurring within a specific gene (or within a gene 
family or pathway) (226, 227).  
 
Figure 4.6: Parent-child trios for identifying de novo mutations 
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4.5.5 Technical and Analytical Limitations of Exome Sequencing:  
 
Discrete filtering of the variants obtained from exome sequencing has been very 
successful in the identification of a novel disease gene(228-231). However, there are 
associated technical and analytical limitations that might hamper the process. This 
might either be due to inadequate capture of the exome which may contain part or all 
of the causative gene or inadequate depth of sequencing of the region that contains a 
causal variant (for example, because of poor capture or poor sequencing) (6). 
It is also possible that due to the presence of small and complex indels, the causal 
variant may have been covered but not called(3). Genetic heterogeneity limits the 
power of discrete filtering. For example, if the disease is caused by mutations in a 
number of different genes (genetic heterogeneity), more than one gene in the sample 
population will have disease causing alleles (3).  
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CHAPTER 5 
 
 
 
 
CLINICAL PHENOTYPE AND WHOLE 
EXOME SEQUENCING RESULTS  
(FAMILY A)  
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5.1 SUMMARY OF CHAPTER 5 
Chapter 5 begins with the introduction of family A with a detailed description of the 
clinical phenotype and the whole exome sequencing results of proband A. 
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5.2 CLINICAL INFORMATION (PROBAND A) 
A 5-year-old girl (Proband A), was born to non-consanguineous Caucasian British 
parents at 42 weeks’ gestation with a birth weight of 4.185 Kg (+1.72 SDS). The 
pregnancy was normal and the 20-week antenatal scan showed polyhydramnios. The 
delivery was complicated by shoulder dystocia, needing resuscitation.  
She was found to be persistently hypoglycaemic (glucose<2.6mmol/L) requiring a total 
glucose load of 25 mg/kg/min (normal: 4-6 mg/kg/min) to maintain normoglycaemia 
(plasma glucose>3.5mmol/L). She had low free thyroxine (FT4) (5.3 pmol/L) and 
suppressed thyroid-stimulating hormone (TSH) (<0.03 mu/L) that persisted even after 
the phase of acute severe illness. She also had an undetectable adrenocorticotropic 
hormone (ACTH) (<1.1 pmol/L) with no cortisol response to synacthen stimulation 
(peak cortisol to synacthen <50 nmol/L). Hydrocortisone replacement was 
commenced followed by levothyroxine therapy.  
The MRI scan of the brain showed a hypoplastic anterior pituitary, absent posterior 
pituitary, interrupted pituitary stalk and a thin corpus callosum (Figure 5.2). The 
hypoglycaemia screen showed an inappropriately high plasma insulin (200 pmol/L) 
and c-peptide (1500 pmol/L) with suppressed plasma free fatty acid (<100 µmol/L) and 
beta hydroxyl butyrate (<100 µmol/L) during hypoglycaemia (plasma blood glucose: 
1.2mmol/L) confirming the diagnosis of CHI.  
A trial of diazoxide (5 mg/kg/day) with chlorothiazide resulted in a significant fluid 
retention. Commencement of octreotide (10 mcg/kg/day) caused a derangement of 
liver enzymes and therefore had to be discontinued after which the liver enzymes 
returned to normal plasma levels. She developed a significant feed intolerance due to 
severe gastroesophageal reflux which persisted despite maximum medical treatment. 
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A gastro-jejonostomy tube was inserted to support feeding. Normoglycaemia was 
maintained by continuous feed via the gastro-jejonostomy tube. Genetic analysis 
performed at the University of Exeter Medical School, Exeter was negative for ABCC8, 
KCNJ11, HNF4A and GCK mutations. The 18F-DOPA PET-CT scan of the pancreas 
suggested a diffuse pancreatic lesion.  
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Figure 5.1: Sagittal view of the MRI scan of the brain: The normal pituitary gland 
cannot be identified, the sella turcica is shallow and poorly defined with possibly a very 
hypoplastic anterior pituitary gland (arrowhead) Also, there is no evidence of the 
normal high signal of the posterior pituitary. There is a very short and thin pituitary 
stalk in its superior third (arrow) which is suggestive of an interrupted pituitary stalk. 
The corpus callosum is also noted to be thin (arrowhead) 
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The facial dysmorphic features comprise of a single median maxillary central (SMMC) 
incisor, congenital nasal pyriform aperture stenosis (CNPAS), which was 
conservatively managed, and a left choroidal coloboma. She does not have any vision 
abnormalities. The cardiac echocardiogram revealed pulmonary stenosis which 
required balloon dilatation. She had a persistent oxygen requirement of unknown 
etiology (negative for respiratory infections, normal chest imaging and bronchoscopy) 
from birth, which gradually resolved at 5 months of age.  
At 1.5 years of age she was diagnosed with growth hormone (GH) deficiency (height<3 
SDS, IGF1<3.3 nmol/L and a peak GH of 1.1 µg/L (normal>7 µg/L) to arginine 
stimulation) and was commenced on rGH (recombinant GH) therapy. She 
demonstrated a good response to treatment with rGH (25 mcg/kg/day) with an 
improvement in the height velocity (Figure 5.3). She developed persistently elevated 
liver transaminases when she was 3 years old, with a negative autoimmune hepatitis 
and infection screen. The liver biopsy showed dense chronic inflammation with portal-
portal bridging fibrosis. The clinical features are summarised in the table 5.2. 
She is currently 5 years old, with persistent CHI, motor, speech and developmental 
delay and continues to be on rGH, levothyroxine and hydrocortisone replacements. 
She has shown response to the reintroduction of diazoxide (5 mg/kg/day) without any 
features of fluid retention, which has enabled her to come off her continuous feeds for 
6 hours.  
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Figure 5.2: The patient’s linear growth curve compared with British contemporary 
references. Recombinant growth hormone (25 mcg/kg/day) was started at 1.5 years 
of age when the linear height was -3SDS. A good response to the GH treatment was 
seen subsequently with an improvement in the height SDS 
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Table 5.1: Summary of clinical features (proband A): 
 
 
Face Single median maxillary central incisor, congenital nasal 
pyriform aperture stenosis 
 
Eye Left choroidal coloboma 
 
Heart Supra-valvular pulmonary stenosis  
 
Gastrointestinal Feed intolerance, severe gastro-esophageal reflux disease 
requiring gastro-jejonostomy feeding 
 
Liver Mild portal-portal bridging fibrosis, elevated transaminases 
 
Lung Persistent oxygen requirement of unknown aetiology 
 
Pancreas Persistent form of hyperinsulinism 
 
Pituitary Hypopituitarism 
 
Neuro-developmental Speech and motor developmental delay 
 
 
 
Figure 5.3: Pedigree of Family A 
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5.3 WHOLE EXOME SEQUENCING RESULTS (FAMILY A) 
 
In this family, whole-exome sequencing was performed on the both the 
parents(unaffected) and the affected child. Assuming a de novo inheritance pattern, 
filters were applied to whole-exome data as shown in the figure 5.5. The potential 
candidate variants are listed in the table 5.3. 
 
Figure 5.4 
 
De Novo Variant Analysis of Proband A (* Novel variants include variants present in 
at least 5% minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP 
exomes excluded; ** Predicted deleterious variants included nonsynonymous coding, 
splice site, frameshift, stop gain variants; *** Variants present in heterozygous state in 
the child and not present in both the parents; ****Variants with biological role related 
to the clinical phenotype of hyperinsulinaemic hypoglycaemia and hypopituitarism) 
 
 
 
 
63426 • Total	variants	in	3	family	members
3718 • Novel	variants*
410 • Predicted	deleterious**
32 • Genetic	analysis***
10 • Biological	context****
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Table 5.2: List of de novo candidate gene variants and their locations in family A  
 
 
Chromosome Gene Gene region Protein variant 
2 ALK Exonic p.G924G 
    
2 PEL1 Exonic p.A68fs*10 
    
7 HIP1 Splice site  
    
10 CHST15 Exonic p.R456fs*50 
    
12 DUSP16 Exonic p.C136* 
    
12 CCNT1 Splice site  
    
16 KAT8 Exonic p.R448fs*9 
    
17 FMNL1 Exonic p.P549L 
    
20 FOXA2 Exonic p.S169P 
 
 
 
 
A brief description on the biological function of the above genes is given below. The 
biological information on the genes were obtained from databases such as Uniprot 
and genecards. 
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ALK (ALK Receptor Tyrosine Kinase) 
 
ALK is involved in the development of specific neurons in the nervous system and 
ALK gene mutations are associated with anaplastic large cell lymphomas, 
neuroblastoma, and non-small cell lung cancer (232) 
 
PEL1 (Phosphatidylglycerophosphate Synthase 1) 
 
This gene catalyzes the synthesis of Phosphatidylglycerophosphate from CDP-
diacylglycerol and glycerol 3-phosphate and functions as the committed and rate-
limiting step in the biosynthesis of cardiolipin (233). 
 
CHST15 (Carbohydrate Sulfotransferase 15) 
 
The protein coded by this gene forms an important structural component of the 
extracellular matrix and which links to proteins to form proteoglycans (234). 
 
DUSP16 (Dual Specificity Phosphatase 16) 
 
This gene encodes a mitogen-activated protein kinase phosphatase. By using 
Northern blot analysis of mouse tissues, an abundant expression of this protein was 
found in in brain, kidney, intestine, and testis, and lower expression in thymus, 
spleen, and bone marrow (235).  
 
CCNT1(Cyclin T1)  
 
The protein encoded by this gene associates with cyclin-dependent kinase 9, and acts 
as a cofactor of human immunodeficiency virus type 1 (HIV-1) Tat protein, necessary 
for full activation of viral transcription (236). 
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KAT8 (Lysine Acetyltransferase 8) 
 
This gene encodes a member of the MYST histone acetylase protein family which may 
be involved in transcriptional activation(237). 
 
FMNL1 (Formin Like 1) 
 
Formin-related proteins have been implicated in morphogenesis, cytokinesis, and 
cell polarity (238). 
 
FOXA2(Forkhead Box A2) 
 
FOXA2 is a transcription factor with a critical role in early embryogenesis of various 
organs including central nervous system (238). Tissue specific deletion of Foxa2 
from the mice pancreatic β-cells leads to the development of CHI (249). 
 
As FOXA2 segregates with the clinical phenotype of proband A, this gene and the 
mutation (p.S169P) have been explored in detail in chapter 6. 
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CHAPTER 6 
 
 
 
 
 
FOXA2 (FORKHEAD BOX A2): 
DESCRIPTION OF THE GENE FUNCTION, 
DESCRIPTION OF THE MUTATION 
(c.505T>C, p. S169P) AND FUNCTIONAL 
ANALYSIS 
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6.1 SUMMARY OF CHAPTER 6 
Chapter 6 begins with the introduction of FOXA2, discussion of the FOXA2 mutation 
(c.505T>C, p.S169P) and detailed description of the results from various functional 
studies to demonstrate the pathogenicity of the mutation followed by a detailed 
discussion. 
 
The manuscript of this chapter is accepted for publication. The pdf of the accepted 
version is attached in the appendix. 
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6.2 ROLE OF FOXA2 IN THE DEVELOPMENT OF CENTRAL NERVOUS SYSTEM 
FOXA2 (formerly hepatocyte nuclear factor-3β, HNF-3β) belongs to the family of the 
Forkhead class of transcription factors and is localised to the cytogenic location 
20p11.21(Figure 6.1). FOXA2 regulates the critical developmental process and has 
been implicated in the development of liver bud, central nervous system, pancreas 
and endodermal tissues. An important role of FOXA2 is its involvement in the 
development of axial mesoderm and formation of the notochord, node and floorplate 
which are important for the vertebrate body axis development (239, 240). Jin et.al. 
demonstrated that that Foxa2 is important in the development of anterior forebrain 
structures, which have the same embryonic origin as the pituitary gland (241). Murine 
studies have shown a genetic interaction between Foxa2 and Sonic Hedgehog (Shh) 
signalling pathway with overlapping expression pattern of Foxa2 and Shh in the 
notochord and floor plate at E8.5. The development of central nervous system is 
dependent on several morphogenetic signals, one of which is the secretion of Shh by 
the notochord and floor plate (242).  
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6.2.1 FOXA2 AND ITS INTERACTION WITH SHH SIGNALLING PATHWAY 
The initiation of the Shh signalling pathway (Figure 6.2) starts with the binding of Shh 
protein to its receptor on target cell, PTCH1(Patched-1). This binding releases 
SMO(smoothened) which is normally under inhibitory control from PTCH-1. SMO is 
then active and enters the cytoplasm and activates Gli1, which is then phosphorylated, 
enters the nucleus and transcriptionally regulates the promoter regions of target genes 
such as FOXA2 and NKx2.2 (243-245). Mavromatakis et. al demonstrated that Foxa2 
plays an important role in  modulation of Shh signalling, contributing to the 
specification of ventral motor neuron progenitor identity (246). Deletion of Foxa2 is 
lethal as the Foxa2 null embryos die during early gestation, at embryonic day 9.5, as 
a result of  failure of formation of axial mesoderm (239).  
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Figure 6.1: FOXA2 is localised at 20p11.21 and consists of 3 domains (Forkhead_N, 
FH and HNF_C). The variant (p. S169P) is located at the FH (DNA binding) domain 
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Figure 6.2 Interaction between Shh signalling pathway and FOXA2. Shh: Sonic hedge 
hog; PTCH1: patched 1; SMO: smoothened. SMO is under the inhibitory control of the 
Shh cell surface receptor PTCH1.Binding of Shh to PTCH1 releases the inhibition and 
activates the downstream signalling pathway 
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6.3 ROLE OF FOXA2 IN MOUSE PANCREAS AND ENDODERM-DERIVED 
ORGANS 
Foxa2 co-operates with Foxa1 and are required for the formation of endoderm-derived 
organs such as the liver (247), lung (248), pancreas (249) and gastrointestinal tract 
(250).  
 
Sund et al. demonstrated that tissue-specific deletion of Foxa2 from the pancreatic β-
cells (Foxa2loxp/loxp; Ins:Cre) leads to the development of CHI in mouse (251). Foxa2 
has been implicated to control multiple pathways involved in insulin secretion form the 
pancreatic ß cells (252). In the islet cells of mature pancreas, Foxa2 has been shown 
to activate components of insulin secretion, such as sulfonylurea receptor1 [SUR1], 
encoding ABCC8 (252) and the inward rectifier potassium channel member 6.2 [Kir 
6.2], encoding KCNJ11(252). In humans, mutations in SUR1 (ABCC8) and Kir 6.2 
(KCNJ11) (150, 253-256) are the most common causes of genetic forms of CHI.  
Thus a mutation in this gene can potentially cause problems in the development of 
pituitary and pancreas, therefore segregates with the phenotype of proband A.  
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6.4 DESCRIPTION OF FOXA2 MUTATION (c.505T>C, p.S169P) 
 
A novel heterozygous FOXA2 mutation (c.505T>C, p.S169P) was identified in the 
affected child but not in the parents. The mutation was confirmed by Sanger 
sequencing (Figure 6.3).  
 
Homo sapiens Forkhead box A2 (FOXA2), transcript variant 1, NM_021784.4, 
CDS with the position of point mutation highlighted in red 
FOXA2(c.505	T>C)			
 
ATGCACTCGGCTTCCAGTATGCTGGGAGCGGTGAAGATGGAAGGGCACGAGCCGTCCGACTGGAGCAGCT 
ACTATGCAGAGCCCGAGGGCTACTCCTCCGTGAGCAACATGAACGCCGGCCTGGGGATGAACGGCATGAA 
CACGTACATGAGCATGTCGGCGGCCGCCATGGGCAGCGGCTCGGGCAACATGAGCGCGGGCTCCATGAAC 
ATGTCGTCGTACGTGGGCGCTGGCATGAGCCCGTCCCTGGCGGGGATGTCCCCCGGCGCGGGCGCCATGG 
CGGGCATGGGCGGCTCGGCCGGGGCGGCCGGCGTGGCGGGCATGGGGCCGCACTTGAGTCCCAGCCTGAG 
CCCGCTCGGGGGGCAGGCGGCCGGGGCCATGGGCGGCCTGGCCCCCTACGCCAACATGAACTCCATGAGC 
CCCATGTACGGGCAGGCGGGCCTGAGCCGCGCCCGCGACCCCAAGACCTACAGGCGCAGCTACACGCACG 
CAAAGCCGCCCTACTCGTACATCTCGCTCATCACCATGGCCATCCAGCAGAGCCCCAACAAGATGCTGAC 
GCTGAGCGAGATCTACCAGTGGATCATGGACCTCTTCCCCTTCTACCGGCAGAACCAGCAGCGCTGGCAG 
AACTCCATCCGCCACTCGCTCTCCTTCAACGACTGTTTCCTGAAGGTGCCCCGCTCGCCCGACAAGCCCG 
GCAAGGGCTCCTTCTGGACCCTGCACCCTGACTCGGGCAACATGTTCGAGAACGGCTGCTACCTGCGCCG 
CCAGAAGCGCTTCAAGTGCGAGAAGCAGCTGGCGCTGAAGGAGGCCGCAGGCGCCGCCGGCAGCGGCAAG 
AAGGCGGCCGCCGGAGCCCAGGCCTCACAGGCTCAACTCGGGGAGGCCGCCGGGCCGGCCTCCGAGACTC 
CGGCGGGCACCGAGTCGCCTCACTCGAGCGCCTCCCCGTGCCAGGAGCACAAGCGAGGGGGCCTGGGAGA 
GCTGAAGGGGACGCCGGCTGCGGCGCTGAGCCCCCCAGAGCCGGCGCCCTCTCCCGGGCAGCAGCAGCAG 
GCCGCGGCCCACCTGCTGGGCCCGCCCCACCACCCGGGCCTGCCGCCTGAGGCCCACCTGAAGCCGGAAC 
ACCACTACGCCTTCAACCACCCGTTCTCCATCAACAACCTCATGTCCTCGGAGCAGCAGCACCACCACAG 
CCACCACCACCACCAACCCCACAAAATGGACCTCAAGGCCTACGAACAGGTGATGCACTACCCCGGCTAC 
GGTTCCCCCATGCCTGGCAGCTTGGCCATGGGCCCGGTCACGAACAAAACGGGCCTGGACGCCTCGCCCC 
TGGCCGCAGATACCTCCTACTACCAGGGGGTGTACTCCCGGCCCATTATGAACTCCTCTTAA 
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Aminoacid sequence of FOXA2 with the point mutation at position 169(serine) 
highlighted in red 
FOXA2 p.(S169P) 
 
atgcactcggcttccagtatgctgggagcggtgaagatggaagggcacgagccgtccgac 
 M  H  S  A  S  S  M  L  G  A  V  K  M  E  G  H  E  P  S  D  
tggagcagctactatgcagagcccgagggctactcctccgtgagcaacatgaacgccggc 
 W  S  S  Y  Y  A  E  P  E  G  Y  S  S  V  S  N  M  N  A  G  
ctggggatgaacggcatgaacacgtacatgagcatgtcggcggccgccatgggcagcggc 
 L  G  M  N  G  M  N  T  Y  M  S  M  S  A  A  A  M  G  S  G  
tcgggcaacatgagcgcgggctccatgaacatgtcgtcgtacgtgggcgctggcatgagc 
 S  G  N  M  S  A  G  S  M  N  M  S  S  Y  V  G  A  G  M  S  
ccgtccctggcggggatgtcccccggcgcgggcgccatggcgggcatgggcggctcggcc 
 P  S  L  A  G  M  S  P  G  A  G  A  M  A  G  M  G  G  S  A  
ggggcggccggcgtggcgggcatggggccgcacttgagtcccagcctgagcccgctcggg 
 G  A  A  G  V  A  G  M  G  P  H  L  S  P  S  L  S  P  L  G  
gggcaggcggccggggccatgggcggcctggccccctacgccaacatgaactccatgagc 
 G  Q  A  A  G  A  M  G  G  L  A  P  Y  A  N  M  N  S  M  S  
cccatgtacgggcaggcgggcctgagccgcgcccgcgaccccaagacctacaggcgcagc 
 P  M  Y  G  Q  A  G  L  S  R  A  R  D  P  K  T  Y  R  R  S  
tacacgcacgcaaagccgccctactcgtacatctcgctcatcaccatggccatccagcag 
 Y  T  H  A  K  P  P  Y  S  Y  I  S  L  I  T  M  A  I  Q  Q  
agccccaacaagatgctgacgctgagcgagatctaccagtggatcatggacctcttcccc 
 S  P  N  K  M  L  T  L  S  E  I  Y  Q  W  I  M  D  L  F  P  
ttctaccggcagaaccagcagcgctggcagaactccatccgccactcgctctccttcaac 
 F  Y  R  Q  N  Q  Q  R  W  Q  N  S  I  R  H  S  L  S  F  N  
gactgtttcctgaaggtgccccgctcgcccgacaagcccggcaagggctccttctggacc 
 D  C  F  L  K  V  P  R  S  P  D  K  P  G  K  G  S  F  W  T  
ctgcaccctgactcgggcaacatgttcgagaacggctgctacctgcgccgccagaagcgc 
 L  H  P  D  S  G  N  M  F  E  N  G  C  Y  L  R  R  Q  K  R  
ttcaagtgcgagaagcagctggcgctgaaggaggccgcaggcgccgccggcagcggcaag 
 F  K  C  E  K  Q  L  A  L  K  E  A  A  G  A  A  G  S  G  K  
aaggcggccgccggagcccaggcctcacaggctcaactcggggaggccgccgggccggcc 
 K  A  A  A  G  A  Q  A  S  Q  A  Q  L  G  E  A  A  G  P  A  
tccgagactccggcgggcaccgagtcgcctcactcgagcgcctccccgtgccaggagcac 
 S  E  T  P  A  G  T  E  S  P  H  S  S  A  S  P  C  Q  E  H  
aagcgagggggcctgggagagctgaaggggacgccggctgcggcgctgagccccccagag 
 K  R  G  G  L  G  E  L  K  G  T  P  A  A  A  L  S  P  P  E  
ccggcgccctctcccgggcagcagcagcaggccgcggcccacctgctgggcccgccccac 
 P  A  P  S  P  G  Q  Q  Q  Q  A  A  A  H  L  L  G  P  P  H  
cacccgggcctgccgcctgaggcccacctgaagccggaacaccactacgccttcaaccac 
 H  P  G  L  P  P  E  A  H  L  K  P  E  H  H  Y  A  F  N  H  
ccgttctccatcaacaacctcatgtcctcggagcagcagcaccaccacagccaccaccac 
 P  F  S  I  N  N  L  M  S  S  E  Q  Q  H  H  H  S  H  H  H  
caccaaccccacaaaatggacctcaaggcctacgaacaggtgatgcactaccccggctac 
 H  Q  P  H  K  M  D  L  K  A  Y  E  Q  V  M  H  Y  P  G  Y  
ggttcccccatgcctggcagcttggccatgggcccggtcacgaacaaaacgggcctggac 
 G  S  P  M  P  G  S  L  A  M  G  P  V  T  N  K  T  G  L  D  
gcctcgcccctggccgcagatacctcctactaccagggggtgtactcccggcccattatg 
 A  S  P  L  A  A  D  T  S  Y  Y  Q  G  V  Y  S  R  P  I  M  
aactcctcttaa 
 N  S  S  -  
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Figure 6.3: Sanger Sequencing showing the point mutation in FOXA2 (c.505 T>C) 
 
 
 
 
 
 
6.4.1 Factors Supporting Pathogenicity of the Variant 
The variant is not present in control databases (ExAc, dbSNP, 1000 genome). Multiple 
sequence alignment shows that the serine residue at position 169 is highly conserved 
across different species, from drosophila, human, mouse, chicken to frog (Figure 6.4), 
suggesting that this residue is functionally important and has been maintained 
throughout evolution in different species.   
Furthermore, the FOXA2 mutation (c.505T>C, p.S169P) lies at the DNA binding 
domain of the transcription factor. In silico analysis using SIFT, PolyPhen, Mutation 
Taster predict this aminoacid substitution to have deleterious impact on the protein 
function.  
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Figure 6.4: The evolutionary conservation of the amino acid residue serine at position 
169 is shown across different species such as drosophila, human, mouse, chicken 
and frog. DROME: drosophila; XENTR: Frog. 
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6.5 FUNCTIONAL ANALYSIS OF FOXA2   
(c.505T>C, p. S169P): 
 
 IN VITRO EXPERIMENTS 
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This section describes a detailed description of various in vitro functional studies such 
as in situ hybridisation, immunohistochemistry, site-directed mutagenesis, dual 
luciferase assay, Immunocytofluorescence, western blot etc. In vitro studies were 
performed in the laboratory at the centre for endocrinology, William Harvey Research 
institute, London under the supervision of Dr Carles Gaston-Massuet and his team. 
The experiments (bacterial transformation, in situ hybridisation, 
immunohistochemistry, site-directed mutagenesis, luciferase assay and western blot) 
were performed by me under the guidance of research fellows-Lillina 
Vignola, Angelica Gualtieri and Valeria Scagliotti. 
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6.5 FUNCTIONAL ANALYSIS OF FOXA2(c.505 T>C, p.S169P) 
6.5.1 Mice 
All mice were housed with a 12-hour light/12-hour dark cycle in a temperature and 
humidity-controlled room (21°C, 55% humidity) with constant access to food and 
water. Timed pregnancies were achieved by mating females and males overnight and, 
the presence of vaginal plug the following morning, was considered as embryonic day 
(e) 0.5.  
All experiments were conducted under the regulations, licenses and local ethical 
review of the UK Animals (Scientific Procedures) Act 1986. 
6.5.2 Fixation, Embedding and Sectioning of Mouse Embryos 
6.5.2.1 Fixation 
The embryos at stages E11.5, E12.5, E.13.5 and E15.5 were dissected and fixed in 4 
% paraformaldehyde (prepared by adding 4 gram of paraformaldehyde to 100 ml of 
1X PBS (phosphate buffered saline) and heating at 65°C with stirring to get a 
homogeneous mixture which is then cooled and filtered on 0.45um disposable filter). 
Reagents used: 
0.85% saline (4.25g NaCl in 500ml ddH2O) 
50% ethanol 
70% ethanol 
4% formaldehyde in 1X PBS  
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The steps for fixation are as follows: 
1. The dissected embryos were rinsed well in PBS 
2. The embryos were placed in labelled 20 ml snap-cap glass vials containing  
4 % paraformaldehyde 
3. The fixation was allowed to proceed at 4°C and incubated overnight. 
4. The embryos were then washed twice with PBS at room temperature and 
decanted to remove as much solution as possible. 
5. Following the previous step, the embryos were washed with 0.85% saline 
(4.25g NaCl in 500ml ddH2O) which helps remove phosphate from PBS to 
avoid it precipitating during ethanol dehydration. 
6. The embryos were incubated for 15 minutes in 50% ethanol, at room 
temperature and then in 70% ethanol for 15 minutes and stored in 70% ethanol 
at 4°C. 
6.5.2.2 Dehydration 
The 70% ethanol was decanted carefully without disturbing or damaging the embryos. 
Dehydration was carried out by adding 95% ethanol and incubating for 20 minutes at 
room temperature. This step was repeated twice. Following this, the 95% ethanol was 
decanted and 100% ethanol was added and incubated for 20 minutes twice. The 100% 
ethanol was replaced with xylenes and incubated for 10 minutes. 
6.5.2.3 Embedding 
The Xylene from the previous step was poured off and 5ml fresh Xylene was added to 
each vial followed by addition of 5 ml of molten wax. The samples were mixed and left 
overnight at room temperature to harden the mixture and enable the paraffin to be 
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dissolved in xylene to start impregnation of the samples. The wax/xylene mixture was 
melted by transferring the samples to 60°C oven. The wax/xylene mixture was then 
poured off from the vials and fresh molten wax was immediately added to the vials 
with a hot glass pipette and transferred to 60°C heating block. The vials were 
incubated for 1 hour at 60°C in an oven. The samples were transferred to wax-filled 
embedding moulds and left at room temperature to harden. 
6.5.2.4 Sectioning of Paraffin Embedded Tissue 
The paraffin-embedded tissue blocks were placed faced down on an ice block for 10 
minutes. The microtome (Leica, Model RM2155) was set at a clearance angle of 5° to 
cut the blocks. The paraffin block was inserted and oriented appropriately and trimmed 
at an initial thickness of 10-30 µm initially to expose the tissue to the surface level. 
Once the tissue was exposed, the trimming was done at a thickness of about 4-5 µm. 
The cut sections were carefully placed on the surface of a pre-prepared water bath 
containing DEPC (diethyl pyrocarbonate) water at 40-45°C.The sections floating on 
the water-bath were picked up on to the surface of clean glass microscopic slides. The 
slides were then placed on warming block in a 65°C oven for 20 minutes to allow 
bonding of the tissue to the glass. Following this, the slides were stored upright in a 
slide rack and allowed to dry overnight at 37oC. 
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6.5.3 BACTERIAL TRANSFORMATION AND PURIFICATION OF MOUSE 
FOXA2 PLASMID 
 6.5.3.1 Bacterial Transformation        
The mouse Foxa2 gene fragment (1567bp) plasmid was kindly provided by 
www.hdbr.org. The plasmid was transformed into DH5α competent cells using heat 
shock protocol.  
The steps of transformation protocol are described below: 
1. 50µl of DH5α competent cells were added to an Eppendorf placed on ice. 
2. The Foxa2 plasmid DNA(2µl) was added, gently swirled and incubated on ice 
for 20 minutes 
3. The tubes were submerged in the 42ºC water bath for 45 seconds. The duration 
of this step is critical as optimal transformation efficiency is observed when cells 
are heat-pulsed for 45-50 seconds. 
4. Following the heat-pulse, the tubes were immediately incubated on ice for 2 
minutes. 
5. 500µl of LB (Lysogeny broth) medium was added to the eppendorf containing 
the competent cells and the plasmid DNA. 
6. The tubes were then incubated at 37ºC for 1 hour with shaking at 225-250 rpm  
7. The transformation mixture(100μL) was plated on LB-ampicillin agar plates.  
8. The plates were incubated overnight at 37ºC. 
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6.5.3.2 Starter Cultures and Midiprep 
 
Four colonies were picked up from the transformation mixture plated on agar plate 
with sterile pipette tips. Each colony was transferred to a flask containing 100 mL of 
LB-broth and 100 µL of ampicillin with a concentration of 10mg/mL. These starter 
cultures were incubated at 37ºC overnight with shaking at 225-250 rpm. The next 
morning, using QIAGEN Hispeed Plasmid Midiprep kit, the plasmid DNA was purified 
by following the manufacturer’s instructions. This procedure is based on alkaline lysis 
of bacterial cells followed by adsorption of DNA onto silica in the presence of high salt. 
Bacteria are lysed under alkaline conditions, and the lysate is subsequently 
neutralized and adjusted to high-salt binding conditions, ready for purification on the 
QIAprep silica-gel membrane. The optimized buffers in the lysis procedure combined 
with the unique silica-gel membrane ensure that only DNA will be adsorbed, while 
RNA, cellular proteins, and metabolites are not retained on the membrane but are 
found in the flow-through. Salts are efficiently removed by a brief wash step with Buffer 
PE. High-quality plasmid DNA is then eluted from the QIAprep column. 
The purified plasmids are quantified using NanoDrop. The plasmid concentrations 
obtained from each colony were as follows (Figure 4.7): 
Colony 1 104.7 ng/µL 
Colony 2 89 ng/ µL 
Colony 3 120.2 ng/ µL 
Colony 4 108.9 ng/ µL 
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Figure 6.5: Agarose gel electrophoresis depicting the four bacterial colonies (double 
linear band representing a colony)  
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6.5.4 PREPARATION OF FOXA2 mRNA PROBE AND LABELLING 
6.5.4.1 Linearization of Plasmid (Digestion with BamHI enzymes) 
Following isolation of Foxa2 plasmid DNA, a diagnostic restriction digest was 
performed with endonuclease BamHI (from Bacillus amyloliquefaciens to confirm the 
cloning of Foxa2 into the plasmid. The gel image of the diagnostic restriction digest is 
shown in figure 4.8. The concentration of the linearized plasmid was quantified using 
NanoDrop and the final concentration obtained was 174ng/µL. 
 
Figure 6.6: mouse Foxa2 linearized plasmid (the single band represents mFoxa2 
shown along with standard DNA ladder) 
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6.5.4.2 Digoxigenein (DIG) Labelled RNA Antisense Probe Transcription 
DIG labeled RNA antisense probes are widely used for in situ hybridization due to their 
high sensitivity and specificity. These probes are highly stable and used for long-term 
studies. 
The following reagents were used during the labelling: 
Linearized Foxa2 plasmid 5.75µL 
DNA labeling mix(Digoxigenein) 2µL 
Transcription buffer 2µL 
RNAase inhibitor 0.5µL 
T3 RNA polymerase 1µL 
RNase and DNase free water 8.25µL(added to make up the total 
volume to 20 µL 
 
The above reagents were added to an Eppendorf and incubated for 2-4 hours at 
37oC.The efficiency of transcription was assessed by running 0.5 µL on 1% agarose 
gel with 1 Kb ladder (Figure 4.9) 
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Figure 6.7:Agarose gel showing the probe after transcription(from left to right:the first 
band represents the standard DNA ladder,the second single band is the linearized 
plasmid and the right most band is the probe). 
 
 
4.6.4.3 Probe Purification 
To the 20µL of the transcription reaction(probe), 40µL DEPC water was added to 
increase the total volume to 60µL.The probe was cleaned by passing through a spin 
column (CHROMA SPIN-1000 DEPC-H20 columns, BD Biosciences) and inverting 
the column up and down. The column is then placed in a 15 ml falcon tube and 
centrifuged at 700g for 5 minutes at 4 oC to dry the columns. 
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6.5.5 IN SITU HYBRIDIZATION 
6.5.5.1 Pre-Hybridization Treatment 
Reagents used: 
4% paraformaldehyde(PFA)-made by adding 16g of PFA, 40 ml 10*PBS, 200µL 
NaOH, made up to 300ml with DEPC water) 
Histoclear 
Ethanol at various concentrations:100%, 90%, 70%, 50%, 25% 
Proteinase K(20 µg/ml) 
Triethanolamine(0.1M) 
Acetic anhydride 
The paraffin slides with mouse embryos (E11.5, E12.5, E.13.5 and E15.5) were 
subjected to deparrafinisation and hydration by washing with the following reagents 
as follows: 
§ Histoclear twice for 10 minutes 
§ 100% ethanol twice for 2 minutes 
§ 90% ethanol twice for I minute 
§ 50% ethanol twice for 1 minute 
§ 25% ethanol twice for 1 minute 
§ 1% PBS for 2 minutes 
Sections were deparaffinised, rehydrated through decreasing ethanol dilutions, fixed 
with 4% PFA, incubated with proteinase K, fixed again with 4% PFA and finally 
incubated with 0.1 M triethanolamine, 0.1% acetic anhydride. 
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6.5.5.2 Hybridization 
Reagents used: 
Hybmix (50% formamide, 0.3M sodium chloride,  
0.02M Tris HCl, 0.005M EDTA,  
10% Dextran sulphate, 1*Denhardt’s solution):                          500µL(100 µL/slide) 
RNAase inhibitor:                                                                        0.5 µL (1 µL/ml) 
tRNA:                               25 µL(0.5mg/ml) 
SSC(saline sodium citrate) solution(175.3 g sodium chloride, 88.2 sodium citrate) 
 
RNAase inhibitor, tRNA and anti-sense probe at 2:100 dilutions were added to the 
slides and mixed briefly. Hybmix was added to the slides followed by addition of 
formamide and SSC. The slides were incubated overnight at 55-65 oC. 
6.5.5.3 Post Hybridization Washing 
The slides were further washed with SSC, formamide at hybridization temperature in 
a glass staining trough in a water bath. The slide rack was first washed in 2XSSC for 
10 minutes. After removing the cover slips from each slide, they were washed with 
formamide twice for 10 minutes each. The slides were washed again in SSC at 
hybridization temperature and then were allowed to cool to room temperature. 
 
 
 
 
 
 
 
 
 
 
122 
6.5.5.4 Antibody Detection 
The following steps were followed for antibody detection: 
1. The slides were washed with buffer consisting of 0.1M Tris-HCl Ph 7.5 and 
0.15M sodium chloride.  
2. Following this, 10% fetal calf serum, 1ml per slide was added and then left to 
stand for 1 hour (blocking antibody). 
3. The slides were then drained and 0.5 ml of anti-Dig antibody (Sigma-Aldrich) 
was added to each slide and incubated in humid chamber at 4 oC overnight. 
4. The next day, the slides were washed with 0.1 M Tris-HCl Buffer (pH = 7.5, 
0.15 M Sodium chloride) followed by 0.1 M Tris-HCl Buffer (pH = 9.5, 0.1 M 
Sodium chloride and 0.05M magnesium chloride) 
5. PVA (Polyvinyl alcohol)-0.5ml/slide was added to 0.1 M Tris-HCl Buffer (pH = 
9.5, 0.1 M Sodium chloride and 0.05M magnesium chloride) to form buffer-PVA 
mix. PVA helps to concentrate and enhance the development process. 
6. 4-Nitro blue tetrazolium chloride solution (NBT, Sigma-Aldrich), 4.5µl/ml and 5-
Bromo-4-chloro-3-indolyl phosphate disodium salt (BCIP, Sigma-Aldrich), 3.5 
µl/ml were added to the buffer-PVA mix.  
7. 0.5ml of the above solution was added to each slide and incubated at room 
temperature. 
8. Once the slides were developed sufficiently, they were washed in running tap 
water and placed at 50 oC for 15 minutes to remove residual PVA. 
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9. The slides are then dehydrated by separate alcohol series as below: 
§ Ethanol 25% for 1 minute 
§ Ethanol 50% for 1 minute 
§ Ethanol 75% for 30 seconds 
§ Ethanol 100% for 30 seconds 
§ Histoclear for 10 minutes 
10. Following alcohol dehydration, the slides were mounted in vector mount and 
images were acquired using a Leica microscope. 
 
6.5.6 IMMUNOHISTOCHEMISTRY 
Paraffin-embedded human tissue samples at 6, 8 and 13 weeks of gestation were 
obtained from the Human Developmental Biology Resource (Institute of Genetic 
Medicine, Newcastle, and Institute of Child Health, London; www.hdbr.org). 
The main steps involved in immunohistochemistry are: 
§ Deparrafinisation and rehydration 
§ Heat induced antigen retrieval 
§ Addition of primary antibody 
§ Addition of secondary antibody 
 
6.5.6.1 Deparrafinisation and Rehydration 
The slides were washed consecutively with the following reagents: 
• Histoclear for 5 minutes 
• 100% ethanol for 2 minutes 
• 75% ethanol for 2 minutes 
• 50% ethanol for 2 minutes 
• 25% ethanol for 2 minutes 
• Water for 5 minutes 
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6.5.6.2 Heat Induced Antigen Retrieval 
1. The slides were incubated with citric buffer (Citric acid 10Mm, Ph 6.0-
prepared by adding 1.2 g of citric acid in 500 ml of water. NaOH 10M was 
added until the Ph was 6.0). 
2. The slides are then placed in a microwave, heated under the following 
settings and cooling down in each step to avoid over-boiling: 
Power 70 for 3 minutes 
Power 90 for 3 minutes 
Power 90 for 3 minutes 
Power HI for 3 minutes 
3. Following this, the slides were removed from the microwave and allowed to 
stand in the citric acid buffer at room temperature for 1 hour. 
6.5.6.3 Addition of Primary Antibody 
1. The slides were rinsed with PBT (1XPBS, 1ml of 0.1% Triton X-100) for 5 
minutes. 
2. To each slide, 200µl of blocking buffer (5% normal goat serum) was added. 
3. The slide was covered with a parafilm and allowed to stand for an hour at room 
temperature. 
4. To each slide, 200µL of primary antibody (primary rabbit monoclonal antibody 
against hFOXA2 (Thermo Fisher Scientific; 701698; 1:250) was added, 
covered with a parafilm and incubated overnight at 4oC. 
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6.5.6.4 Addition of Secondary Antibody 
1. The slides were rinsed with PBT by gentle agitation. 
2. To each slide, 200µL of secondary biotinylated goat anti-rabbit antibody (Vector 
Laboratories; BA-1000; 1:300) was added 
3. The slides were incubated for 1 hour at room temperature 
4. Following this, the slides were washed with PBT and mounted  
5. Images were acquired using a Leica microscope  
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6.5.7 HUMAN FOXA2 PLASMID  
Full length cDNA of human FOXA2 (GENE Bank RefSeq NM 021784.4) was cloned 
in ORF mammalian expression vector pCMV3 (pCMV3-hFOXA2, Sino Biological Inc). 
The physical map of the plasmid is shown in figure 4.10. The plasmid information is 
shown in table 4.3 
 
Table 6.1: Human FOXA2 insert in pCMV3 
Gene Forkhead box A2, FOXA2 
cDNA  size 1392bp 
RefSeq NM 021784.4 
Vector name pCMV3-untagged 
Vector size 6223 bp 
Promoter CMV 
Antibiotic resistance Ampicillin 
Restriction site KpnI + XbaI (6.1kb + 1.39kb) 
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Figure 6.8: Physical map of plasmid(pCMV3) with FOXA2 insert cloned into the open 
reading frame(ORF). 
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6.5.7.1 Verification of Plasmid by Sequencing 
As PCR based cloning carries the risk of insertion of mutations depending on the 
fidelity of DNA polymerase used, the entire FOXA2 insert in the vector pCMV3 was 
sequenced to confirm no mutations have been inserted by error.  
The primer sequences of the oligonucleotides used to sequence FOXA2 insert in 
pCMV3 vector the insert are shown below: 
 
Oligonucleotide Sequence 
T7 Promoter  TAATACGACTCACTATAGGG  
FOXA2_F CCCTACGCCAACATGAACTCC   
FOXA2_R GTCGTTGAAGGAGAGCGAGTG 
BGH Reverse TAGAAGGCACAGTCGAGG 
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6.5.8 MUTAGENIC PRIMER DESIGNING 
 
The mutagenic primers were designed according to the following guidelines from the 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). 
1. Both of the mutagenic primers must contained the desired mutation and anneal 
to the same sequence on opposite strands of the plasmid. 
2. Primers should be between 25 and 45 bases in length. 
3. Melting temperature (Tm) of the primers as estimated by the following formula 
should be ≥78ºC. 
             Tm =81.5 +0.41(%GC) _ 675 _  % mismatch 
                                                       N 
N is the primer length in bases 
 
% GC and % mismatch must be whole numbers 
 
4. For primers designed to introduce insertions or deletions, the following formula 
should be used 
          Tm =81.5 +0.41(%GC) _ 675/N 
 
N does not include the bases, which are being inserted or deleted. 
                                                  
5. The desired mutation should be in the middle of the primer with 10-15 bases 
of correct sequence on both sides 
6. Optimally, the primers should have a minimum GC content of 40% and should 
terminate in one or more C or G bases. 
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Table 6.2: Mutagenic Primers used to insert mutations in the FOXA2 gene carried  
                  in the vector 
Forward primer CAAAGCCGCCCTACCCGTACATCTCGCTC 
Reverse Primer GAGCGAGATGTACGGGTAGGGCGGCTTTG 
 
6.5.9 SITE-DIRECTED MUTAGENESIS(SDM)  
The SDM reaction was prepared on ice in thin-walled PCR tubes utilizing the designed 
mutagenic primers and the double-stranded DNA vector containing the wild-type gene 
as shown in the table. 
6.5.9.1 SDM reaction 
Table 6.3: SDM reaction preparation 
Reagent Amount 
10 X  Reaction Buffer 5 μL  
dNTP mix 1 μL 
Forward mutagenic primer 125 ng 
Reverse mutagenic primer 125 ng 
Quickchange solution 1 μL 
Vector 94 ng 
ddH2O To a final volume of 50 μL 
PfuTurbo DNA Polymerase (2.5 U/ μL) 1 μL 
 
 
 
 
 
 
 
 
 
 
131 
The SDM reaction was put on to the PCR machine on the program “MARK SDM” for 
12 cycles according to the settings shown below 
 
Table 6.4: PCR settings for the SDM reaction 
Stage Cycles Temperature Time 
1 1 95 oC 1 minute 
2 12 95 oC 
60 oC 
68 oC 
 
50 seconds 
50 seconds 
1 minute/kb of 
plasmid length 
3 1 68 oC 7 minutes 
 
After the PCR cycles, the PCR product was cooled on ice and assessed by running 
10µL on 1% agarose gel with HyperLadder(BIOLINE). The image is shown as below 
(figure 4.11). 
Figure 6.9: PCR product verified on 1% agarose gel (from left to right: standard DNA 
HyperLadder and the single linear band on the right side of the image represents 
hFOXA2 plasmid). 
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6.5.9.2 Digestion 
 
After the PCR cycles, the product from the SDM reaction was cooled by placing on ice 
for 2 minute and Dpn I restriction enzyme (1 μL; 10 u/μL) was added to the reaction 
mixture. It was mixed thoroughly first by pipetting and then spinning the mixture in a 
microcentrifuge for 1 minute. The reactions were then incubated at 37ºC for 1 hour. 
Dpn I is a restriction enzyme that recognises and cuts the methylated plasmid DNA 
and digests them leaving behind the mutation-containing synthesized DNA. 
 
6.5.9.3 Transformation 
 
‘Pure Gold’ ultra-competent cells at -80 ºC were taken out and thawed gently on ice. 
45 μL of the ultra-competent cells were added to new tubes and labelled. Following 
this, 2 μL of ß-mecaptoethanol was added to each tube, put on ice for 10 minutes. To 
this, 2 μL of PCR product from the SDM reaction were added to the tubes and stirred 
using pipette. The mixture was left to stand on ice for 30 minutes. After 30 minutes, 
the transformation reactions were heat-pulsed for 30 seconds in 42ºC water bath. The 
reactions were then placed on ice for 2 minutes and 500 μL of pre-warmed LB medium 
(42ºC) was added. Following this, the reaction mixtures were put on a shaker at 37ºC 
for 1 hour. 
 
6.5.9.4 Inoculating Agar Plates 
250 μL of the transformed cells were added to the middle of agar plates at 37ºC. The 
transformed cells were spread uniformly across the plate using a sterile spreader. The 
plates were incubated overnight at 37ºC. 
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6.5.9.5 Starter Cultures, Midiprep and Double Digestion 
 
One individual colony picked up from the transformation mixture plated on agar plate 
with sterile pipette tips. Each colony was transferred to a flask containing 100 mL of 
LB-broth and 100 µL of ampicillin with a concentration of 10mg/mL. These starter 
cultures were incubated at 37ºC overnight with shaking at 225-250 rpm. The next 
morning, using QIAGEN Hispeed Plasmid Midiprep kit, the plasmid DNA was purified 
by following the manufacturer’s instructions. This procedure is based on alkaline lysis 
of bacterial cells followed by adsorption of DNA onto silica in the presence of high salt. 
Bacteria are lysed under alkaline conditions, and the lysate is subsequently 
neutralized and adjusted to high-salt binding conditions, ready for purification on the 
QIAprep silica-gel membrane. The optimized buffers in the lysis procedure combined 
with the unique silica-gel membrane ensure that only DNA will be adsorbed, while 
RNA, cellular proteins, and metabolites are not retained on the membrane but are 
found in the flow-through. Salts are efficiently removed by a brief wash step with Buffer 
PE. High-quality plasmid DNA is then eluted from the QIAprep column. 
The purified plasmids are quantified using NanoDrop. The concentration of the mutant 
plasmid hFOXA2 was 314 ng/ μL. The restriction enzymes KpnI and XbaI, 1 μL each, 
were added to 1 μg or 3.2 μL of the plasmid along with 3 μL of buffer and ddH2O to 
make up the total volume of the mixture to 30 μL. The restriction enzymes cleave the 
plasmid at the respective sites resulting in its linearization. The point mutation in the 
mutant plasmid was confirmed by sanger sequencing. 
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6.5.10 DUAL LUCIFERASE REPORTER(DLR) ASSAY 
 
Principle 
 
Luciferases are a class of oxidative enzymes found in several species that enable the 
organisms to produce bioluminescence or emit light. Under experimental conditions, 
by transfecting mammalian cells with a genetic construct containing the luciferase 
gene under the control of a promoter gene of interest, the transcriptional activity of the 
gene of interest can be measured and quantified by the luciferase reporter 
activity(257).   
Dual reporter assay is a genetic reporter system that is used to study the effect of 
gene expression and transcriptional activity in eukaryotes. The dual reporter refers to 
the simultaneous expression and measurement of two individual reporter enzymes 
(experimental reported and control reporter) within a single system. While the 
experimental reporter correlates with the effect of the specific experiment, the control 
reporter serves as a baseline and provides as an internal control. 
The Dual-Luciferase Reporter (DLRTM) Assay allows the measurement of activities of 
two enzymes-firefly (Photinus pyralis) luciferase and Renilla (Renilla reniformis) 
luciferase from a single sample. 
 
 
 
 
 
 
 
 
 
 
135 
Firefly luciferase is a 61kDA monomeric protein that functions as a genetic reporter 
immediately upon translation. The bioluminescent reaction from firefly luciferase is 
shown below (Figure 4.12): 
 
Figure 6.10: Bioluminescent Reaction-Firefly luciferase (Photinus pyralis) [ Adapted 
from Dual-Luciferase® Reporter Assay System Technical Manual TM040] 
 
 
Renilla luciferase is a 36kDA monomeric protein that catalyses the conversion of 
coelenterazine to coelenteramide with the help of oxygen. The bioluminescent 
reaction is shown below (Figure 4.13): 
 
Figure 6.11: Bioluminescent reaction-Renilla luciferase (Renilla reniformis) 
[Adapted from Dual-Luciferase® Reporter Assay System Technical Manual TM040] 
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In the DLRTM Assay, Luciferase Assay Reagent (LAR II) is added first to measure and 
quantify the firefly luciferase reporter luminescence. The reaction is quenched and is 
followed by addition of Stop & Glo reagent to the same tube that simultaneously 
initiates the Renilla luciferase luminescent reaction which then decays over the course 
of the measurement. This integrated assay format provides a rapid quantification of 
both the reporters in transfected cells 
The luminescent signals generated in the Dual-Luciferase Reporter (DLRTM) Assay by 
firefly and Renilla luciferases are shown below (figure 4.14): 
 
Figure 6.12: Comparison of luminescent signals generated by firefly and Renilla 
luciferases 
[Adapted from Dual-Luciferase® Reporter Assay System Technical Manual TM040] 
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The transcriptional assay experiment using DLR assay consists of the following 
steps 
 
1. Culture of HEK293T cells and seeding in 24-well plates 
 
2. Addition of reagents containing the wild type and mutant protein with promoter 
to the cells in the well plate 
 
3. Transfection the cells with Opti-Mem and Lipofectamine 
 
4. Obtaining the cell lysate and measurement of luciferase activity in 
luminometer 
 
 
6.5.10.1 Cell culture and Transfection 
 
Reagents used: 
 
phGT2-294-promoter-luc reporter 
 
Renilla SV-40(pRL-SV40 (Promega)) 
 
hFOXA2(Wt) 
 
hFOXA2(mutant) 
 
pBluescript 
 
Opti-MEM 
 
Lipofectamine 2000 Reagent 
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6.5.10.1.1 Cell culture  
 
HEK293T cells were grown in Dulbecco modified Eagle medium (DMEM) 
supplemented with 10% FBS. 2.5 x 105 cells/well were seeded in 24-well plates.  
 
Table 6.5: Quantity of reagents added to each well plate is shown  
             
 1 2 3 4 5 6 7 8 
Renilla SV-40 100ng 100ng 100ng 100ng 100ng 100ng 100ng 100ng 
pGL2(empty) 200 
ng 
       
hFOXA2(Wt)   25 ng 50 ng 75 ng 150ng   
hFOXA2(mutant)       25 ng 50 ng 
         
pBluescript 200ng 200ng  175ng  150ng  125ng  50ng 175ng  150ng  
         
 
 9 10 11 12 13 14 15 16 
Renilla SV-40 100ng 100ng 100ng 100ng 100ng 100ng 100ng 100ng 
phGT2-294   100ng 100ng 100ng 100ng 100ng 100ng 
hFOXA2(Wt)    25 ng 50 ng 75 ng 150ng   
hFOXA2(mutant) 75ng 150ng      25ng 50ng 
         
pBluescript 125ng  50ng 300ng  275ng  250ng  225ng  150ng  250ng  
 
 17 18 19 20 21 22 23 24 
Renilla SV-40 100ng 100ng 100ng 100ng     
phGT2-294   100ng  100ng     
hFOXA2(Wt)         
hFOXA2(mutant) 25 ng 50 ng 75 ng 150ng      
         
pBluescript 275ng  250ng  225ng  150ng      
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6.5.10.1.2 Transfection 
1. Opti-Mem medium 150 μL was added to each well.  
 
2. Lipofectamine (2.5 μL) was diluted with 50 μL of Opti-MEM medium and 
mixed for 5 minutes and added to each well to allow transfection. 
3. The transfected HEK293T cells and the cells are incubated at 37ºC for 24 
hours. 
 
6.5.10.1.3 Preparation of Cell Lysates 
1. Passive Lysis Buffer 1X working solution was prepared by adding 1 volume of 
5X Passive Lysis Buffer to 4 volumes of distilled water and mixing well. 
2. The growth medium was removed from the cultured cells and sufficient amount 
of phosphate buffered saline(PBS) was added to wash the surface of the culture 
vessel. 
3. 100 μL of 1X Passive Lysis Buffer was added to each well and the culture plates 
were placed on a rocking platform at room temperature for 15 minutes. 
 
6.5.10.1.4 Preparation of Luciferase Assay Reagent II (LAR II) 
LAR II was prepared as per the manufacturer’s instructions by re-suspending the 
lyophilized Luciferase Assay Substrate in 10 ml of Luciferase Assay Buffer II 
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6.5.10.1.5 Preparation of Stop & Glo Reagent 
Stop & Glo is supplied at 50X concentration. 1 volume of 50X stop & Glo substrate 
was added to 50 volumes of Stop & Glo buffer. 
The steps followed to record the luciferase activities from the luminometer are 
described below and represented in figure 4.15: 
1. The luminometer was set to dispense 100μL of luciferase and the injector was 
primed initially with 100 μL LAR II. 
2. 20 μL of the cell lysate was added to the wells of the multiwell plate. 
3. The samples were then placed in the luminometer which will cause the LAR II 
solution to be injected into the reaction vessel. 
4. The measurement of the luciferase activity was recorded by the attached 
computer. 
5. Following this, the luminometer was formatted to dispense 100 μL of Stop & 
Glo reagent. 
6. As before, 20 μL of the cell lysate was added to the wells of the multiwell plate 
and the Renilla luciferase activity was recorded. 
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Figure 6.13: Sequential steps inside the luminometer 
[Adapted from Dual-Luciferase® Reporter Assay System Technical Manual TM040] 
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6.6 BRIEF DESCRIPTION OF SPECIFIC METHODS 
6.6.1 In situ hybridization 
Wild type mouse embryos at different embryonic stages of development (e.11.5, 
e12.5, e13.5, e15.5 and e18.5) were collected, fixed with 4% paraformaldehyde (PFA) 
and washed in PBS before proceeding with paraffin embedding. Following this, the 
paraffin-embedded embryos were sectioned at 7 μm thickness for histochemical 
evaluation. Using decreasing ethanol dilutions, the sections were deparaffinised, 
rehydrated and fixed with 4% PFA and incubated with triethanolamine and acetic 
anhydride. The digoxigenin-labeled anti-sense probe for mFoxa2 was generated by in 
vitro transcription using T3 RNA polymerase and hybridization was carried out 
overnight at 65°C. The sections were washed in 0.1 M Tris-HCl Buffer followed by 1 
hour blocking at room temperature and overnight incubation at 4°C with anti-Dig 
antibody. Detection of mFoxa2 was achieved by colorimetric reaction using 4-Nitro 
blue tetrazolium chloride solution and 5-Bromo-4-chloro-3-indolyl phosphate disodium 
salt Images were acquired using a Leica microscope. 
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6.6.2 Immunohistochemistry 
Paraffin-embedded human embryonic tissue samples at 6, 8 and 13 weeks of 
gestation were obtained from the Human Developmental Biology Resource (Institute 
of Genetic Medicine, Newcastle, and Institute of Child Health, London; www.hdbr.org). 
The sections were deparaffinised and rehydrated through decreasing ethanol 
dilutions. This was followed by heat-induced antigen retrieval with a microwave in 10 
mM sodium citrate buffer (pH 6). The sections were incubated for 1hr in blocking buffer 
[1XPBS, 0.1% Triton X-100, 5% Normal Goat Serum (Vector Laboratories)]. 
Endogenous hFOXA2 was detected with a primary rabbit monoclonal antibody against 
hFOXA2 (Thermo Fisher Scientific; 701698; 1:250) followed by a secondary 
biotinylated goat anti-rabbit antibody (Vector Laboratories; BA-1000; 1:300). Staining 
was achieved using DAB Peroxidase Substrate Kit (Vector Laboratories; SK-4100). 
The colorimetric reaction was stopped with washes in water and the sections were 
counterstained using Haematoxylin (Sigma-Aldrich). Images were acquired using a 
Leica microscope. 
 
6.6.3 Plasmids and Site-Directed Mutagenesis 
Full length cDNA of human FOXA2 (GENE Bank RefSeq NM 021784.4) was cloned 
in ORF mammalian expression vector pCMV3 (pCMV3-hFOXA2, Sino Biological Inc).  
E.coli DH5a competent cells were transformed with hFOXA2 (cDNA size: 1392 bp). 
The detected mutation was introduced by site-directed mutagenesis using 
QuikChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies) according to 
the manufacturer`s instructions (primers used, Forward strand: 5’-
CAAAGCCGCCCTACCCGTACATCTCGCTC-3’. Reverse strand: 5’-
GAGCGAGATGTACGGGTAGGGCGGCTTTG-3’). Sanger sequencing confirmed the 
point mutation.  
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6.6.4 Cell Culture and Luciferase Assays  
HEK293T cells were grown in Dulbecco modified Eagle medium (DMEM) 
supplemented with 10% FBS. 2.5 x 105 cells/well were seeded in 24-well plates. 
phGT2-294-promoter-luc reporter (kindly provided by Professor Yong-Ho Ahn), 200ng 
and Renilla SV-40, 100ng were transiently co-transfected with either i) equal amounts 
(50 ng and 75 ng) of Wt or mutant p.S169P hFOXA2 expression plasmids or ii) both 
Wt and mutant p.S169P hFOXA2 expression plasmid (25 ng or 37.5 ng of each 
plasmid) using Lipofectamine 2000 (Life Technologies) according to the 
manufacturer’s instructions. 500 ng of pBluescript plasmid was added to keep the total 
amount of transfected DNA constant. The cells were harvested 24h after transfection 
and the luciferase activity was measured using the Dual-Luciferase Reporter Assay 
System (Promega) in a BMG LABTECH Microplate reader (Omega, Germany) 
according to manufacturer’s instructions. Firefly luciferase activity was normalised to 
the Renilla luciferase expression from pRL-SV40 (Promega). The experiments were 
independently repeated four times in triplicates and statistical analysis was performed 
using one-way ANOVA. 
 
6.6.5 Western Blotting 
Equal amounts (200 ng) of Wt or mutant p.S169P hFOXA2 expression plasmids were 
transiently transfected in HEK293T cells in 24-well plates using Lipofectamine 2000 
and harvested 24 hours after the transfection in a lysis buffer. 300 ng of pBluescript 
plasmid were added to each transfection mix to maintain the total amount of DNA 
constant at 500 ng. The samples were than loaded on 12% polyacrylamide gel and 
transferred on a nitrocellulose membrane. Using 5% dried skimmed milk in PBS-T, the 
nonspecific binding sites were blocked for 1h. This was followed by the incubation of 
membrane overnight at 4°C with the primary antibody, rabbit anti-FOXA2 followed by 
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one-hour incubation with IRDye 800CW Donkey anti-rabbit antibody. Anti-GAPDH 
(Santa Cruz; 1:5000, rabbit polyclonal) levels were used to normalise the total level of 
protein. Blots were analysed using Odyssey 2.1 Imaging System (LI-COR 
Biosciences). The experiments were independently repeated six times and the 
statistical analysis was performed using one-way ANOVA.  
 
6.6.6 Immunocytofluorescence 
1 x 105 cells/well were seeded in 4-well cell culture slide (Millipore, Fisher Scientific) 
and transiently transfected with 200 ng of Wt or mutant p.S169P hFOXA2 expression 
plasmids and 300 ng of pBluescript plasmid using Lipofectamine 2000  according to 
the manufacturer’s instructions. 24h after transfection, the cells were fixed in 2% PFA 
in 1X PBS for 10 min and washed with 1X PBS three times. Samples were 
permeabilised with 0.1% Triton X-100 in 1X PBS for 30 min and blocked with blocking 
buffer (5% Normal Goat Serum in 1X PBS) for 30 min. The staining was performed by 
incubating the samples with α-FOXA2 antibody (Thermo Fisher Scientific; 701698, 
2ug/ml) in blocking buffer for 1h, followed by a 30 min incubation with goat α-rabbit 
Alexa fluor 594 (ThermoFisher Scientific; 1:250) and α-PHALLOIDIN Alexa fluor 488 
(Molecular Probes; 1:1000) antibodies. The cell nuclei were stained with DAPI (4',6-
diamidino-2-phenylindole). 
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6.7 RESULTS FROM THE IN VITRO 
EXPERIMENTS 
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6.7.1 Foxa2 mRNA expression during Murine Embryonic Development 
The mRNA expression panels are shown in figure 6.5.  
At embryonic day e11.5 (A) Foxa2 mRNA transcripts were expressed within the 
midbrain(MB) and ventral hindbrain(HB). The mRNA was also localised to a few cells 
localised in the forebrain (FB) (A, asterisk). At this stage of development, no transcripts 
were detected in the primordium of the anterior pituitary gland, the Rathke’s pouch(RP) 
(dotted line in A and A’), or in the infundibulum(Inf).  
 
At e12.5 (B and B’) Foxa2 mRNA transcripts were detected in the epithelial structures 
lining the main bronchus (MBr) (B, arrowhead) and in the epithelium lining the lung 
and oesophagus (B’, arrowheads). By e13.5, expression of Foxa2 appears localised 
in the ventral side of the anterior lobe(AL) of the developing pituitary gland (C, arrow) 
with transcripts localised in the ventral marginal zone (C’, arrowhead). Foxa2 mRNA 
expression was stronger at e15.5 (D) with robust expression in the ventral 
diencephalon (VD) (asterisk), posterior lobe (PL) and anterior lobe (AL) (arrowheads 
in D’) of the pituitary gland. At embryonic day e18.5 (E), expression was found wide 
spread in the central nervous system, with strong expression in the lumen surrounding 
the lateral ventricles (LV) (E, arrowheads) and the third ventricle (TV) (E, asterisks). 
The mRNA expression was also localised in in the hypothalamic area (Hyp) (E’, 
arrowheads) at e18.5 with distinct pattern in the luminal area where the hypothalamic 
precursors tanycytes reside (arrowheads in E’). mRNA transcripts were also localised 
in both the posterior and anterior lobes of the pituitary gland (arrows in E’). 
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Figure 6.14: mRNA expression of Foxa2 during mouse embryonic development 
A-D represent sagittal sections, with anterior to the left side, and E is a coronal section. 
A’, C’, D’, E’ show higher-magnification views of the boxed areas in A, C, D, E, 
respectively. Abbreviations: midbrain, MB; hindbrain, HB; forebrain, FB; Rathke’s 
pouch, RP; infundibulum, Inf; main bronchus, MBr; lung, Lu; oesophagus, OE; ventral 
diencephalon, VD; pituitary gland posterior lobe, PL; pituitary gland anterior lobe, AL; 
lateral ventricles, LV; third ventricle, TV; hypothalamus, Hyp. Scale bars represent: 50 
μm (A’, B, C’, D’); 100 μm (B’), 250 μm (A, C, D, E’); 500 μm (E). 
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6.7.2 FOXA2 Expression during Human Embryonic Development 
 
The hFOXA2 expression panels are shown in figure 6.6.  
The immunohistochemical analysis in human embryos at various developmental 
stages showed FOXA2 expression at 6 weeks of gestation (Carnegie stage 16) (A, 
figure 6.6) and in the developing neural tube (NT) (A’) and diencephalon (Dc) 
(arrowheads in A’’).  The expression is localised in the epithelium surrounding the third 
ventricle (TV) (B’) and in the cells lining the diencephalon (Dc) from 8 weeks of 
gestation (arrowheads in B’’). (Carnegie stage 23) No expression of Foxa2 was 
detected in the primordium of the pituitary gland (Rathke’s pouch, RP) at CS16 (A’’’) 
nor in the developing pituitary gland at CS23 (B’’’). In the pancreas at 13 weeks of 
gestation (C) Foxa2 was specifically localised in the cytoplasm of cells scattered in the 
pancreatic parenchyma (cells pointed by arrowheads in C’ and C’’). 
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Figure 6.15: FOXA2 expression during human embryonic development 
 
A-C represent coronal sections of human embryos at 6 weeks (Carnegie stage 16), 8 
weeks (Carnegie stage 23) and 13 weeks of gestation, respectively. A’-C’’ show 
higher-magnification views of the boxed areas in A, B, C, respectively. Abbreviations: 
neural tube, NT; diencephalon, Dc; Rathke’s pouch, RP; pituitary gland, P; third 
ventricle, TV. Scale bars represent: 50 μm (A’, A’’, A’’’, B’, C’’); 100 μm (B’’, B’’’), 250 
μm (C’). 
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6.7.3 Immunocytofluorescence 
Using double immunofluorescence on transiently transfected HEK293T cells, it was 
demonstrated that both the Wt hFOXA2 and mutant hFOXA2 are expressed in the 
nucleus and the mutation did not result in changes to cellular localization 
 
 
 
Figure 6.16:	Double-immunofluorescence using anti-FOXA2 antibody (red A,B) and 
anti-PHALLOIDIN (green A’,B’) performed in HEK293 cells transiently transfected with 
either 200 ng of Wt hFOXA2 (A-A’’’) or mutant hFOXA2 p.S169P (B-B’’’) shows 
nuclear expression of both Wt and mutant FOXA2 (A,B) which overlaps with the 
nuclear DNA marker DAPI staining (A’’, B’’) but not with the cytoskeletal marker 
phalloidin. Abbreviation: DAPI, 4',6-diamidino-2-phenylindole. Scale bars in A and B 
represent 10 µm.      
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6.7.4 Dual Luciferase Transcriptional Assay 
 
Transcriptional activation assay was performed using the GLUT2 promoter coupled to 
luciferase (phGT2-294-promoter-luc) and using HEK293T cells. HEK293T cells were 
transiently co-transfected with equal quantities of Wt hFOXA2 or mutant hFOXA2 
p.S169P and it was demonstrated that the hFOXA2 p.S169P significantly impaired the 
transcriptional activation of the GLUT2 luciferase reporter (Figure 6.8). 
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Figure 6.17: Dual luciferase transcriptional assay (graph represents 4 independent 
experiments performed in triplicate, * p<0.05, one-way ANOVA). 
 
 
 
 
The serine to proline change in position 169 of hFOXA2 results in decreased protein 
expression levels leading to impairment of transcriptional activation of the human GT2 
promoter. Dual luciferase assay in HEK293T cells transiently transfected with 50 ng 
or 75 ng of Wt hFOXA2 or mutant hFOXA2 p.S169P indicates that Wt hFOXA2 is able 
to transactivate the human GT2 reporter, whilst  the hFOXA2 p.S169P transcriptional 
activation is impaired. 
 
 
 
154 
 
6.7.5 Western Blot Assay 
 
The quantification of protein expression using western blot showed that mutant 
hFOXA2 p.S169P resulted in significantly reduced protein expression levels compared 
to the Wt hFOXA2 (figure 6.9). Three independent western blots showed that the 
levels of the variant hFOXA2 p.S169P protein were reduced compared to the Wt 
hFOXA2, indicating that the mutation is functional and affects protein levels.  
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Figure 6.18: Western blot assay 
 
 
 
 
 
 
Graph of the quantification of the western blots as percentage of Wt hFOXA2 and 
hFOXA2 p.S169P normalised to GAPDH indicates that hFOXA2 p.S169P variant 
results in half of the protein expression levels compared to Wt hFOXA2 (results from 
6 independent experiments; ****  p< 0.0001, one-way ANOVA). Abbreviation: NT, non-
transfected; Wt, wild-type 
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6.8 DISCUSSION 
 
Deletions within the cytogenetic location 20p11.2 which contains FOXA2 as one of the 
genes have been noted to be associated with clinical phenotype that include 
hypopituitarism, central nervous system (CNS) defects, hypoglycaemia, facial 
dysmorphic features and congenital abnormalities of the heart, liver and 
gastrointestinal tract (258-262). The minimal critical region in this region of 20p11.2 
has been mapped to contain 20 genes including FOXA2 (261) (258). All the patients 
reported to have the 20p11.2 chromosomal deletion have hypopituitarism, CNS 
abnormalities and facial dysmorphic features as shared features, strongly indicating 
that a gene or multiple genes within this chromosome region have a key role in CNS, 
pituitary and facial development.  
Proband A with the rare clinical phenotype of hypopituitarism, CHI, dysmorphic 
features, liver, pancreas, heart and gastrointestinal abnormalities was found to have 
a de novo heterozygous mutation in the developmental transcription factor FOXA2 
thus identifying the gene responsible for the clinical phenotype of hypopituitarism and 
hypoglycaemia at the 20p11.2 region. The c.505T>C, p.S169P genetic variant 
occurring  at the conserved forkhead DNA binding domain may provide tissue-specific 
gene regulation important for the development of multiple organs. The biochemical 
data demonstrate that the mutation impairs the transcriptional activation of FOXA2 
resulting in lower activation of the glucose transporter type 2 gene (GLUT2). 
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Furthermore, the clinical phenotype of proband A: hypopituitarism, CHI and facial 
dysmorphic features overlaps with the clinical data published in patients with 20p11.2 
deletions (258-262). The impaired transcriptional activation of the phGT2-294-
promoter-luc reporter and significant reduction in the protein expression by hFOXA2 
p.S169P compared to wild type hFOXA2 demonstrates the pathogenicity of the 
mutation.  
The key signalling pathways important in ventral midline, pituitary and CNS 
development such as Shh signalling have been shown to be regulated by FOXA2.  
Data from in vivo studies using Wnt1:Cre;Foxa2flox/flox  embryos showed that Foxa2 
has an early role in the initiation of Shh expression (244). Hence it is potentially 
possible that hFOXA2 mediates the development of pituitary by regulating the 
expression of Shh. Furthermore, the expression of intracellular transducers and 
downstream targets of Shh signalling such as Ptch1,Gli1 and Gli2, which regulate the 
patterning of the ventral midbrain (246) have been shown to be downregulated by 
Foxa2 in combination with Foxa1. 
The midline defects encountered in proband A such as single median maxillary central 
incisor (SMMC), congenital nasal pyriform aperture stenosis (CNPAS) are often 
associated with pituitary abnormalities, as described in an extensive literature review 
by Lo et al. (263). The authors described that hypopituitarism or growth hormone 
deficiency were present in 43-48% of patients with CNPAS or SMMC. This is 
consistent with the clinical presentation of proband A, who has hypopituitarism along 
with hypoplastic pituitary, thin corpus callosum and thin pituitary stalk on the MRI.  
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The potential role of FOXA2 in the pituitary development is suggested by the detection 
of Foxa2 mRNA transcripts from the early stages of mouse pituitary and brain 
embryonic development Furthermore, the detection of hFOXA2 by 
immunohistochemistry in human embryos at various developmental stages, along with 
the biochemical experiments demonstrating that the variant p.S169P mutation in 
FOXA2 impairs transcriptional activation and protein expression levels, strongly 
indicate that FOXA2 has a pivotal role in hypothalamic-pituitary axis formation in 
humans. 
 
Hypoglycaemia in CHI is caused by unregulated insulin secretion while in 
hypopituitarism it is due to the lack of counter-regulatory hormonal response due to 
the deficiency of ACTH and GH. Diagnosis can often be challenging, as the hallmark 
of CHI is detectable insulin in the presence of hypoketotic hypoglycaemia while 
hypopituitarism causes ketotic hypoglycaemia. The co-existence of hypopituitarism 
along with a persistent form of hyperinsulinism, as encountered in proband A, is 
extremely uncommon.  Almost half of the patients with persistent CHI do not have 
mutations in the already recognized genes known to cause CHI. Genetic diagnosis is 
important as it will inform the prognosis, recurrence risk and guide the medical 
management besides providing valuable insight into β-cell physiology. The negative 
mutations in the known CHI genes in proband A together with strong biochemical 
evidence of CHI makes it highly likely that the CHI is due to a novel genetic aetiology 
(FOXA2). The immunohistochemistry data from this study supports this as there is a 
good expression of hFOXA2 in the developing human pancreas and a functional role 
of the hFOXA2 p.S169P mutation.  
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The closure of ATP dependent potassium channels situated on the β-cell membrane 
with the resultant depolarization of the membrane results in glucose-stimulated insulin 
secretion by the exocytosis of the insulin granules (264, 265). The most common form 
of genetic CHI is due to the mutations in genes encoding the KATP channels (ABCC8 
and KCNJ11) (264, 265). Lantz et al. demonstrated that when SUR1 or Kir6.2 
promoter/luciferase reporter was transfected with Foxa2 expression plasmids, Foxa2-
Sur1 promoter constructs showed 6-fold activation and 4-fold activation was 
demonstrated on Foxa2-kir6.2 constructs implying a vital role of Foxa2 in the 
transcriptional activation of the KATP subunits (252). Mutations in HADH cause CHI 
in humans. HADH encodes L-3-Hydroxyacyl-CoA-dehydrogenase (HADH), an 
enzyme involved in the penultimate step of the beta-oxidation pathway (266). Foxa2 
has also been shown to directly target HADH causing its transcriptional activation 
(252, 267) in mice experiments. Pancreatic  β-cell specific knock out of Foxa2 in mice 
has been shown to have a 3-fold downregulation of Hadh mRNA resulting in severe 
hyperinsulinaemic hypoglycaemia (251, 268). Wang et al. demonstrated that mRNA 
levels of glucokinase(GCK) is decreased upon induction with Foxa2 in rat insulinoma 
cell line (INS-1) while loss of Foxa2 function causes GCK upregulation (196). 
 
The regulation of genes involved in insulin secretion by FOXA2 is represented in the 
figure 6.10. 
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Figure 6.19: Regulation of genes involved in insulin secretion by FOXA2. FOXA2 
upregulates KCNJ11, ABCC8, HADH and downregulates GCK. 
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The main role of GLUT2, located in the plasma membrane of the pancreatic β-cells, 
liver, kidney, intestine and its main role is to facilitate the transport of glucose across 
the membrane and the secretion of insulin (197).The mRNA level of GLUT2 is 
influenced by the plasma concentrations of glucose and insulin(269). Cha et. al 
demonstrated GLUT2 has binding sites for FOXA2 and showed that the promoter 
activity of GLUT2 is synergistically activated by HNF1 and HNF3β (268). The reduction 
in the transcriptional activation of the GLUT2 reporter (phGT2-294-promoter-luc) by 
the mutant hFOXA2 (p.S169P) shown in the  transcriptional luciferase assay 
experiment, could imply that the GLUT2 tissue expression is reduced in the pancreatic 
β-cells contributing to CHI in proband A.  
 
Furthermore, data from Lantz et al., demonstrate that FOXA2 potentially affects the 
activation of other genes involved in the insulin secretion, and thus a potential 
candidate gen for CHI. It is also plausible that Foxa2 could play a role in the 
development of the pancreas as well as β-cells. Foxa2 has not only been shown to 
regulate Pdx1, a homeobox gene essential for pancreatic development (267) but has 
also been linked to regulating the mRNA levels of pancreatic transcription factors such 
as Hnf4a and Hnf1a, mutations of which can cause monogenic forms of diabetes. 
However, some studies contradict that Foxa2 is an upstream regulator of Pdx1,Hnf4a 
and Hnf1a (269) . While it has been shown that β-cell-specific deletion of Foxa2 in 
mice causes a phenotype of hypoglycaemia (251), it also has been demonstrated it 
can cause downregulation of Pdx1 mRNA causing the reduction of PDX-1 protein 
levels in the pancreatic islets (270) and a targeted β-cell-specific deletion of Pdx1 
results in diabetes in transgenic mice (271). Thus, FOXA2 is a crucial transcription 
factor that controls the expression of multiple genes involved both in glucose sensing 
 
 
 
162 
and glucose homeostasis and therefore has a potential role in diseases involving 
insulin secretion and glucose homeostasis.  
 
 
Diazoxide is used as an effective treatment in majority of patients with CHI except in 
those situations where the CHI is due to mutations abolishing the KATP channel 
activity (ABCC8 or KCNJ11) or activating mutations in GCK. Proband A’s response to 
the treatment with diazoxide could potentially imply that the KATP channel activity has 
not completely abolished by the variant p.S169P.  
 
FOXA2 (p.S169P) is the first disease-causing mutation in proband A with an extremely 
rare complex phenotype of CHI, cranio-facial dysmorphic features, CH, cardiac, liver 
and gastrointestinal abnormalities. Identification of the genetic cause contributing to 
such a unique clinical phenotype will help medical management and provide valuable 
insights into molecular mechanisms underlying pituitary development and β-cell 
physiology.  
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CHAPTER 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL PHENOTYPE AND WHOLE 
EXOME SEQUENCING RESULTS  
 
(FAMILY B) 
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7.1 SUMMARY OF CHAPTER 7 
Chapter 7 begins with the detailed description of the phenotype of proband B from 
Family B, results from whole exome sequencing followed by a detailed discussion of 
compound heterozygous ASXL3 mutations (c.2965C>G, p.R989G and c.3078G>C, 
p.K1026N).  
 
The manuscript of this chapter is now published. The pdf of the published version is 
attached in the appendix.  
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7.2 CLINICAL INFORMATION (PROBAND B) 
 
Proband B is a 16-year-old Caucasian British boy born at full term following an 
induction of labour by ventouse delivery to non-consanguineous Caucasian British 
parents. The antenatal scans were normal and the birth weight was 4.1 kg (1.84 SDS). 
He was admitted to the neonatal unit as he was noted to be grunting soon after birth. 
Whilst in the special care, he had feeding difficulties and required tube feeding. At 4 
months of age he required surgical fixation for scaphocephaly. He had bilateral 
undescended testes and required orchidopexy. From 5 weeks of age he had persistent 
severe constipation and required daily bowel washouts from 18 months of age 
followed by colostomy at 3 years. He also has global developmental delay and 
complex learning difficulties requiring additional support at school. He also has been 
diagnosed with autism. He was referred to endocrinology assessment of his severe 
short stature at 7 years of age (-4.11 SDS, Mid Parental Height: -1.1 SDS). He was 
found to have a normal growth hormone (GH) response (peak GH 11.7µg/l) 
(Normal:>6.7 µg/l) to an arginine stimulation test. He had a bone age delay of 3 years 
and the IGF1 was persistently low at 4.9nmol/l (-3.2 SDS). The other baseline pituitary 
hormones including thyroid function, ACTH, prolactin and cortisol concentrations were 
all within the normal range. A trial of hGH (50µg/kg/day) was ineffective in improving 
height velocity (Figure 7.1). An IGF1 generation test after 33 µg/kg of hGH did not 
produce any response. Subsequently, recombinant IGF1 therapy (mecasermin) was 
commenced which resulted in improvement of height velocity to -3SDS (Figure 7.1). 
He has dysmorphic features such as strabismus, prominent forehead and nasal 
bridge, thin lips, small lower jaw, low set cupped ears, short fifth fingers on both hands, 
short stature, thickened toenails on his little toes of his feet. He has a normal muscle 
tone and normal deep tendon reflexes. His cranial MRI scan of brain and spine were 
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normal. The hearing has been normal. The echocardiogram and renal ultrasound did 
not identify any abnormalities. The plasma amino acids, urine organic acids, pyruvic 
acid analysis were within the normal limits. CGH microarray did not reveal any copy 
number changes. Targeted sequencing of IGF1, IGF1R and GHR did not reveal any 
mutations. Currently, the patient continues to require rIGF1 therapy to improve his 
height. The weight gain continues to be suboptimal (Figure 7.1). 
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Figure 7.1: Growth chart showing height and weight. Improvement in height velocity 
was noted after commencement of rIGF1 
 
 
 
 
 
 
 
 
 
Figure 7.2: Pedigree of Family B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GH rIGF1 
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7.3 WHOLE EXOME SEQUENCING RESULTS FROM FAMILY B 
 
In this family, whole-exome sequencing was performed on the both the 
parents(unaffected) and the affected child. Assuming a de novo inheritance pattern, 
filters were applied to whole-exome data as shown in the figure 7.3. The potential 
candidate variants are listed in the table 7.1. 
 
 
Figure 7.3:De Novo variant analysis of proband B  
 
De Novo Variant Analysis of Proband B (* Novel variants include variants present in 
at least 5% minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP 
exomes excluded; ** Predicted deleterious variants included nonsynonymous 
coding, splice site, frameshift, stop gain variants; *** Variants present in 
heterozygous state in the child and not present in both the parents) 
 
 
 
 
 
 
62168 • Total	variants	in	3	family	members
3598 • Novel	variants*
331 • Predicted	deleterious**
7 • Genetic	analysis	***
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The list of de novo variants in proband B are shown below in the table 7.1: 
 
 
Table 7.1: List of de novo variants in Proband B 
 
Chromosome Gene Gene region Protein variant 
2 PEL1 Splice site  
    
3 ZBTB11 Splice site  
    
4 CORIN Splice site  
    
9 EHMT1 Exonic p.A275V 
    
11 DPF2 Exonic p.W369R 
    
17 KSR1 Exonic p.T137P 
    
19 POP4 Exonic p.l177F 
 
 
A brief description of these genes is presented next. From the available biological 
information about these genes, the phenotype of proband B could not be explained 
with variations in these genes. 
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Description of de novo variants from proband B 
 
PEL1  
 
From the current literature, the biological information on this gene function is limited. 
 
 
ZBTB11 (Zinc Finger and BTB Domain Containing 11) 
 
From the current literature, the biological information on this gene function is limited. 
 
 
CORIN (corin, Serine Peptidase) 
 
This belongs to the member of the type II transmembrane serine protease class of 
the trypsin superfamily that converts pro-atrial natriuretic peptide to biologically 
active atrial natriuretic peptide (272).Missense mutations of this gene have been 
associated with pre-eclampsia (273). 
 
EHMT1 (Euchromatic Histone Lysine Methyltransferase 1) 
 
The protein encoded by this gene is a histone methyltransferase that is part of the 
E2F6 complex, which represses transcription. Mutations in this gene are associated 
with 9q subtelomeric deletion syndrome, Kleefstra syndrome (274).  
 
DPF2 (Double PHD Fingers 2, also called as Requiem) 
 
This protein functions as a transcription factor which is necessary for the apoptotic 
response (275). 
 
KSR1 (Kinase Suppressor of Ras 1) 
 
This gene promotes phosphorylation of Raf family members and activation of MAPK1 
and/or MAPK3 (276). 
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POP4 (Processing of Precursor 4) 
 
This gene encodes one of the protein subunits of the small nucleolar ribonucleoprotein 
complexes: and is involved in processing of precursor RNAs (277). 
 
Assuming a recessive inheritance, the filtering strategy applied to whole-exome 
sequencing data. 
 
Figure 7.4: Recessive Inheritance Analysis  
 
Recessive Variant Analysis of Proband B (* Novel variants include variants present in 
at least 3% minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP 
exomes excluded; ** Predicted deleterious variants included nonsynonymous coding, 
splice site, frameshift, stop gain variants; *** Variants present in 
homozygous/compound heterozygous state in the child) 
 
 
 
 
62168 • Total	variants	in	3	family	members
3598 • Novel	variants*
681 • Predicted	deleterious**
5 • Genetic	analysis***
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The list of compound heterozygous/homozygous variants from proband B are shown 
below in table 7.2 
 
Table 7.2: List of compound heterozygous/homozygous variants in Proband B 
 
Chromosome Gene Gene region  Protein variant 
    
1 MST1L Exonic p.H81D/p.G300fs*89 
    
12 KLRF2 Exonic p.T98R 
    
13 PABPC3 Exonic p.R272del/p.Q292* 
    
14 WDR89 Exonic p.D98E/p.C89Y 
    
18 ASXL3 Exonic p.R989G/p.K1026N 
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Description of Homozygous and Compound Heterozygous variants from 
proband B 
 
MST1L (Macrophage Stimulating 1 Like) 
 
This is a protein coding gene with limited information on its biological function from 
the current literature. 
 
KLRF2 (Killer Cell Lectin Like Receptor F2) 
 
This gene comprises of an activating homodimeric C-type lectin-like receptor 
(CTLR), expressed on natural killer cells and stimulates their cytoxicity and cytokine 
release (278). 
 
PABPC3 (Poly(A) Binding Protein Cytoplasmic 3) 
 
PABPC3 is an important component of the 3-prime poly(A) tail of eukaryotic mRNA 
and required for the shortening of poly(A) and initiation of translation (279). 
 
WDR89 (WD Repeat-Containing Protein 89) 
 
There is no biological information on the function of this gene from the current 
literature. 
 
ASXL3 (Additional Sex Combs Like 3, Transcriptional Regulator) 
 
This gene encodes a protein containing a plant homeodomain (PHD) zinc finger 
domain that plays a role in the regulation of gene transcription. Nonsense and 
frameshift mutations in this gene have been associated with Bainbridge Roper’s 
syndrome(BRPS). ASXL3 and BRPS have been described in detail in the next section. 
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7.4 BAINBRIDGE-ROPERS SYNDROME(BRPS) 
 
Bainbridge-Roper’s syndrome (BRPS: OMIM: 615485) was described for the first time 
by Bainbridge and his colleagues in the year 2013 (280). De novo truncating mutations 
in the additional sex combs-like 3 (ASXL3) gene are implicated in BRPS characterised 
by severe intellectual deficit, feeding difficulties, failure to thrive and cranio-facial 
features (280-283). BRPS has been reported only in a  few patients in the literature 
(280-283)  Majority of the patients had either frameshift or truncating mutations in 
ASXL3. Splicing mutation in ASXL3 resulting in BRPS has been reported in one 
patient (282).BRPS has overlapping clinical phenotype with Bohring-Opitz syndrome 
(BOS:OMIM:605039), a developmental syndrome characterised by a severe 
intellectual deficit, distinct posture and cranio-facial abnormalities, feeding problems 
and failure to thrive [Bohring et al., 2006;]. De novo truncating mutations in ASXL1, 
belonging to the same family as ASXL3 have been implicated to cause BOS (284). 
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7.5 ASXL3: GENE DESCRIPTION 
ASXL3 belongs to the ASXL gene family, the mammalian homologues of Drosophila 
Asx. ASXL1, ASXL2 and ASXL3 are the three orthologues of ASXL. They encode the 
Putative Polycomb group (PcG) protein that has a role in regulating the homeotic 
genes (Hox)(285). PcG proteins have a role in regulating the Hox genes by either as 
transcriptional repressors or activators (285).ASXL group of genes share a common 
domain architecture consisting of ASXN, ASXM1, ASXM2(HARE-HTH associated) 
domains, ASXH and a PHD finger (Figure 7.5), and have a tendency to form 
complexes with other proteins via methylation of histones (283, 285, 286).  
The deubiquitination of histone H2A lysine 119(H2AK119Ub1), a component of the 
Polycomb repressive deubiquitination (PR-DUB) complex is dependent on ASXL3 
(283).The formation of PR-DUB complex is critical for normal function. The mono-
ubiquitin (Ub1) from the H2AK119Ub1 is removed by the interaction of ASXL3 with 
BAP1 a ubiquitin terminal hydroxylase (287).Srivastava et al. demonstrated a 
significant increase in the H2AK119Ub1 due to impaired deubiquitination in the 
fibroblasts of patients with BRPS (283).  
The expression of ASXL3 in human tissues have been studied and it was found that 
in the human brain, ASXL3 expression was found in the white matter, insula, cingulate 
gyrus and amygdala (288). The expression of ASXL3 and ASXL1 follow  a similar 
pattern, however the  ASXL3 expression is relatively less compared to ASXL1, which 
may explain the overlap of some phenotypic features seen in BRPS and BOS (289). 
The spinal cord, kidney, bone marrow and liver also express ASXL3, but at a lower 
level when compared to ASXL1 (289). 
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Figure 7.5: ASXL3 gene with domains 
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In this study, by WES, a novel compound heterozygous mutation in ASXL3 was 
identified in proband B with severe short stature secondary to IGF1 (Insulin Growth 
Factor 1) deficiency, developmental delay, intellectual deficit, cranio-facial 
abnormalities. This gene has been explored in detail as the phenotype of proband B 
segregates with that of BRPS. However, this is the first time, a compound 
heterozygous mutation in ASXL3 contributing to BRPS with primary IGF1 deficiency 
has been described. 
 
7.6 EXOME SEQUENCING 
 
A detailed description of the exome sequencing workflow is described in chapter 4. 
 
DNA extracted from blood samples of the child and both the biological parents (trio) 
using the QIAmp DNA blood Midi Kit (Qiagen, Hilden, Germany) as per the 
manufacturer’s instructions The samples (3 µg/sample) were sheared with the 
Picoruptor to a size approximately 150-200 bp. The samples were cleaned with 1.8x 
AMPure beads (Agencourt) and end repaired at 20°C for 30 minutes. The products 
were A tailed by incubation at 37°C for 30 minutes, cleaned with AMPure beads again 
and ligated to index adapters at 30°C for 10 minutes to make a pre-capture library 
using the Agilent Sureselect XT target enrichment system for Illumina. Exons were 
captured using SureSelect XT Human All Exon V5 capture library and DNA 
sequencing was carried out using the Illumina HiSeq4000 at 2x150 bp paired-end 
sequencer.  
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7.7 BIOINFORMATICS 
 
The sequence data were aligned to the reference genome (GRCh37/hg19). Reads 
were mapped to the reference sequences using BWA mem version 0.7.5a with default 
parameters (290). The mapped reads were locally re-aligned to improve the 
alignments around small insertions/deletions (indels) using the Genome Analysis Tool 
Kit (GATK) version 2.1.13 (291). The read duplicates were identified and filtered to 
retain only a single representative, using the Picard “MarkDuplicates” tool, version 
1.85. Base quality scores were recalibrated using GATK 
BaseQualityScoreRecalibrator(BQSR).  BQSR is a module of GATK to create more 
accurate base qualities, which in turn improves the accuracy of our variant calls. 
Functional consequences of the variants identified were annotated using SnpEff. The 
variants present in at least 5 % minor allele frequency in 1000 Genomes Project, 
dbSNP142, and NHLBI ESP exomes were excluded. The predicted deleterious 
variants included non-synonymous coding, splice site, frameshift, stop gain variants. 
 
The conservation of the positions of the two mutations in proband B, R989G and 
K1026N, was assessed using the UCSC Genome Browser (292). General, sequence-
based assessment of the potentially deleterious nature of the mutations was carried 
out with PolyPhen-2 (293) and SIFT (293). Bespoke interpretation considered 
predictions of intrinsic disorder made with IUPred (294). Matches to known protein 
linear motifs were sought in the ELM database (295)  and the general likelihood of 
regions to harbour such motifs – known or novel – was assessed with SLiMPred (296) 
and ANCHOR (297). 
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7.8 ASXL3 MUTATIONS IN PROBAND B 
 
Two novel heterozygous mutations in ASXL3 [NM_030632.1]: c.2965C>G, p. R989G 
inherited from the mother and c.3078G>C, p. K1026N, inherited from the father were 
found in the proband B. The mutations were subsequently confirmed by Sanger 
sequencing (Figure 7.6).  
 
Figure 7.6: Compound heterozygous mutations, confirmed by sanger sequencing 
C.2695 C>G 
 
 
C.3078 G>C 
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7.8.1 Description of ASXL3 Compound Heterozygous Mutations 
The mutations occur in exon 11 and proximal part of exon 12 (Figure 7.6). Both the 
mutated positions are strongly conserved at the protein level as visualised using the 
UCSC Genome browser. The conservation is across vertebrates as diverse as lemur, 
bat, fish and frog, implying that mutation could potentially affect the protein structure 
or function. Besides, in silico analyses using PolyPhen-2 and SIFT predict the amino 
acid substitutions to be potentially deleterious to the protein function.  
 
Exon 11 and proximal part of exon 12 harbour most of the pathogenic mutations in 
ASXL3. The reported mutations in ASXL3 retain the ASXN and ASXH domains. In 
proband B, both the compound heterozygous mutations lie on exon 11 and proximal 
exon 12, and retain the ASXN and ASXH domains similar to previously described 
mutations (Figure 7.7). Both these mutations occur on the conserved ASXM1 domain 
in ASXL3 (Figure 7.7) and hence could potentially contribute to the loss of function of 
the protein contributing to the BRPS like phenotype. 
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Figure 7.7: ASXL3 gene with domains.1-12 represent the exon numbers. Some of the 
previously reported frameshift, truncating and splice site mutations have been shown. 
Compound heterozygous mutations in proband B are highlighted in bold. 
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Proband B   has features that overlap with those described in previous reported cases 
of BRPS (Table 7.3) 
Table 7.3: Comparison of phenotypic features of proband B with patients with BRPS 
reported in the literature 
Phenotype Proband B Bainbridge 
et al.(4 
patients) 
Dinwiddie 
et al. 
(1 patient) 
Srivastava et al 
(3 patients) 
Hori et al. 
(1 
patient) 
Balasubramanian 
et al 
(12 patients) 
Kuechler et 
al. 
(6 patients) 
Clinical        
Feeding 
problems  
+ + + + + 9/12 6/6 
     
Failure to 
thrive 
+ + + + +   
Short stature + +  ND + 2/12 2/6 
IUGR - 3/4 + 2/3 +   
Craniofacial        
Trigonocephaly - 1/4 + 1/3 +   
Microcephaly - 2/4 + - + +  
Scaphocephaly + - - - - +  
Palate High arched 1/4 ND ND ND High arched(9/12) High 
arched(5/6) 
Prominent 
forehead 
+ 2/4 ND 1/3 ND + 5/6 
Prominent eyes - - + - ND ND ND 
Palpebral 
fissures 
downslanting  upslanting downslanting(2/3) - Downslanting-
10/12 
Upslanting-2/12 
downslanting 
Nasal bridge long - depressed Broad(1/3) depressed Long,prominent 6/6(prominent 
columella) 
Low set ears + 1/4 ND 1/3 - + ND 
Posteriorly 
rotated 
ears 
Cupped ears 2/4 + + - +  
 
Anteverted 
nares 
- + + 1/3 - ND 5/6 
Small chin + ND ND 2/3 + + ND 
Ophthalmic        
Strabismus + ND ND 1/3 + 7/12 5/6 
Astgmatism myopia ND Myopia(1/3) Hyperopia(1/3) myopia ND  
Neurological        
Developmental 
delay 
+ + + + +  6/6 
Intellectual 
deficit 
+ + + 2/3 + 12/12 5/6 
Seizures - - + 1/3  3/12 2/6 
Autism + ND ND ND + 9/12 Not formally 
diagnosed 
Other Features        
large fontanelle + 1/4 ND ND ND ND ND 
Undescended 
testes 
+ 1/4 ND ND ND   
Chronic 
constipation 
+ ND ND 1/3 ND ND ND 
+: present -:not present; ND: not described 
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7.8.2 Bioinformatic Analysis of the ASXL3 Compound Heterozygous Mutations, 
c.2965C>G, p.R989G and c.3078G>C, p.K1026N 
 
A possible molecular mechanism by which the first of the mutations R989G might lead 
to a functional defect is suggested by a detailed bioinformatics analysis. An analysis 
of ELM (Eukaryotic Linear Motif) database shows a stretch of amino-acid residues 
from the position 989 to 997 within the wild-type ASXL3 that matches with an 
interaction motif (LIG_14-3-3_CanoR_1; Accession ELME000417) that describes 
canonical phosphopeptide binding motif of 14-3-3 group of proteins.  
 
14-3-3 proteins are important cell regulators (298), and are best known for their role 
in cell cycle control. The main determinant of interaction with 14-3-3 proteins is the 
mutated arginine at position 989 together with a phosphorylated serine residue, 3-5 
residues downstream. Besides, the 14-3-3 proteins also have been implicated as 
histone modification readers (299). This links suggestively to the recently determined 
role of ASXL3 in histone deubiquitination (283).According to this hypothesis, mutation 
of R989 to glycine would prevent the interaction of ASXL3 with an as-yet unidentified 
14-3-3 protein, thereby damaging function through the impairment of its ability to 
scaffold epigenetic protein complexes (300).Although appealing, it should be pointed 
at that there is currently no evidence of phosphorylation of any of the relevant Serine 
residues in the PhosphoSite database (301).However, the content of this database is 
obviously restricted to cell types and experimental conditions already sampled so the 
absence does not disprove the hypothesis.  
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The presence of the R989G mutation in the mother implies that the additional 
presence of the K1026N is required for pathogenesis. The molecular mechanism for 
this remains unclear at this point but at least three possibilities can be proposed - 1) 
the second mutation perturbs the functionality of an additional phosphorylation-
dependent 14-3-3 binding motif covering nearby residues 1036-1043; 2) although not 
lying at one of currently defined key positions, the K1026N mutation affects 
phosphorylation of ASXL3 through its location within recognition motifs for kinases 
(PIKK group, motif from 1024-1030 or GSK3, motif from 1024-1031); or 3) the mutation 
destroys or creates an interaction motif not currently in the ELM database: the list of 
such motifs continues to grow (295).The molecular defects caused by the two 
mutations would specify the disorder additively or synergistically by simultaneously 
impacting on two points of the molecular interaction network of ASXL3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
185 
7.9 ASSOCIATION WITH PRIMARY IGF1 DEFICIENCY 
 
The association of primary IGF1 deficiency in BRPS has not been described before. 
In normal individuals, IGF-1 circulates as part of a ternary complex with a molecular 
weight of 150 kDa. IGF-1, acid-labile subunit (ALS), and a protein that binds IGF-1 
(IGFBP-3) combine and constitute the ternary complex. IGF-1 is a 70-amino acid 
peptide hormone and growth factor that is structurally homologous to proinsulin (302).  
A low basal IGF-1 £ -3 SDS with a height of £ -3 SDS with normal or elevated levels 
of GH is indicative of primary IGF-1 deficiency  (302). The insulin-like growth factor 1 
receptor (IGF1R), is the specific receptor for IGF-1, the binding of which mediates the 
action. The binding of IGF1 to IGF1R initiates intracellular signalling and IGF-1 is one 
of the most potent natural activators of the Akt signalling pathway, which stimulates 
cellular growth and proliferation (303). 
 
In patients with BRPS, the transcriptome analysis of ASXL3 fibroblasts examining the 
differentially expressed genes (DEGs) showed that the genes regulating the cellular 
proliferation are downregulated (283). Since IGF1 plays a vital role in activating the 
Akt signalling pathway, a potent stimulator for cell proliferation and growth (304) it is 
possible  that ASXL3 potentially has a role in transcriptional activation of IGF1 involved 
in this pathway potentially via epigenetic mechanisms which could be contributing to 
short stature encountered in these patients (305).  
 
7.10 CONCLUSION 
The compound heterozygous mutations thus potentially contribute to the loss of 
function in ASXL3, causing a phenotype similar to BRPS. Although with our current 
knowledge, the molecular interaction between ASXL3 and IGF1 is unclear, it may be 
important to look for IGF1 deficiency in patients with ASXL3 mutation. 
 
 
 
186 
 
 
CHAPTER 8 
 
 
 
 
 
 
CLINICAL PHENOTYPE AND WHOLE 
EXOME SEQUENCING RESULTS  
 
 (FAMILY C) 
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8.1 SUMMARY OF CHAPTER 8 
Chapter 8 begins with the detailed description of the phenotype of proband C from 
family C and describes the results from whole exome sequencing followed by a 
detailed discussion of de novo frameshift mutation, p.Gly539fs*4 
(c.1611_1614dupAAAA) in CaMKK2 
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8.2 CLINICAL INFORMATION (PROBAND C) 
 
Proband C is a male infant born to non-consanguineous healthy British parents at 33 
weeks gestation by normal vaginal delivery with a birth weight of 1.85 kg. He presented 
at 7 months of age with a hypoglycaemic seizure (true blood glucose:1.9mmol/L). 
There had been a history of irritability settling with feeds, 6 weeks prior to the 
presentation. The investigations showed an elevated plasma insulin of 37pmol/L at 
the time of hypoglycaemia(1.2mmol/L) with inappropriately supressed free fatty 
acids(<100umol/L) and beta hydroxyl butyrate(<100umol/L), suggestive of a diagnosis 
of CHI.  
The 18F-DOPA PET CT scan was suggestive of a diffuse disease. The hypoglycaemia 
responded to diazoxide therapy (10mg/kg/day). He has developmental and speech 
delay. Genetic testing performed at the University of Exeter Medical School, Exeter 
was negative for mutations in KCNJ11, ABCC8, GLUD1, GCK, HADH, HNF4A, INSR, 
SLC16A1, TRMT10A and HNF1A. 
Figure 8.1 Pedigree of Family C 
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8.3 WHOLE EXOME SEQUENCING RESULTS OF FAMILY C 
 
In this family, whole-exome sequencing was performed on the both the 
parents(unaffected) and the affected child. Assuming a de novo inheritance pattern, 
filters were applied to whole-exome data as shown in the figure 8.2. The potential 
candidate variants are listed in the table 8.1. 
 
 
Figure 8.2: De Novo variant analysis of Family C  
 
De Novo Variant Analysis of Family C (* Novel variants include variants present in at 
least 5% minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP 
exomes excluded; ** Predicted deleterious variants included nonsynonymous coding, 
splice site, frameshift, stop gain variants; *** Variants present in heterozygous state in 
the child and not present in both the parents) 
 
 
 
 
 
 
 
62455 • Total	variants	in	3	family	members
7306 • Novel	variants*
1688 • Predicted	deleterious**
13 • Genetic	analysis***
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Table 8.1: List of de novo variants from Proband C 
 
 
Chromosome Gene Gene region Protein variant 
    
1 IGFN1 Exonic p.S1583G 
    
4 CNOT6L Exonic p.Q510fs*4 
    
4 ABCE1 Splice site  
    
4 STOX2 Exonic p.V108F 
    
6 NUP153 Splice site  
    
6 PEX7 Splice site  
    
7 KMT2C Exonic p.N279D 
    
8 VPS13B Splice site  
    
8 SPATC1 Exonic p.V332del 
    
9 ORM2 Exonic p.Y96S 
    
12 KMT2D Exonic p.S4919fs*13 
    
12 CAMKK2 Exonic p.G539fs*4 
    
17 EFNB3 Exonic p.G280fs*7 
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Brief Description of de novo Variants  
 
 
IGFN1 (Immunoglobulin-Like and Fibronectin Type III Domain Containing 1) 
 
Mansilla et al. showed that IGFN1 is expressed in skeletal muscle and plays a role in 
ribosomal protein synthesis (306). 
 
 
CNOT6L (CCR4-NOT Transcription Complex Subunit 6 Like) 
 
CNOT6 was characterized by Chen et al. following expression in a yeast strain lacking 
the endogenous yeast Ccr4 gene and was found to show poly(A) exonuclease activity 
against a substrate containing five 3-prime adenines (307). 
 
ABCE1 (ATP Binding Cassette Subfamily E Member 1) 
 
The protein encoded by this gene is a member of the superfamily of ATP-binding 
cassette (ABC) transporters. ABC proteins transport various molecules across extra- 
and intra-cellular membranes. 
 
STOX2 (Storkhead Box 2) 
 
Nagase et al. by RT-PCR ELISA detected highest expression of STOX2 in whole adult 
brain and heart, followed by fetal brain and adult spleen and ovary (308). 
 
NUP153 (Nucleoporin 153) 
 
Nuclear pore complexes regulate the transport of macromolecules between the 
nucleus and cytoplasm.Walther et al. localized Xenopus NUP153 to the nuclear ring 
of the nuclear pore complex (309). 
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PEX7 (Peroxisomal Biogenesis Factor 7) 
 
Disease associated with PEX1 mutation include Rhizomelic chondrodysplasia 
punctata, type 1(310). 
 
KMT2C (Lysine Methyltransferase 2C) 
 
This gene is a  member of the myeloid/lymphoid or mixed-lineage leukaemia (MLL) 
family and ubiquitously expressed in testis and ovary, followed by brain and liver 
(311).  
 
VPS13B (Vacuolar Protein Sorting 13 Homolog B) 
 
This gene encodes a potential transmembrane protein that may function in vesicle-
mediated transport and sorting of proteins within the cell. This protein may play a role 
in the development and the function of the eye, hematological system, and central 
nervous system. 
 
 
SPATC1 (Spermatogenesis And Centriole Associated 1) 
 
Using immunohistochemical analysis Spatc1 expression was found in exclusively in 
mouse testis, in the cytoplasm of spermatocytes, spermatocytes undergoing meiotic 
division, round spermatids, and condensed spermatids (312). 
 
ORM2 (Orosomucoid 2) 
 
ORM2 is key acute phase plasma protein and is increased in acute inflammation, and 
thus classified as an acute-phase reactant.  
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KMT2D (Lysine Methyltransferase 2D) 
 
The protein encoded by this gene is a histone methyltransferase that methylates the 
Lys-4 position of histone H3 and mutations associated with this gene is associated 
with Kabuki syndrome (8).Although Kabuki syndrome can he associated with 
hyperinsulinaemic hypoglycaemia, this gene was excluded as proband C did not have 
any dysmorphic features that may suggest Kabuki syndrome. 
  
EFNB3 (Ephrin B3) 
 
EFNB3 is expressed in the midterm fetus, the highest EFNB3 mRNA level in brain, 
followed by heart, kidney, and lung; In adults the expression is restricted to brain and 
is particularly high in forebrain subregions, suggesting that EFNB3 is important in both 
brain development and maintenance (313). 
 
CaMKK2 (Ca2+/calmodulin-dependent protein kinase 2) 
 
Ca2+/calmodulin-dependent protein kinase 2 (CaMKK2) belongs to the 
Serine/Threonine protein kinase family and alternative splicing results in multiple 
transcripts encoding distinct isoforms.  
In mice, lacking CaMKK2 in their islets (CaMKK2-/-), the insulin levels were significantly 
high when compared to their wild-type littermates(CaMKK2+/+), suggesting that 
CaMKK2 and calcium signalling play an important role in the regulation of insulin 
production from the pancreatic ß cells (314). 
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As CaMKK2 segregates with the clinical phenotype of proband C, this gene has been 
explored in detail and the CaMKK2 mutation (p.Gly539fs*) is characterized by 
functional studies, explained in the next section 8.4. 
 
     8.4 CAMKK2 (Ca2+/CALMODULIN-DEPENDENT PROTEIN KINASE 2) AND  
           EFFECT OF MUTATION CAMKK2 (p. Gly539fs*4)  
This section begins with a brief introduction on CaMKK2, its role in insulin secretion. 
This is followed by a detailed description of the de novo heterozygous CaMKK2 
mutation (p. Gly539fs*4) from proband C and functional studies to demonstrate the 
pathogenicity of the mutations. 
  
8.4.1 Calcium/Calmodulin dependent protein kinase 2(CaMKK2) 
 
Human CaMKK2 maps to chromosome 12q24.2 and spans over 40kb pairs.  The 
major full length isoform of CaMKK2 is isoform 1, however alternative splicing of exons 
14 and/or 16 gives rise to multiple transcripts (isoforms 2, 3 ,4, 5, 6 and 7) (315). 
8.4.2 Role of CaMKK2 in Insulin Secretion 
The secretion of insulin from the β-cells of the pancreas is a tightly co-ordinated 
process and is closely linked to glucose metabolism by pancreatic β-cell ATP-sensitive 
potassium channels. Increased blood glucose concentration drives glucose uptake 
into pancreatic b-cells via the glucose transporter 2, encoded by GLUT2, which 
increases ATP production and raises the cytosolic ATP/ADP ratio resulting in closure 
of ATP-sensitive potassium channels (KATP) (130).  Glucose-dependent closure of 
KATP channels facilitates cell membrane depolarization, which stimulates Ca
2+ influx 
into the pancreatic β-cell via opening of voltage-gated Ca2+ channels.  The increase 
in the intracellular Ca2+ triggers exocytosis and release of insulin (141); however, the 
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molecular mechanisms that control Ca2+-triggered insulin release in response to 
glucose stimulation in b-cells is poorly understood (130). 
 
The intracellular effects of calcium(Ca2+) in the pancreatic β-cells are largely 
transduced via CaM (Calmodulin), and Ca2+-CaM complex through the activation of 
tightly regulated set of protein kinases such as the Ca2+-CaM-dependent protein 
kinases 1 and 4 (CaMK1 and CaMK4), and the AMP activated protein kinase (AMPK) 
(314).  These kinases are activated by increasing intracellular Ca2+ and belong to a 
diverse group of enzymes with a role in many cellular responses (314).  An important 
component of this kinase cascade is the Ca2+-CaM-dependent protein kinase kinase-
2 (CaMKK2), which is activated by increased intracellular Ca2+ and directs the 
downstream actions of CaMK1 and CaMK4, the AMP activated protein kinase 
(AMPK)(316, 317), and the histone deacetylase Sirtuin-1 (Sirt1) (318, 319).  Thus 
CaMKK2 is important and acts as a Ca2+-sensor with a potential key role in glucose-
stimulated insulin secretion and therefore a potential candidate gene in disorders 
relating to glucose homeostasis.  
 
The mechanism of insulin secretion from the pancreatic ß-cell via the Ca2+-CaM 
dependent pathway is shown in the figure 8.3. 
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Figure 8.3: Mechanism of insulin release from ß-cell via the kinase cascade regulated 
by Ca2+-CaM-dependent protein kinase kinase-2 (CaMKK2), activated by increased 
intracellular Ca2+ and directs the downstream actions of CaMK1 and CaMK4. 
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8.5 METHODS 
DNA extraction, exome sequencing and bioinformatics have been described in detail 
in chapter 4. 
A brief description of the specific methodologies used for functional analysis of the 
CaMKK2 isoform 7 pG539fs*4 variant is described below. All the functional work was 
done in close collaboration with Dr John Scott, University of Melbourne, Australia. 
8.5.1 Plasmid 
Plasmid constructs for full length N-terminal Flag-tagged human CaMKK2 isoform-1, 
isoform-7 and isoform-7 pG539fs*4 mutant were generated by custom gene synthesis 
(General Biosystems), and cloned into the pcDNA3(-) mammalian expression vector 
using XhoI/HindIII restrictions sites.  All constructs were verified by sequencing the 
entire open reading frame.  Plasmid DNA for COS7 cell transfection was prepared 
using Wizard Plus SV Miniprep DNA Purification Kits (Promega). 
 
8.5.2 Expression of human CaMKK2 isoforms and pGly539fs*4 mutant  
COS7 cells were grown in DMEM (Sigma) media with 10% fetal calf serum at 37 °C 
with 5% CO2.  Cells were transfected at 60% confluency with 2 µg of pcDNA3 
containing N-terminal Flag-tagged human CaMKK2 isoform-1, isoform-7 and 
Gly539fs*4 mutant using FuGene HD (Roche).  Transfected cells were harvested after 
48 hr by washing with ice-cold phosphate-buffered saline (PBS) followed by rapid lysis 
in situ using 1 ml of lysis buffer (50 mM Tris.HCl [pH 7.4], 150 mM NaCl, 50 mM NaF, 
1 mM NaPPi, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1% [v/v] Triton X-100) containing 
Complete protease inhibitor cocktail (Roche).  Cellular debris was removed by 
centrifugation and total protein in the cell lysate was determined using the Bradford 
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protein assay (Pierce).  Recombinant CaMKK2 was purified from 10 µg of cell lysate 
using 10 µl of anti-Flag M2 agarose (50% v/v) (Sigma) pre-equilibrated in lysis buffer, 
followed by successive washes in lysis buffer containing 1 M NaCl, and finally into 50 
mM HEPES [pH 7.4].  The immobilized CaMKK2 was then sedimented by 
centrifugation and used for kinase assays. 
 
8.5.3 CaMKK2 Assay 
CaMKK2 activity was measured using a synthetic peptide substrate (CaMKKtide) 
(318).  Briefly, 10 µl of recombinant CaMKK2 immobilized on anti-Flag M2 agarose 
beads (50% v/v) was incubated in assay buffer (50 mM HEPES [pH 7.4], 1 mM DTT, 
0.02% [v/v] Brij-35) containing 200 µM CaMKKtide, 50 µM CaCl2, 1 µM CaM (Sigma), 
200 µM [g-32P]-ATP (Perkin Elmer) and 5 mM MgCl2 in a standard 30 µl assay for 10 
min at 30 °C.  Reactions were terminated by spotting 15 µl onto P81 phosphocellulose 
paper and washing extensively in 1% phosphoric acid.  Radioactivity was quantified 
by liquid scintillation counting, and CaMKK2 activity was corrected for minor 
differences in expression as determined by immunoblotting using an anti-Flag 
antibody and Odyssey Infrared Imager.   
 
Kinase activity of CaMKK2 isoforms and pGly539*fs4 mutant was measured over a 
range of CaM concentrations (0-1000 nM) in the presence of 50 µM Ca2+.  CaMKK2 
activity was express in nmol.min-1.mg-1 of cell lysate. 
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8.5.4 Immunoblotting 
50 µg of total COS7 cell lysate containing recombinant CaMKK2 was denatured in 
SDS sample buffer, resolved on a 4-15% Mini-Protean Gradient gel (Bio-Rad), before 
transferring onto Immobilon PVDF membrane (Millipore).  The membrane was blocked 
for 30 min in PBS/1% Tween-20 (PBS-T) supplemented with 2% non-fat milk, and then 
incubated with rabbit anti-Flag antibody (Cell Signalling; Cat No 2368S; Lot No 6; 100 
ng/ml) for a further 30 min.  The membrane was then briefly washed in PBS-T, followed 
by incubation with goat anti-rabbit IgG IRDye680 (Li-Cor) for 30 min.  After successive 
washing with PBS-T, the membrane was scanned with an Odyssey CLx Infrared 
Imager (Li-Cor). 
 
8.5.5 CaMKK2 isoform-7 (c.1611_1614dupAAAA) (pG539fs*4) mutation 
Exome sequencing of family C (proband and the unaffected parents) identified a total 
of 13   de novo variants (IGFN1, CNOT6L, ABCE1, STOX2, NUP153, PEX7, KMT2C, 
VPS13B, SPATC1, ORM2, KMT2D, EFNB3, CaMKK2). A review of literature 
suggested a potential role of CaMKK2 in insulin secretion from pancreatic ß-cells and 
thus segregating with the phenotype of CHI in proband C. The de novo heterozygous 
mutation (c.1611_1614dupAAAA) in CaMKK2 isoform-7 (NM_001270486.1) that 
results in a frameshift at glycine-539 (pG539fs*4), producing CaMKK2 isoform-7 with 
a short alternate C-terminal sequence (Figure 8.4 A). None of the other variants 
segregated with the patient’s phenotype and thus were not studied further. 
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By immunoblotting, it was demonstrated that the pG539fs*4 mutant can be readily 
expressed in COS7 cells to a similar level as WT CaMKK2(isoform 7) and 
CaMKK2(isoform 1) (Figure 8.4 B). 
The measurement of Ca2+-CaM dependent kinase activities showed that pG539fs*4 
mutant had significantly higher basal and maximal Ca2+-CaM dependent kinase 
activities (2.86 and 1.38-fold, respectively) relative to WT CaMKK2 isoform 7 (Figure 
8.4 C).  Furthermore, both WT CaMKK2(isoform 7) and the pG539fs*4 mutant have 
considerably higher basal activities compared with WT CaMKK2(isoform 1), the most 
abundant isoform in the majority of tissues.  Although the pG539fs*4 mutant has 
increased kinase activity relative to the other isoforms, the concentration of CaM 
required for half-maximal stimulation of the pG539fs*4 mutant is similar to WT 
CaMKK2.7 and WT CaMKK2.1, indicating that CaM sensitivity is unaffected (Table 
8.2).  
 
 
 
 
 
 
 
 
 
 
201 
Table 8.2:  Ca2+-CaM stimulated activities of CaMKK2.1 (isoform 1), CaMKK2.7 
(isoform 7) and pG539*fs4 mutant measured over a range of CaM concentrations (0-
1000 nM) in the presence of a fixed concentration of Ca2+ (50 nM), expressed relative 
to activity in the absence of CaM.  Data are presented as mean ± SEM; n=4.   
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CaMKK2 Isoform Concentration of CaM required for half-maximal 
stimulation (nM) 
CaMKK2.1 62.1 ± 5.93 
CaMKK2.7 51.3 ± 7.99 
CaMKK2.7 
pG539*fs4 
63.8 ± 10.2 
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Figure 8.4 A: Linear domain structure of the CaMKK2 isoforms showing the kinase 
domain, autoinhibitory sequence (AIS), calmodulin-binding (CaMBS) sequence, and 
divergent C-terminal sequences (CTS).   
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Figure 8.4 B: Immunoblotting with rabbit anti-Flag antibody demonstrating the 
expression of pG539fs*4 mutant at a similar level as wild-type(Wt) isoform-7 in COS7 
cells  
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Figure 8.4 C: pG539fs*4 mutant showing a significantly higher baseline and Ca2+-
CaM dependent kinase activity compared with Wt isoform-7. Both isoform-
7(CaMKK2.7) and the pG539fs*4 mutant have elevated baseline activity compared 
with isoform-1(CaMKK2.1) 
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8.6 DISCUSSION 
WES in proband C identified a frameshift mutation (c.1611_1614dupAAAA) found in 
our study occurs within the last exon (exon 16) of CaMKK2 isoform 7. Isoform 1 is the 
most characterized of the CaMKK2 isoforms. A little is known about isoform 7 which 
has 16 exons. The occurrence of the frame-shift mutation in the last exon results in a 
shorter C-terminal sequence.  
Nonsense mediated decay (NMD) is a post-transcriptional surveillance mechanism 
that degrades transcripts with nonsense mutations (320).As a result of NMD the 
synthesis of the C-terminally truncated protein is limited. However, the synthesis of 
the truncated protein depends on the position of the nonsense mutation. The 
mutations that occur in the beginning of  mRNA or residing at least 50 nucleotide 5′ to 
an exon junction direct the affected mRNA to rapid decay (320).Mutations that occur 
within the last exon do not activate NMD and yield a stable mRNA that directs the 
synthesis of C-terminally truncated polypeptides. These aberrant translated protein 
can act in a dominant negative fashion (321, 322).  
The frameshift mutation (c.1611_1614dupAAAA) found in proband C occurs within the 
last exon (exon 16) of CaMKK2.7, and thus may potentially escape NMD mRNA decay 
and be translated into protein.  Consistent with this view, the data from this study 
demonstrate that the CaMKK2.7 pG539fs*4 mutant can be readily expressed in 
mammalian cells to similar levels as WT CaMKK2.7 (Figure 8.4 B), therefore it is 
reasonable to consider that the pG539fs*4 mutant would be stably translated and 
functional in the pancreatic β-cells.   
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Intracellular Ca2+ plays a key role in mediating glucose-stimulated insulin secretion, 
insulin biosynthesis and acts as the key mediator for glucose-stimulated insulin 
secretion (323-325). Calcium also plays an important role in the transcription of insulin 
gene and there is evidence this is mediated in part by CaMKs, as treatment of islets 
or insulin-secreting HIT cells with the CaM antagonist KN-62 blocks Ca2+-dependent 
stimulation of insulin gene transcription (326, 327). The cAMP responsive elements of 
the human insulin gene is regulated by a transcription factor called activating 
transcription factor-2(ATF), the activation of which is enhanced by Ca2/CaM-KIV 
(328). Thus there is increasing body of evidence from the literature that Calcium 
dependent Calmodulin Kinases (CaMKs) have a potentially important role in the 
insulin secretion from the pancreatic β-cells. 
CaMK1 and CaMK4 are activated by CaMKK2 through phosphorylation of a 
conserved threonine residue within the activation loop of the protein (329). In mice 
lacking CaMKK2 in their islets, insulin levels were significantly higher when compared 
to their wild-type littermates, suggesting that CaMKK2 and Ca2+-signalling play an 
important role in the regulation of insulin production from the pancreatic b-cells 
(330).Yu et al demonstrated the role of CaM dependent protein kinase cascade in 
glucose up-regulation of insulin secretion by exposing INS-1 cells to glucose (11.2 
mmol/L) (319).  This caused an increase in insulin promoter activity and stimulation of 
CaMKK1 and CaMK4 activity, indicating a role for the CaM-KK/CaM-KIV cascade in 
the transcriptional activation of the insulin gene (319).  
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CaMKK2 isoform 1 is the most abundantly expressed isoform in many tissues. There 
is only limited information available in the literature about isoform-7. Studies in murine 
pancreatic islet cells and in the insulin-secreting cell line, INS-1 have demonstrated 
expression of  mRNA encoding CaMK4 and its upstream kinase, CaMKK (319). The 
mutation found in proband C, occurs in isoform-7. Therefore, comparison of Wt isoform 
7, Wt isoform 1 and the mutant pG539fs*4 in COS7 cells using immunoblot 
demonstrated that the pG539fs*4 mutant can be readily expressed in COS7 cells to a 
similar level as wild-type(Wt) isoform-7 (Figure 8.4 B).  
 
CaMKK2 requires Ca2+ and CaM for maximal activity and in the case of CaMKK2.7, 
the activity rises from 1.8 nmol.min.mg to 10 in the presence of Ca2+-CaM (Figure 8.4 
C).  The basal activity of the pG539fs*4 mutant is approximately 40% of the WT 
CaMKK2.7 maximum activity (Figure 8.4 C), indicating that the regulatory pathways 
downstream of CaMKK2 would be substantially switched on in the presence of the 
pG539fs*4 mutant.  CaMKK2 is an upstream activator of CaMK4, which has been 
reported to play a role in enhancing insulin gene expression in response to glucose 
stimulation in pancreatic β-cells.  Expression of a constitutively active CaMK4 mutant 
in the pancreatic cell line INS-1 was shown to stimulate the insulin gene promoter, 
whereas this effect was completely blunted by expression of a dominant negative 
CaMK4 mutant (319).  One possibility is that insulin gene expression is increased by 
this CaMKK2-CaMK4 pathway in proband C carrying the pG539fs*4 frameshift 
mutant. Since the frame-shift mutation results in a significant increase in the kinase 
activity when compared with the wild type, it is hypothesised that the increase in 
CaMKK2 activity as a result of the pG539fs*4 mutation, to be increasing the insulin 
secretion (Figure 8.5), probably via the up-regulated transcription of INS-1 gene. 
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In vivo experiments, examining the effect pancreatic b-cell specific inhibition of  
CaMKII activity in transgenic mice demonstrated that CaMKII inhibition significantly 
impaired the glucose tolerance by reducing L-type Ca2+  facilitation, Ca2+ entry and 
insulin secretion(331). Whilst the inhibition of CaMKII has been shown to reduce the 
insulin secretion from in vivo studies, it is plausible that an increased activity of 
CaMKK2 as a result of the mutation pG539fs*4 demonstrated in our study is 
contributing to high insulin secretion seen in the proband C. Furthermore, Dadi et.al 
also demonstrated that CaMKII inhibition did not have any detectable effect on the K+ 
channel activities in b cells implying that CaMKII modulates glucose stimulated insulin 
secretion downstream of KATP channels(331).  
Diazoxide is the first line medication used in the treatment of CHI that acts as an 
agonist of KATP channel, thus reducing the insulin secretion. Proband C is currently 
responding to high dose of diazoxide (10 mg/kg/day). Calcium channel antagonists 
(such as nifedipine) could be potentially considered in patients with CaMKK2 mutation 
if they do not respond or tolerate diazoxide.  
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Figure 8.5: Schematic representation of the mechanism of excess insulin release from 
ß-cell via increased activation of the kinase cascade by CaMKK2 (pG539fs*4). 
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Thus CaMKK2 is a potential candidate gene for CHI. Screening for more patients with 
CHI for mutations in CaMKK2 will help in more understanding of the genotype-
phenotype correlation. CaMKK2 isoform 1 is the predominant isoform and much less 
is known on CaMKK2 isoform 7. Developing CaMKK2 isoform-7 specific antibody and 
studying the expression in pancreatic islets will be useful to understand the specific 
role of CaMKK2 isoform 7 in modulating the insulin secretion. In this study, the direct 
relationship between the increased kinase activity and insulin secretion has not been 
explored. Development of mouse model and with the application of gene editing 
technologies such as CRISPR/CAS9 (Clustered Regularly Interspaced Short 
Palindromic Repeats/CRISPR-associated system) (380), it is now potentially possible 
to study the direct effect of the frame-shift mutation and examine the relationship 
between the increased kinase activity and insulin secretion. 
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CHAPTER 9 
 
 
 
 
 
 
CLINICAL PHENOTYPE AND WHOLE 
EXOME SEQUENCING RESULTS 
(FAMILIES D, E, F) 
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9.1 SUMMARY OF CHAPTER 9 
Chapter 9 begins with the detailed description of the phenotypes of proband D, E, and 
F from families D, E, F followed by the results from whole exome sequencing. 
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FAMILY D 
9.2 CLINICAL INFORMATION (PROBAND D) 
 
Proband D, a female infant was born at 34 weeks gestation with a birth weight of 1.9 
kg to non-consanguineous Caucasian parents. The antenatal history was 
unremarkable. She was noted to have a cloacal anomaly with a posterior cloaca which 
was subsequently corrected by urogenital mobilisation reconstructive surgery at 2 
years of age. She also has congenital sensorineural deafness, ventricular septal 
defect and pulmonary stenosis requiring surgical correction. Her renal ultrasound was 
normal. At 4 years of age, she was diagnosed with growth hormone(GH) deficiency 
because of her short stature(<2.5SD) and poor linear growth velocity and suboptimal 
response to glucagon stimulation test (peak GH 3.7 ug/L). She was subsequently 
commenced on GH with a good response (figure 9.2). The MRI of the pituitary gland 
showed small anterior pituitary. The other pituitary hormones were within the normal 
range. She was investigated for recurrent hypoglycaemic episodes and the results of 
the investigations following a prolonged control fasting were consistent with ketotic 
hypoglycaemia. The investigations of prolonged fast are summarised in the table 
below (Table 9.1). She had multiple dysmorphic features such as anteverted nares, 
small upturned nose, hypertelorism, slight frontal bossing, short proximal bones, 
femur, humerus, hypermobile joints and down slanting palpebral fissures. There was 
a history of short stature and dysmorphism in father’s side and learning difficulty in 
mother. There was also a history of still-born previous sibling with midline cleft palate, 
absent uvula, small jaw, depressed nasal bridge, abnormalities on MRI brain with 
absence of the inferior cerebellar vermis, partial agenesis of corpus callosum, 
congenital heart defects and short bones.  
 
 
 
214 
Due to persistent hypoglycaemia, a targeted exome sequencing of genes associated 
with disorders of ketogenesis, ketolysis, carbohydrate metabolism, fatty acid oxidation 
defects and hyperammonaemia performed at the University of Manchester molecular 
genetics department did not identify any pathogenic mutations. The genes that were 
sequenced for the above disorders are as follows: 
ABAT, ACAD9, ACADM, ACADS, ACADVL, ACAT1, ACAT2, AHCY, ARG1, ASL, 
ASS1, CPS1, CPT1A, CPT2, DECR1, ETFA, ETFB, ETFDH, GLUD1, HADHA, 
HADHB, HMGCL, HMGCS2, IVD, MMAA, MMAB, MMACHC, MMADHC, MUT, 
NAGS, OTC, OXCT1, PCCA, PCCB, SLC22A5, SLC25A13, SLC25A15, SLC25A20 
AGL, ALDOA, ENO3, EPM2A, FBP1, G6PC, G6PC3, GALE, GALK1, GALT, GBE1, 
GYS1, LAMP2, LDHA, NHLRC1, PFKM, PGAM2, PGK1, PGM1, PHKA1, PHKA2, 
PHKB, PHKG1, PHKG2, PRKAG2, PYGL, PYGM, SLC2A1, SLC2A2, SLC37A4. 
 
Table 9.1: Results of investigations following a 19 hour fast: 
 
True blood glucose 2.3mmol/L 
Insulin <14pmol/L 
C-peptide <33pmol/L 
Plasma Free fatty acids 2673umol/L 
3 hydroxy butyrate 1205umol/L 
Plasma free carnitine 13.2umol/L 
17 OHP <1nmol/L 
Plasma amino acids Normal 
Urinary organic acids Normal 
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Figure 9.1 Pedigree of Family D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.2: Growth chart of Proband D showing a good response to GH 
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9.3 WHOLE EXOME SEQUENCING RESULTS FROM FAMILY D 
 
In this family, whole-exome sequencing was performed on the affected child and 
biological mother as biological father was unavailable. Filters were applied to whole-
exome data as shown in the figure 9.3. The potential candidate variants are listed in 
the table 9.2. 
 
 
Figure 9.3: Variant analysis of Family D 
 
 
 
 
Variant Analysis of Proband D (* Novel variants include variants present in at least 5% 
minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP exomes 
excluded; ** Predicted deleterious variants included nonsynonymous coding, splice 
site, frameshift, stop gain variants; *** Variants present in heterozygous state in the 
child; **** Variants with biological role related to the clinical phenotype of short stature, 
facial dysmorphia, skeletal abnormalities and congenital heart defects ). 
 
 
55355
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•Genetic	Analysis***
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Table 9.2 List of variants from proband D 
 
Chromosome Gene Gene region Protein variant 
1 COL24A1 Exonic p.R635W 
    
3 PLXND1 Splice site  
    
4 TECRL Exonic p.E11D 
    
8 EBF2 Exonic p.N477H 
    
10 ABLIM1 Exonic p.D169H 
    
11 B3GAT3 Splice site  
 
 
 
A brief description of the genes is given below 
 
 
COL24A1 
This gene is a member of the collagen gene family, encoding Collagen Type XXIV 
Alpha 1 Chain. This protein has a specific regulatory role in type I collagen 
fibrillogenesis during foetal development. The gene is associated with a disease such 
as Miller-Dieker Lissencephaly which consists of muscular dystrophic symptoms 
COL24A1 is associated with osteoblast differentiation through interacting with a 
transmembrane integrin β3, whilst silencing expression of Smad7 and inhibiting the 
phosphorylation of the Smad2/3 (332).  
 
PLXND1 
PLXND1 contributes towards the development of the cardiovascular, nervous and 
immune systems. It is suggested that Plexin D1 interacts with Sema through paracrine 
signalling to guide axonal and other tissues patterning (333). Throughout 
embryogenesis PLXND1 is dynamically activated to ensure this patterning structure. 
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TECRL 
This gene encodes Trans-2,3-Enoyl-CoA Reductase Like protein. Symptoms 
associated with this gene include ventricular tachycardia, catecholaminergic 
polymorphic 3 and catecholaminergic polymorphic ventricular tachycardia. TECRL 
has been quoted as a ‘new sudden death gene’ (334) 
 
EBF2 
This gene encodes Early B-Cell Factor 2, as part of the Collier/Olf/EBF (COE) family 
of genes to produce helix-loop-helix transcription factors. Kieslinger et al. 
demonstrated that EBF2 regulates osteoblast and osteoclasts through activation of 
the RANK decoy receptor (335). 
 
ABLIM1 
This gene encodes Actin Binding LIM Protein 1, playing a key role in regulation of 
developmental pathways through its LIM domain. Abnormal splicing of ABLIM1 has 
been reported in cases of myotonic dystrophy type 1 (336).  
 
 
9.4 B3GAT3  
B3GAT3, encoding β-1,3-glucuronyltransferase 3, has an important role in 
proteoglycan biosynthesis. Homozygous B3GAT3 mutations have been associated 
with short stature, skeletal deformities and congenital heart defects. As this gene 
appears to segregate with the clinical phenotype of proband D, it has been described 
in detail along with the splice site mutation (c.888+262T>G) in the sections below. 
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9.4.1 B3GAT3 mutation (c.888+262T>G) 
A heterozygous B3GAT3 mutation (c.888+262T>G) in the invariant “GT” splice donor 
site was identified in proband D. This variant is considered to be pathogenic as it 
decreases the splicing efficiency in the mRNA as predicted by a MaxEntScan score 
decrease of 100% (from 11.01 to -0.14) thereby creating an alternative splice site 
resulting in a frame shift and truncation of the protein through misfolding. 
9.4.2 Biological Function of B3GAT3 
B3GAT3 is involved in glycosaminoglycan (GAG) biosynthesis, which provides 
structural support within the extracellular matrix surrounding the cells(337). Genetic 
defects can thus lead to multi-system disorders. Several papers have classified a 
homozygous mutation in B3GAT3 as the reason for their patients’ congenital heart 
defects, short stature, and mild dysmorphic features (337-340).  
 
A comparison of the phenotype of proband D with that of patients with B3GAT3  
mutations reported in the literature is shown below in the table 9.3. 
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Table 9.3: Comparison of clinical features between proband D and patients with 
B3GAT3 mutations reported in the literature 
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Number of Patients 1 5 1 1 1
Skeletal Malformations
Short Stature a a (5/5) r a a
Fractures r a r a
Anteverted Nares a a (4/5) r a a
Small Upturned Nose a a a a
Hypertelorism a a
Frontal Bossing a a
Short Proximal Bones a a a
Hypermobile Joints a
Dislocating Joints r a a a
Joint Laxity r a a
Diffuse Demineralisation r a a r a
Down Slanting Palperbral Fissures a a (3/5) a
Congenital Heart Defects
Ventricular Septal Defect a a (2/5) r a
Pulmonary Stenosis a r
Bicuspid Aortic Valve r a (3/5) a r
Aortic Root Dilation r a (3/5) a
Mitral Valve Prolapse r a (4/5) r
Neurological
Small Anterior Pituitary a r r r
Partially Empty Sella a
Other Features
TSH Abnormality r a
Cognitive Delay r r a
Still-Born Sibiling a
GH Deficiency a
Congenital Sensorineural Deafness a a
Ketotic Hypoglycaemia a
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Proteoglycans are an influential component of the extracellular matrix, orchestrating 
the cell-cell and cell-matrix interactions (337). Without a functional B3GAT3 gene, the 
loss of β-1,3-glucuronlytransferase 3 causes incomplete proteoglycan production due 
to the final glucuronic acid linkage stage being absent (339). Cell signalling pathways, 
most notably developmental pathways, may become disrupted and processes such 
as skeletal development and cardiovascular maturation will halt before they are fully 
complete (339). Proteoglycans are produced through the secretory pathway in the 
endoplasmic reticulum followed by the construction of the glycosaminoglycan (GAG) 
side chain within the Golgi complex (341). Multiple post-translational modifications 
occur in the Golgi complex; including the addition of disaccharides as well as 
epimerisation and sulfation of saccharide units, all performed by various 
glycosyltransferases, epimerases and sulfotransferases (341). 
β-1,3-glucuronyltransferase 3 (GlcAT-I), encoded by B3GAT3 is located on 
chromosome 11q12.3 and consists of 335 amino acids with one N-linked glycan chain 
GlcAT-I is a glucuronyltransferase involved in the biosynthesises of GAG-protein 
linkers for proteoglycans. Specifically, GlcAT-I contributes to the addition of the 
terminal four saccharides –xylose-galactose-galactose-glucuronic acid, hence its 
presence in the cis-Golgi(342). The addition of this tetra saccharide provides an 
external face for binding by extracellular signals. 
Homozygous mutations in B3GAT3 have previously been reported throughout the 
literature with Larsen-like syndrome symptoms. Larsen syndrome is defined as a 
development disorder of the bones throughout the body, individuals frequently express 
symptoms such as skeletal dislocations, hearing loss and facial dysmorphism 
(depressed nasal bridge, frontal bossing and telecanthus) (338).  
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9.5 DISCUSSION 
B3GAT3 transcribes the 335 amino acid glucuronyltransferase I (GlcAT-I) protein 
which catalyses the final step in proteoglycan biosynthesis through the addition of a 
xylose-galactose-galactose-glucuronic acid tetra saccharide linkage molecule(340). 
Homozygous missense mutations in B3GAT3 have previously been described as 
‘linkeropathies’. Glycosaminoglycan linkeropathies are characterised by their 
enzymatic inability to synthesise the common linker region which joins the core protein 
with its respective glycosaminoglycan side chain(343).  Proteoglycans are crucial for 
effective communication between cells. Disruption of the linkage region caused by 
mutations in B3GAT3 have been reported to cause severe developmental defects. 
A novel heterozygous splice site mutation in B3GAT3 (c.888+262T>G) in the invariant 
“GT” splice donor site was found in proband D. In silico modelling of this variant 
categorised the variant as pathogenic. This variant decreases the splicing efficiency 
of the mRNA; as predicted by a MaxEntScan score decrease of 100 % (from 11.01 to 
-0.14). MaxEntScan is a in silico splicing defect prediction tool used to analyse the 
affinity of an intronic sequence to the splicing machinery (344). A decrease of 100 % 
suggests that the splice site is completely lost, thus incurring a frameshift. Subsequent 
truncation of the protein would lead to incomplete biosynthesis of the xylose-
galactose-galactose-glucuronic acid terminus of the glycosaminoglycan side chain of 
the proteoglycan 
After extensive reviewing of current literature (332-334, 336, 345, 346) it was found 
that the biological function of the filtered genes such as COL24A1, PLXND1, TECRL, 
EBF2, ABLIM1, and POSTN did not segregate with the clinical phenotype whereas 
B3GAT3 showed notable traits. 
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The phenotype of proband D aligns with several other phenotypic features described 
to be associated with B3GAT3 mutation (table 9.3). All reported cases of B3GAT3 
have short stature, anteverted nares, down slanting palpebral fissures and ventricular 
septal defects. However, these have all been associated with homozygous missense 
mutations such as c.671 T>A (p.Leu224Gln) [2], c.830 G>A (p.Arg277Gln) [1] and c. 
667 G>A (p.Gly223Ser) (338). Splice site mutations contributing to B3GAT3 
phenotype as encountered in proband D has not been described in the literature. 
In addition to some similarities in phenotypic features shown in table 9.3, proband D 
also has growth hormone deficiency and recurrent ketotic hypoglycaemia. An initial 
targeted exome sequencing experiment was conducted to discover any mutated 
genes involved in ketogenesis, ketolysis, carbohydrate metabolism, fatty acid 
oxidation defects and hyperammonaemia; no pathogenic mutations were identified. 
It is noteworthy to mention that the patient’s biological father was also short with facial 
dysmorphism and short bones. Besides, a history of stillborn elder sibling with facial 
dysmorphism, short bones and heart defects suggests a likely strong penetrance of a 
monogenic genetic aetiology in the family. The genetic analysis in the biological father 
and the elder sibling would have convincingly established the underlying monogenic 
aetiology. However, this has not been possible due to the non-availability of the DNA 
samples. After filtering the WES data from proband D, the splice site mutation in 
B3GAT3 segregated with many of the phenotypic features. Further functional studies 
are required to fully characterise the role of this splice site variant in B3GAT3. 
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FAMILY E 
9.6 CLINICAL INFORMATION (FAMILY E) 
Proband E is a 7-year-old boy who was referred for an endocrinology consultation for 
severe shore stature (height: -3.5 SDS). He was born at 39 weeks gestation to non-
consanguineous, healthy British parents with a birth weight of 2.5 kg. There were no 
neonatal concerns. There was no evidence of dysmorphism or skeletal dysplasia. The 
investigations to look into the cause for the short stature revealed a persistently low 
IGF1 of 5-8nmol/L (12-62). An IGF-1 regeneration test following 33ug/kg of GH did not 
result in the improvement of serum IGF1 concentration. A growth hormone stimulation 
test, using glucagon showed a good GH response of 11.2ug/L. A trial of high dose 
rGH treatment(40ug/kg/day) was commenced with a reasonable response (height: -
2.5SDS) (figure 9.5). CGH microarray did not reveal any copy number changes. 
Targeted sequencing of IGF1, IGF1R and GHR performed at Barts, London, did not 
reveal any mutations. 
 
Figure 9.4: Pedigree of Family E 
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Figure 9.5: Growth chart of proband E showing reasonable response to GH therapy 
 
 
 
 
 
9.7 WHOLE EXOME SEQUENCING RESULTS FROM FAMILY E  
 
In this family, whole-exome sequencing was performed on the both the 
parents(unaffected) and the affected child. Assuming a de novo inheritance pattern, 
filters were applied to whole-exome data as shown in the figure 9.6. The potential 
candidate variants are listed in the table 9.4. 
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Figure 9.6: De Novo variant analysis of Family E 
 
 
 
De Novo Variant Analysis of proband E (* Novel variants include variants present in at 
least 5% minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP 
exomes excluded; ** Predicted deleterious variants included nonsynonymous coding, 
splice site, frameshift, stop gain variants; *** Variants present in heterozygous state in 
the child and not present in both the parents) 
 
 
 
 
 
 
 
 
 
62834
• Total	variants	in	3	family	members
7363
• Novel	variants*
529
• Predicted	deleterious**
6
• Genetic	analysis***
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The potential candidate gene variants and their locations in proband E are shown in 
table 9.4 
 
 
Table 9.4: List of Genes with Novel, Predicted Deleterious Variants Not Present in 
both the parents  
 
 
Chromosome Gene Gene region Protein variant 
2 TSGA10 Splice site  
    
5 YTHDC2 Splice site  
    
5 SAR1B Splice site  
    
5 NOTCH4 Exonic p.L16del 
    
8 VPS13B Splice site  
    
13 SKA3 Splice site  
 
 
A brief description of these genes is presented next. From the available biological 
information about these genes, the phenotype of proband E could not be explained 
with variations in these genes. 
TSGA10 (Testis specific protein 10) 
 
Northern blot analysis detected the expression of this gene in testis and may play a 
role in the formation of sperm tail fibrous sheath (347). 
YTHDC2 (YTH Domain Containing 2) 
 
Members of this family function in RNA processing and metabolism, including 
transcription, alternative splicing, and degradation (348). 
SAR1B (Secretion Associated Ras Related GTPase 1B) 
 
Recessive SAR1B mutations have been reported to cause chylomicron retention 
disease (349). 
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NOTCH4 (Neurogenic Locus Notch Homolog Protein 4) 
 
The NOTCH4 gene encodes a member of Notch family. The members of this family 
are transmembrane proteins with an extracellular domain consisting of multiple 
epidermal growth factor-like (EGF) repeats, and an intracellular domain of various 
different types (350).In Drosophilia, the members of Notch family interacts with its cell-
bound ligands (delta, serrate) and this interaction plays a key role in development. In 
humans, Notch4 functions as a receptor for membrane bound ligands Jagged 1, 
Jagged 2 and Delta 1(351).By studying the Notch-4 deficient mouse, Krebs et al. 
concluded that Notch4 and Notch1 genes have partially overlapping roles during 
embryogenesis (352). Mutants mice with constitutive overexpression of Notch4 
developed brain arteriovenous malformations, suggesting Notch pathway to be an 
inhibitor of vessel sprouting (353). 
 
VPS13B (Vacuolar Protein Sorting 13 Homolog B) 
 
Homozygous mutations in this gene causes autosomal recessive condition, Cohen 
syndrome (354) 
 
SKA3 (Spindle And Kinetochore Associated Complex Subunit 3) 
This gene encodes a component of the spindle and kinetochore-associated protein 
complex that regulates microtubule attachment to the kinetochores during mitosis. 
The encoded protein localizes to the outer kinetechore and may be required for 
normal chromosome segregation and cell division (355). 
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Assuming a recessive inheritance, the filtering strategy applied to whole-exome 
sequencing data 
 
Figure 9.7: Recessive Inheritance Analysis  
 
Recessive Variant Analysis of Proband E (* Novel variants include variants present in 
at least 3% minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP 
exomes excluded; ** Predicted deleterious variants included nonsynonymous coding, 
splice site, frameshift, stop gain variants; *** Variants present in 
homozygous/compound heterozygous state in the child). 
 
 
 
 
 
 
 
 
 
 
62834 • Total	variants	in	3	family	members
6087 • Novel	variants*
1501 • Predicted	deleterious**
6 • Genetic	analysis***
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Table 9.5:  List of Genes with Novel, recessive predicted deleterious variants 
(Family E) 
 
Chromosome Gene Gene region Protein variant 
    
1 MST1L Exonic p.G300fs*89 
    
4 ZNF141 Exonic p.L70fs*34/p.K69fs*4 
    
10 CFAP46 Exonic p.G1162R/p.D1126G 
    
12 CAPZA3 Exonic p.R39C/p.R39H 
    
13 SACS Exonic p.R2844H/p.P2651Q 
    
17 GH1 Promoter c.-93delG 
 
 
A brief description of these genes is presented next.  
MST1L (Macrophage Stimulating 1 Like) 
 
There is only a limited biological information available in the literature. 
 
ZNF141 (Zinc Finger Protein 141) 
 
Defects in this gene have been associated with autosomal recessive postaxial 
polydactyly type A (356). 
CFAP46 (Cilia And Flagella Associated Protein 46) 
 
This gene is thought to play an important role in ciliary movement 
 
CAPZA3 (Capping Actin Protein of Muscle Z-Line Alpha Subunit 3) 
 
The gene encodes a protein that is localized to the neck and tail region of the 
spermatozoa and may play a role in male fertility (357). 
SACS (Sacsin Molecular Chaperone) 
 
This protein is thought to integrate the ubiquitin-proteasome system and Hsp70 
chaperone machinery and implicated in the processing of ataxin-1(358).Homozygous 
mutations are implicated in Spastic ataxia, Charlevoix-Saguenay type (359). 
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9.8 GH1(Growth Hormone 1) 
Growth hormone (GH), encoded by GH1, is a member of the somatotropin family of 
hormones (360) which stimulates growth during early postnatal somatic development 
(361).  GH regulates glucose, protein and fat metabolism in the body and is essential 
for tissue maintenance and repair throughout the duration of an individual’s life(362). 
GH consists of 191 amino acids, weighing 22 kDa, arranged in four α-helices 
connected by two cysteine bridges; forming two distinct domains which have different 
affinities for binding to growth hormone receptor (GHR) (363). 
Binding of GH to GHR induces receptor dimerization leading to transphosphorylation 
of the intracellular domains of the receptors. Phosphate groups for SH2/SH3 domains 
of intracellular second messengers to bind are then present on the intracellular side of 
the plasma membrane. Janus kinase 2 (Jak2) interacts through its SH2 domain and 
activates a downstream effector, signal transducer and activator of transcription 
(STAT5) (364). Phosphorylation of STAT5 causes its dissociation from GHR and the 
phosphorylated STAT5 translocates to the nucleus to activate transcription (365).  
Short stature is frequently characterised by a deficiency in growth hormone, known as 
isolated growth hormone deficiency (IGHD) (366). IGHD is caused by genetic 
mutations in the promoter region of the GH1 gene.  
Since the biological function of GH1 segregates with the clinical phenotype of proband 
E, a detailed description of the mutation GH1(c.-93delG) is given in the next section. 
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9.8.1 GH1 promoter variant(c.-93delG) 
Proband E has a homozygous promoter region variant (c.-93delG) in the GH1 gene 
that could be potentially contributing to the impaired transcription of the GH1 leading 
to short stature. An impairment of transcription due to promoter mutation usually 
causes GHD. Although proband E had a normal GH response to glucagon stimulation 
test, he responded well to exogenous rGH with subsequent normalisation of IGF1. It 
is therefore hypothesised that the promoter mutation in proband E to be contributing 
to the production of biologically inactive GH.  
Bioinactive GH was first reported by Kowarski et al. when they noted two children who 
expressed: normal-high immunoassayable GH levels, low basal IGF-1 levels and an 
increase in IGF-1 circulating concentrations as well as improved somatic growth 
following exogenous GH administration (367). Bioinactive GH is a rare condition in 
which there is significant difference between physiological concentrations of GH and 
the activity that is generated due to them. Bioinactive GH is associated with low insulin-
like growth factor-1 (IGF-1), short stature and a response to exogenous GH treatment 
(368). 
Homozygous point mutation in the promoter region of GH1(c.-233C>T) has been 
shown to reduce the GH1 expression, leading to isolated GH deficiency(366). Beeson 
et.al identified a homozygous missense GH1 mutation in a patient with severe short 
stature(height:-3.6SDS), persistent low basal IGF1,normal GH response on 
provocation test and a good improvement in height velocity after administration of 
rGH(111). The authors proposed that the mutation led to the disruption of the 
disulphide bridge Cys-53 to Cys-165 in the GH peptide leading to the production of 
biologically inactive GH. By in vitro experiments it was demonstrated that GHR binding 
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and Jak2/Stat5 signalling pathway was significantly reduced in the mutant GH1 when 
compared to the wild type GH1(111).  
Proband E has similar phenotypic features as the patient described by Beeson et.al. 
It is therefore possible that the improvement in height velocity to rGH with normal 
endogenous GH peak on provocation test is probably because of biologically inactive 
endogenous GH. The pathogenic effect of the homozygous promoter variant(c.-
93delG) identified in proband E on GH1 is currently unclear.  Future functional work 
such as GH binding assay may be needed to study the pathogenicity of the variant.  
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FAMILY F 
 
 
9.9 CLINICAL INFORMATION (FAMILY F) 
 
Proband F, a 15-year-old boy presented with a long standing history of tiredness and 
lethargy. He was born to non-consanguineous British parents and does not have any 
significant past medical history. His height and weight were appropriate for his age 
and the systemic examinations were normal, apart from high blood pressure 
(150/90mm Hg). His elder sibling passed away due to Hurler’s disease. 
Further investigations revealed a high serum calcium and parathyroid hormone(PTH) 
concentration, low vitamin D, low albumin and a low urinary calcium creatinine ratio. 
The investigations are charted in detail in the table below (Table 9.6). The serum 
calcium profile and PTH from both the parents were within the normal range. The 
hypercalcemia persisted in the range between 2.82-2.93mmol/L with an unsuppressed 
PTH and proband F continued to exhibit symptoms of persistent tiredness and 
lethargy. The vitamin D concentration was persistently low despite the administration 
of 300,000 IU of ergocalciferol injection. The urinary calcium creatinine ratio was 
consistently low (<0.01). A differential diagnosis of familial hypoclaciuric 
hypercalcemia and primary hyperparathyroidism was considered. Microarray did not 
identify any copy number variants. Genetic testing for familial hypocalciuric 
hypercalcemia did not identify any pathogenic mutations in CASR, GNA11 and 
AP2S1. Targeted sequencing for genes associated with familial isolated 
hyperparathyroidism did not detect any mutation in MEN1, RET, CDC73, CDKN1A, 
CDK1B, CDK2B and CDKN2C. Sestamibi parathyroid scan to localise parathyroid 
adenoma was negative. Subsequently the patient was recruited into the study for WES 
to identify a potential monogenic etiology for hypercalcemia. 
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Further investigations for persistent hypalbuminaemia included a renal biopsy which 
showed a slight increase in the mesangial cell matrix and mild increase in the 
mesangial cell numbers with no evidence of endocapillary crescents. The electron 
microscopy of the basement membrane showed a variable thickness of the basement 
membrane with electron-dense deposits. This was consistent with a form of nephrotic 
syndrome and currently being managed by losartan. 
Table 9.6: Summary of investigations in proband F 
 
Serum calcium 2.82 mmol/L to 2.93 mmol/L(2.15-2.74) 
PTH 11.6-14.6 pmol/L(1.1-6.9) 
Vitamin D 6-10 nmol/L(>50) 
Urine calcium creatinine ratio <0.01 
Albumin 23-25 g/L(40-60) 
Phosphate Normal 
Magnesium 0.66 mmol/L(0.78-1.02) 
Thyroid Function Normal 
Urine dipstick 2+ blood, 3+ protein 
Ultrasound renal tract Normal 
Liver function test Normal 
Renal functions(Urea, creatinine) Normal 
 
Figure 9.8 Pedigree of Family F 
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9.10 WHOLE EXOME SEQUENCING RESULTS FROM FAMILY F 
 
In this family, whole-exome sequencing was performed on the both the 
parents(unaffected) and the affected child. Assuming a de novo inheritance pattern, 
filters were applied to whole-exome data as shown in the figure 9.9.  
 
 
Figure 9.9 De Novo variant analysis of Family F 
 
 
 
 
 
 
De Novo Variant Analysis of Proband F (* Novel variants include variants present in 
at least 5% minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP 
exomes excluded; ** Predicted deleterious variants included nonsynonymous coding, 
splice site, frameshift, stop gain variants; *** Variants present in heterozygous state in 
the child and not present in both the parents) 
 
 
62685
• Total	variants	in	3	family	members
7410
• Novel	variants	*
587
• Predicted	deleterious	variants	**
12 • genetic	analysis	***
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The potential candidate gene variants and their locations in family F are shown in 
table 9.7 
 
 
Table 9.7: List of Genes with Novel, Predicted Deleterious Variants Not Present in 
both the parents (Family F) 
 
Chromosome Gene Gene 
region 
Protein 
variant 
2 AGPS Splice 
site 
 
    
4 ABCE1 Splice 
site 
 
    
7 MGAM2 Splice 
site 
 
    
14 SYT16 Splice 
site 
 
    
14 TTLL5 Exonic p.D219V 
    
20 SLC4A11 Splice 
site 
 
    
1 CPSF3L Exonic p.A13G 
    
6 FAM8A1 Exonic p.L135P 
    
7 AUTS2 Exonic p.Q449H 
    
13 PABPC3 Exonic p.E372G 
    
17 MPDU1 Exonic p.R169fs*44 
    
17 SRCIN1 Exonic p.R1011P 
 
 
A brief description of these genes is presented next. From the available biological 
information about these genes, the phenotype of proband F could not be explained 
with variations in these genes. 
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AGPS (Alkylglycerone-phosphate synthase) 
AGPS catalyzes the second step of ether lipid biosynthesis Mutations in this gene 
have been associated with rhizomelic chondrodysplasia punctata, type 3 and 
Zellweger syndrome (369). 
 
ABCE1(ATP Binding Cassette Subfamily E Member 1) 
 
ABCE1 belongs to the superfamily of ATP binding cassette proteins and plays an 
important role in protein translation initiation, elongation, termination, and ribosome 
recycling in eukaryotes (370). 
MGAM2 (Maltase-Glucoamylase 2 (Putative)) 
No information is currently available on the biological function of this gene. 
 
SYT16 (Synaptotagmin 16) 
 
SYT16 may have a role in the trafficking and exocytosis of secretory vesicles in non-
neuronal tissues. Is Ca(2+)-independent. RT-PCR detected highest SYT16 
expression in mouse heart and testis, with weaker expression in kidney and lung (371). 
 
TTLL5 (Tubulin Tyrosine Ligase Like 5) 
 
TTLL5 may act as a co-regulator of glucocorticoid receptor mediated gene induction 
and repression. Recessive mutations in TTL5 have been associated with cone-rod 
dystrophy (372). 
 
SLC4A11 (Solute Carrier Family 4 Member 11) 
 
This gene encodes a voltage-regulated, electrogenic sodium-coupled borate 
cotransporter that is essential for borate homeostasis, cell growth and cell 
proliferation. Recessive mutations have been associated with corneal endothelial 
dystrophy and perceptive deafness (373). 
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CPSF3L (Cleavage and Polyadenylation-Specific Factor 3-Like Protein) 
 
It is a part of integrator complex and involved in the processing of small nuclear RNAs 
U1 and U2.(374) 
 
FAM8A1 (Family with Sequence Similarity 8 Member A1) 
 
It is a protein coding gene with limited information on its biological function. 
 
 
AUTS2 (Autism Susceptibility Candidate 2) 
 
AUTS2  has been implicated in neurodevelopment and as a candidate gene for 
numerous neurological disorders, including autism spectrum disorders and autosomal 
dominant intellectual disability (375). 
 
PABPC3 (Poly(A) Binding Protein Cytoplasmic 3) 
 
Poly(A)-binding proteins (PABP) are involved in messenger RNA stability and initiation 
of translation. By Northern blot analysis of multiple tissues, it was  found to have weak 
but distinct testis-specific expression (376) 
 
MPDU1 (Mannose-P-Dolichol Utilization Defect 1) 
 
MPDU1 encodes an endoplasmic reticulum membrane protein and plays a role in the 
synthesis of lipid-linked oligosaccharides and glycosylphosphatidylinositols. Mutations 
in this gene result in congenital disorder of glycosylation type If (377) 
 
SRCIN1 (SRC Kinase Signaling Inhibitor 1) 
 
SRC kinase signalling inhibitor 1 acts as a negative regulator of SRC and downstream 
signalling, leading to impaired cell spreading and migration (378). 
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Assuming a recessive inheritance, the filtering strategy applied to whole-exome 
sequencing data 
 
Figure 9.10: Recessive Inheritance Analysis  
 
Recessive Variant Analysis of Proband F (* Novel variants include variants present in 
at least 3% minor allele frequency in 1000 Genomes Project, ExAC and NHLBI ESP 
exomes excluded; ** Predicted deleterious variants included nonsynonymous coding, 
splice site, frameshift, stop gain variants; *** Variants present in 
homozygous/compound heterozygous state in the child). 
 
 
 
 
 
 
 
 
 
 
 
 
62685
• Total	variants	in	3	family	members
6109
• Novel	variants	*
1603
• Predicted	deleterious	variants	**
10 • genetic	analysis	***
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Table 9.8: List of Genes with novel, recessive Predicted Deleterious Variants 
(Family F) 
 
Chromosome Gene Gene 
region 
Protein variant 
1 INTS11 Splice 
site 
 
    
2 CFAP65 Promoter  
    
2 ABCB6 Exonic p.A446T,p492T 
    
5 PDZD2 Exonic p.A1649V 
    
9 BRINP1 Exonic p.R358H 
    
11 DRD4 Promoter  
    
11 MRPL16 Exonic p.R199Q 
    
16 HAS3 Exonic p.R173H 
    
13 SKA3 Splice 
site 
 
    
13 PABPC3 Splice 
site 
 
 
A brief description of the above genes is given as below 
 
INTS11 (Integrator Complex Subunit 11) 
This gene associates with the C-terminal domain of RNA polymerase II large subunit  
and mediates the 3-prime end processing of small nuclear RNAs U1 and U2 (374). 
CFAP65(Cilia and Flagella associated protein) 
Tang et al. (2017) identified homozygous nonsense mutation, in CFAP65, in man 
with morphological abnormalities of the flagella in spermatozoa (379). 
 
 
ABCB6(ATP binding cassette subfamily B, member 6) 
This gene has a role in the transport of porphyrins into the mitochondria(380). 
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PDZD2(PDZ domain containing 2) 
This gene interacts with the PKP4 PDZ domain and Ma et al. (2006) localized rat 
PDZD2 specifically to pancreatic beta cells, with no expression detected in alpha 
cells(381). 
BRINP1 (Bone Morphogenetic Protein/Retinoic Acid Inducible Neural-Specific 1) 
Diseases associated with this gene mutation include transitional cell carcinoma and 
bladder carcinoma. The 5' CpG island in the gene is a frequent target for 
hypermethylation, and it may undergo hypermethylation-based silencing in some 
bladder cancers(382). 
DRD4(Dopamine receptor D4) 
This gene is localised at 11p15.5 and is associated with dominantly inherited attention 
deficit hyperactivity disorder(383) 
MRPL16(Mitochondrial ribosomal protein L-16) 
This gene has an essential role in the oxidative phosphorylation in the 
mitochondria(384). 
 
HAS3(Hyaluronon synthase 3) 
This gene has been implicated to have an important role in the biosynthesis of 
hyaluronon (385). 
 
Based on the known biological functions of these genes, the phenotype of proband F 
could not be explained with variations in these genes. 
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CHAPTER 10 
 
 
 
 
 
 
GENERAL DISCUSSION, CONCLUSIONS 
AND FUTURE DIRECTIONS 
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10.1 GENERAL DISCUSSION 
 
The use of next generation sequencing in children with undiagnosed or unidentified 
syndromic disorders is becoming more popular in the recent years and increasing the 
ability to discover novel genes and mutations contributing to novel clinical phenotypes. 
WES is a cost effective technique in comparison to whole genome sequencing and 
has the ability to target the coding regions of the genome and thus has an increased 
chance of uncovering a potential underlying genetic etiology especially in rare 
undiagnosed diseases. WES has been used increasingly in the field of paediatric 
endocrinology over the last decade contributing to the discovery of novel genes and 
genetic pathways. In this study a cohort of patients with varied phenotypes such as 
persistent CHI, congenital hypopituitarism, dysmorphic short stature with primary IGF1 
deficiency, short stature with cardiac and other dysmorphic features, severe short 
stature with persistent low IGF1 and disorder of calcium metabolism was recruited for 
WES to identify the underlying genetic etiology. The results from the study have 
revealed the following: 
1. A novel mutation in the transcription factor FOXA2 that has been shown to 
cause hypopituitarism and CHI by further functional studies. 
2. A novel compound heterozygous mutation in ASXL3 contributing to Bainbridge 
Ropers like syndrome in association with primary IGF1 deficiency. 
3. A novel frame-shift mutation in CaMKK2 contributing to increased insulin 
secretion in a patient with CHI. 
4. A novel splice site mutation in B3GAT3 potentially contributing to severe short 
stature, facial dysmorphism and skeletal abnormalities. 
5. A homozygous mutation in the promoter region of GH1 possibly causing severe 
short stature. 
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The pituitary gland is a master regulator of vital physiological functions such as growth, 
puberty, lactation, metabolism, stress response and reproduction. The development 
of the pituitary gland is tightly controlled by signalling molecules and transcription 
factors that dictate pituitary cell lineage specification, cell proliferation and terminal 
differentiation into hormone-producing cell (56, 386).  Abnormal pituitary development 
can lead to congenital hypopituitarism (CH) resulting in deficiency in one of more 
pituitary hormones.  CH comprises of a spectrum of disorders with variable 
phenotypes that can range in severity, from isolated hormone deficiency [isolated 
growth hormone deficiency being the most common] to combined pituitary hormone 
deficiency (CPHD) when two or more pituitary hormones are deficient. Hypopituitarism 
may present as part of a syndrome with abnormalities in structures that share a 
common embryological origin with the pituitary gland, such as the forebrain and eyes, 
leading to septo-optic dysplasia  (SOD) or holoprosencephaly (HPE) (386). SOD is a 
rare condition with a prevalence of 1:10,000 (387) live births and comprises the 
following features: optic nerve hypoplasia, midline forebrain defects and 
hypopituitarism (388, 389). Mutations in transcription factors such as HESX1 (68), 
PROP1 (390), POU1F1 (266), LHX3 (84), LHX4 (391), PITX1, PITX2 (392), OTX2 
(393), SOX2 (394) and SOX3 (395, 396) have been associated with CH in mouse and 
humans. However, these mutations account only for a small proportion of CH patients 
with the majority of patients having an unknown genetic cause for their symptoms. 
CHI is a rare condition with an estimated prevalence of 1 in 50,000 live births, 
characterized by an inappropriate secretion of insulin from the β-cells of the pancreas 
during hypoglycaemia (264). CHI is the most common cause of severe and persistent 
hypoglycaemia in the neonatal period. The identification and appropriate 
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management of this condition is very important to avoid hypoglycaemic episodes and 
prevent the consequent neurological impairment. Mutations in genes ABCC8 (150, 
253-256), KCNJ11 (150, 253-256), GLUD1 (397), GCK (398), HADH (171), UCP2 
(399), HNF4A (400), HNF1A (400), MCT1 (189), HK1 (194)and PGM1 (197) have 
been associated with genetic forms of CHI (265). However, the genetic cause for many 
CHI patients remains elusive.  
The combination of CHI and CHI in a single patient is extremely rare and the 
underlying genetic etiology causing this complex phenotype is unknown. In this study, 
a de novo heterozygous mutation in the developmental transcription factor, Forkhead 
box A2, FOXA2 (c.505T>C, p. S169P) was identified in proband A who presented with 
CHI, CH, craniofacial dysmorphic features, choroidal coloboma and endoderm-
derived organ malformations in liver, lung and gastrointestinal tract. The mutation is at 
a highly conserved residue within the DNA binding domain. A strong expression 
of Foxa2 mRNA was demonstrated in the developing hypothalamus, pituitary, 
pancreas, lungs and oesophagus of mouse embryos using in situ hybridization. 
Expression profiling on human embryos by immunohistochemistry showed strong 
expression of hFOXA2 in the neural tube, third ventricle, diencephalon and in the 
pancreas. Transient transfection of HEK293T cells with Wt (Wild type) hFOXA2 or 
mutant hFOXA2 showed impairment in transcriptional reporter activity by the mutant 
hFOXA2. Further analyses using western blot assays showed that the FOXA2 
p.(S169P) variant is pathogenic resulting in lower expression levels when compared 
with Wt hFOXA2. 
The results thus demonstrate, the causative role of FOXA2 in a complex congenital 
syndrome with CH, CHI and endoderm-derived organ abnormalities.  
 
 
 
247 
As discussed before, in around 50% of the patients with persistent CHI, the underlying 
molecular genetic etiology is unknown (217). Due to the heterogeneity of CHI, WES 
studies have been less successful in identifying novel genes involved in the secretion 
of insulin from the pancreatic ß-cell, the mutation of which might result in CHI. The 
downstream signalling pathway that follows the entry of calcium into ß-cell, triggered 
by membrane depolarisation is not fully understood. In this study, a de novo 
heterozygous frameshift mutation (p.G539fs*4) was found at the terminal exon (exon 
16) of CaMKK2 (NM_001270486.1) (isoform-7) in proband C with persistent CHI with 
no known genetic etiology. Ca2+/calmodulin-dependent protein kinase 2 (CaMKK2) 
belongs to the Serine/Threonine protein kinase family and alternative splicing results 
in multiple transcripts encoding distinct isoforms.  
Calcium has been found to have a key role in mediating glucose stimulated insulin 
secretion via the action of multifunctional kinases (CaM-KI and CaM-KIV), activated 
by CaMKK2, an upstream kinase (329). The entry of calcium into the ß-cell via the 
voltage gated calcium channel triggers the cascade of kinases, regulated by an 
upstream kinase, encoded by CaMKK2. The frameshift mutation in CaMKK2 
(p.G539fs*4) causes an excess insulin secretion by increasing the Ca2+/calmodulin-
dependent protein kinase activity. This was shown by expressing CaMKK2 isoform-7 
(WT) and the pG539fs*4 mutant in COS7 cells and it was found that pG539fs*4 mutant 
was noted to have significantly higher basal and Ca2+-CaM dependent kinase activity 
compared with WT isoform-7.  Furthermore, the isoform-7 and the pG539fs*4 mutant 
have elevated basal activity compared with isoform-1, the major CaMKK2 isoform 
expressed in most tissues. It is therefore hypothesised that the increase in the Ca2+-
CaM dependent kinase activity as a result of the mutation, to be increasing the insulin 
secretion, probably via upregulated transcription of INS-1. 
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De novo truncating and splicing mutations in the additional sex combs-like 3 (ASXL3) 
gene have been implicated in the development of Bainbridge-Ropers syndrome 
(BRPS) characterised by severe developmental delay, feeding problems, short stature 
and characteristic facial features (280). In this study, a novel compound heterozygous 
mutation in ASXL3 was found in proband B with severe short stature, learning 
difficulties, feeding difficulties and dysmorphic features with. Additionally, the patient 
also has primary insulin like growth factor-1 (IGF1) deficiency. The mutations occur in 
exon 11 and proximal part of exon 12 and are strongly conserved at the protein level 
across various species. In silico analyses using PolyPhen-2 and SIFT predict the 
amino acid substitutions to be potentially deleterious to the protein function. Detailed 
bioinformatics analysis show that the molecular defects caused by the two compound 
heterozygous mutations synergistically impact on two points of the molecular 
interaction network of ASXL3. 
Homozygous missense mutations in B3GAT3 have previously been described as 
‘linkeropathies’ characterized by short stature, skeletal deformities and congenital 
heart defects (340) and also been described in patients with Larsen-like syndrome, 
defined as a development disorder of the bones throughout the body; individuals 
frequently express symptoms such as skeletal dislocations, hearing loss and facial 
dysmorphism(338). In this study, a novel heterozygous splice site mutation in B3GAT3 
was identified in proband D with severe short stature, growth hormone (GH) 
deficiency, facial dysmorphism and congenital heart defects amongst other symptoms. 
The heterozygous mutation in B3GAT3 (c.888+262T>G) in the invariant “GT” splice 
donor is predicted to be pathogenic as it decreases the splicing efficiency in the mRNA 
that might result in the formation of truncated protein. 
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Homozygous mutation in the promoter region of GH1 has been described in the 
literature before to be causing an isolated growth hormone deficiency(366). In this 
study, a homozygous GH1 promoter mutation was identified in a child with severe 
short stature and persistent low IGF1. Although there was no evidence of GH 
deficiency on dynamic stimulation test, the child demonstrated a good response to a 
trial of recombinant GH. This may suggest the possibility of bio-inactive GH which has 
been previously reported in children with short stature(111). However, the mechanism 
of the promoter mutation leading to the production of biologically in-active GH peptide 
is currently unclear and requires further functional studies. 
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10.2 CONCLUSIONS  
WES is a useful and powerful technique in identifying novel genetic etiologies and 
pathways in rare endocrine disorders in children.  
In this study, a novel genetic etiology(FOXA2) is characterised for the first time as a 
cause for an extremely rare phenotype of CHI and CH. In vitro studies demonstrated 
a strong expression of pattern of FOXA2 not only during the various stages of murine 
pituitary development but also during human pituitary development and pancreas. 
A novel type of mutation contributing to BRPS was demonstrated in this study and 
characterized by detailed bioinformatics methods. Only de novo truncating and splice 
site mutation have been described so far in BRPS. This study identified a compound 
heterozygous mutation in ASXL3, contributing to BRPS with an expanding clinical 
spectrum of primary IGF1 deficiency. 
A novel frameshift mutation in CaMKK2 contributing to increased insulin secretion in 
a patient with persistent CHI was characterised in this study by demonstrating an 
increase in the kinase activity induced by the frameshift variant when compared to the 
wild type. 
This study also identified a novel splice site invariant in B3GAT3 contributing to short 
stature, facial dysmorphism, congenital heart defects segregating with phenotypic 
features previously defined in patients with homozygous mutation in B3GAT3. 
A homozygous mutation in the promoter region of GH1 possibly contributing to short 
stature with the production of biologically inactive GH was identified in a patient with 
severe short stature and low IGF1.  
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10.3 FUTURE DIRECTIONS 
 
The identification of FOXA2 mutation in an individual with an extremely rare complex 
phenotype of CHI, cranio-facial dysmorphic features and CH will certainly provide 
valuable insights into the molecular mechanisms underlying pituitary development β-
cell physiology. Screening more patients with similar phenotype will give further insight 
into the role of this transcription factor in the insulin secretion and in related diseases 
like neonatal diabetes mellitus and maturity onset diabetes of the young (MODY). 
Furthermore, this will provide more information on genotype-phenotype correlations in 
patients with FOXA2 mutations. 
CaMKK2 has various isoforms generated by alternative splicing of the mRNA. The 
frameshift mutation pG539fs*4 leading to an increased insulin secretion is at the 
terminal C-sequence of CaMKK2 isoform 7. However, a very little is known about 
CaMKK2 isoform 7. Screening for mutations in CaMKK2 in patients with persistent 
CHI without known genetic etiology will help in understanding the precise role of 
CaMKK2 in governing the insulin secretion thereby establishing the precise function 
of isoform 7. Furthermore, clinical trials will help to establish the efficacy of nifedipine 
(calcium channel antagonist) in patients with persistent CHI and CAMKK2 mutation 
especially when patients do not respond to diazoxide or develop significant side 
effects. 
Advances in CRISPR/Cas9 gene editing technology has enabled the induction of 
target modifications in a variety of model organisms (381, 401). CRISPR/Cas9 system 
can potentially be used as a genetic tool in studying the specific molecular 
mechanisms of the FOXA2 mutation in regulating the insulin secretion and its role in 
pituitary development.  
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In addition, the blood or skin cells from the patients with CaMKK2 pG539fs*4 mutation 
can be used to generate induced pluripotent stem cells in vitro that can differentiate 
into insulin secreting cells. The insulin secretion can be measured from these cells 
under basal and glucose stimulated conditions. Using CRISPR technology, the 
pG539fs*4 can be repaired back to wild-type sequence to examine if the insulin 
secretion returns back to normal. 
 
The biological role of the splice site invariant (c.888+262T>G) in B3GAT3 causing the 
typical phenotypic features in proband D is not well understood. Further functional 
studies are required needed to fully characterise the role of this splice site variant 
mutation in B3GAT3. Similarly, the role of GH1 promoter variant (c.-93delG), causing 
severe short stature in proband E with persistent low IGF1, normal endogenous GH 
secretion on stimulation test but a good response to exogenous recombinant GH is 
not entirely clear. Further in vitro experiments involving GHR binding and Janus kinase 
(Jak)2/signal transducer and activator of transcription (Stat)5 activation will be 
required to study the impact of the promoter mutation (111). 
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Parents of participating children Information Sheet 
 
Aim of the project 
 
The aim of this project is to investigate the genetic causes of endocrine problem (hormonal 
problem) in newborn, infants and children. Previous research has already identified a number 
of abnormalities in certain genes that can contribute to endocrine disorder(s) but we still don’t 
know the cause in the majority of children. The aim of this study is to unravel further genetic 
causes that can cause or contribute to endocrine disorders. 
 
 
Why has been my child identified to participate in this study? 
 
Your child has been identified as having an endocrinological (hormonal) problem for which a 
potential genetic diagnosis is not known. We feel that, by this project we may be able to identify 
the genetic diagnosis, which may help in the future management of the condition. 
 
How is the study being done? 
 
If you agree to participate in this study, your child will have an additional blood sample taken 
when they are having their routine investigations. We will use this blood sample to extract 
DNA (genetic material). The DNA will then be used to analyse certain genes by the method of 
whole exome sequencing. The extra blood sample that we take will do no harm to your child, 
as the amount of blood that we will take is extremely small. As a part of the study, we might 
request blood samples from you or other related family members. This blood sample will be 
used to extract DNA that will be used only for the purpose of establishing a genetic cause for 
your child’s hormonal problem. 
 
What are the risks and discomfort? 
 
No risk to the child can be foreseen. Your child might have a cannula inserted for routine 
medical treatment and we will then take the blood sample from the cannula. There is 
discomfort from the insertion of the cannula but we would normally numb the skin anyway with 
a local anaesthetic cream. 
 
For further understanding and information about genes/DNA/whole exome sequencing, 
please refer to the information below. 
 
 
1. What are Genes? 
The human body is made of cells. The cells contain DNA. The DNA is made of genes. 
Genes are chemical instructions that tell a cell what job to perform. A gene is like a recipe 
for making a particular protein. Proteins do important jobs in every cell of the body. Genes 
are written in code, with four chemicals (represented by the letters A, T, C, and G) that 
spell out the instructions to make a protein. People generally have two copies of most 
genes, one copy from each parent. 
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2. What is a genome and what is an exome? 
Most genes are made up of introns and exons. Exons are the parts of the gene that contain 
the information used to make a protein. They are the “coding” part of the gene. Introns are 
regions of DNA in between exons and do not code for proteins. 
The genome includes a person’s entire DNA, both the introns and the exons. The exome 
includes only the exons (the parts used to make proteins). The introns and other non-
coding sequences of DNA are not part of the exome. 
 
                                              
                    
3. What is whole exome sequencing (WES)? 
Some genetic tests “read” the genetic code of a single gene to see if that gene has any 
changes. Other genetic tests look for extra or missing pieces of DNA. Whole exome 
sequencing reads through the exons of most of the genes all at once. The exome is 
estimated to comprise approximately 1% of the genome, yet contains approximately 85% 
of disease-causing pathogenic variants. 
 
4. What is the purpose of WES? 
The purpose of whole exome sequencing is to try to find a genetic cause of your child’s 
signs and symptoms. Because WES looks at more genes than most genetic tests, it may 
find a genetic cause for your child’s signs and symptoms even if previous genetic testing 
did not.  
 
5. How is the WES performed? 
This test requires 3mls (about 1 teaspoon) of blood from the patient having WES. 
Sometimes blood samples from parents or other family members are also tested. The 
laboratory will isolate DNA from the blood sample. The exons (coding parts) of most genes 
will be examined. This is done for both the person having exome sequencing and for any 
family members that give DNA for comparison. 
 
6. How is WES interpreted? 
Your child’s DNA will be compared to a normal “reference” DNA sequence and (if 
applicable) to family members’ DNA. WES will identify some changes in the DNA that differ 
from the normal sequence. The researcher will use the clinical information, as well as 
many different scientific tools in the laboratory, to decide which genetic changes are likely 
to be responsible for your child’s signs and symptoms.  
 
7. What are the benefits of WES? 
WES may find a genetic cause for your child’s signs and symptoms. This may help guide 
medical care. A genetic diagnosis may give your family information about the chance that 
you could have other children affected with the same condition. This information may also 
be useful for other family members. 
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8. What are the limitations of WES? 
It is possible that this test will not always find a reason for your child’s signs and 
symptoms. WES may reveal information that is unexpected or unwanted. 
Approximately 85-92% of the exons are sequenced by this test. This test does not 
sequence every exon well enough to find all mutations in each exon. 
 
9. What kind of results can I expect from WES? 
The results could either show that there is a change to the usual sequence of the genetic     
material found in your child’s sample (a variant) or there is not. If a variant is found, 
laboratory scientists will check to see if that specific variant has been found in other 
people who have a similar condition to your child. We all have some variations in our 
genetic material; no two people have exactly the same DNA sequence. However, many 
of the variations are completely normal and have no clinical effect, others enable us to 
have different characteristics and features. At this stage of our understanding of 
genetics, we do not always know if a rare variant could be harmful or not. Depending 
on the answer to this, you may receive one of the following results: 
 
• The variant is thought to be definitely the cause of your child’s condition or 
contributes to it in some way. Usually we know this because it has been found 
in many others with the same condition. Professionals call this a pathogenic or 
disease-causing variant.  
• There is a variant but it is not certain if this is connected with your child’s 
condition. This is sometimes called a variant of unknown significance and we 
may have to wait until science has advanced further to find out what it means 
for your child.  
• The variant is thought to be harmless and not the cause of your child’s 
condition. This is called a polymorphism or benign variant. 
• If we don’t find a variant, it does not necessarily mean there is no genetic cause 
for your condition. We still do not have enough understanding of genetics to 
recognise the underlying causes for all conditions. 
                                         
10. What are secondary findings? 
A secondary finding is a test result that is not expected and is not related to the reason 
for doing the test. For example, a mutation in a gene that is not related to the patient’s 
condition is considered a secondary finding. Secondary findings may have important 
implications for your or your child’s health.   
 
Some genetic disorders do not have any effective treatment and may lead to death or 
lifelong disability.  These types of results can be incidentally picked up during the 
research study. In whole exome sequencing the chance of finding an unexpected 
variant has been estimated to be three in every 100 tests performed.  
 
11. Can I opt out from receiving the secondary findings? 
Yes. The findings that are related to the disease/condition that is being tested for will 
be reported. You will have an option to choose not to receive (or receive) the information 
while signing the consent form about the secondary findings that are not related to the 
condition that is being tested for.  
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12. Could there be results that affect others in my family?  
With any genetic test, there could be results that affect your blood relatives. For 
example, your condition may be one that could be inherited, and this might then be of 
importance to your children, brothers and sisters or parents. If this is the case, your 
health professional will explain this.  
 
13.  Do I have to take part in this study? 
If you decide, now or at a later stage, that you do not wish to participate in this research 
project, that is entirely your right and will not in any way prejudice any present or future 
treatment. 
 
14. Who do I speak to if problems arise? 
  
If you have any complaints about the way in which this research project has been, or 
is being conducted, please, in the first instance, discuss them with the research 
team.  
Thank you for your help and cooperation 
 
Dr Dinesh Giri 
Clinical Research Fellow in Paediatric Endocrinology 
Alder Hey Children’s Hospital & Institute of Child Health, University of 
Liverpool 
Eaton Road 
Liverpool L12 2AP. Email:Dinesh.Giri@alderhey.nhs.uk 
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We would like you to read this with your mum or dad. The doctors 
can also help you. 
 
You are invited to join a research study. Ask your mum and dad or 
the doctors if you have any questions. 
 
 
What is a research study? 
 
Research studies help us learn new things.  We can test new ideas.  By doing research 
we try to find an answer to a scientific question.   
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Why are we doing this research? 
 
Genes are information passed on by your Mum and Dad. They decide everything about 
you and how your body works. Genes tell our bodies how to keep us healthy. But 
sometimes things go wrong and people may develop a problem that can make them 
become ill. Imagine, you are baking a cake and following the instructions from the 
recipe book. The genes are like the instructions in the recipe book. If you put the wrong 
thing in the cake then it doesn’t turn out how you expected. Similarly, if there is 
something wrong in the genes and if the genes do not work properly, then it may cause 
people to become ill. This research is to try and find out if there is anything wrong in the 
way the genes work.  
 
This is how the genes look like. 
 
  
 
Why me? 
 
Hormones are special chemicals your body makes to help it do certain things - like 
growing up. They are important and keep us healthy and strong. We are doing this 
research to find out more about your hormone problem and to see if it the problem is 
caused by some of your genes that don't work right. 
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What would happen if I join this research? 
 
If you decide to be in the research, we will need to take a small amount of your blood. 
We will try to get blood at the same time when you are having blood test in the clinic. If 
we cannot do this we will ask your permission to take a separate blood test, for this we 
will put special cream on to numb the skin beforehand.   
We will look at your past doctor visits and use information about your care. 
 
What will you do with my blood? 
There are very small building blocks in your body called cells. The cells are so small you 
can’t even see them. We will get some of your cells out of your blood. We need to get 
your body’s recipe out of your cells. Then we need to look at what it tells your body to 
do. 
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What other things can happen if i want to join the study? 
  
If we have to take a separate blood test, this will hurt a little, but we will put numbing 
cream on first.  Sometimes the needle can leave a bruise on the skin.   
 
You can say ‘no’ to what we ask you to do for the research at any time and we will stop. 
 
Could the research help me? 
 
This research may not help you immediately.  We do hope to learn something from this 
research though.  And someday we hope it will help other kids who have similar 
problems like you do. 
 
 
 
 
What else should I know about this research? 
 
If you don’t want to be in the study, you don’t have to be. It is also OK to say yes and 
change your mind later.  You can stop being in the research at any time.  If you want to 
stop, please tell the research doctors. We will still take good care of you no matter what 
you decide. 
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Thank You for reading this. Please ask any 
questions. 
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PATIENT INFORMATION 
SHEET FOR CHILDREN 
AGED 9-12 YEARS 
 
 
 
 
This paper talks about our research. Please ask 
us any questions that you have.   
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What is a research study? 
Research studies help us learn new things.  We can test new ideas.  First, we ask a 
question.  Then we try to find the answer.   
 
.  
Why are we doing this research?  
Genes are information passed on by your Mum and Dad. They decide everything about 
you and how your body works. There are over 30,000 genes on each chromosome 
which act as special carrier for your genes. They are tightly packed inside the cells 
which are body’s building blocks. They are so small that you can only see them under a 
microscope. The genes give out instructions to the body that tells it to work properly. 
The instructions are also called as proteins. Sometimes, faulty instructions can cause 
problems. We are doing this research to find out more about your hormone problem and 
to see if it the problem is caused by some of your genes that don't work right. 
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Why have I been asked to take part?  
As you may know, that you are seeing your Doctor in the hospital because you have 
hormone problem. Hormones are special chemicals your body makes to help it do 
certain things - like growing up. They are important and keep us healthy and strong. 
There are different hormones in our body, each of which has a specific role of action. 
We are doing this research to find out more about your hormone problem and to see if it 
the problem is caused by some of your genes that don't work right. 
 
 
What would happen if I join this research? 
If you decide to be in the research, we will ask you to do the following: 
x Blood test: We will try to get blood at the same time when you are having blood 
test in the clinic without a new needle. If we cannot do this we will ask your 
permission to take a separate blood test, for this we will put special cream on to 
numb the skin beforehand.   
x Medical records: We will look at your past doctor visits and use information about 
your care. 
 
 Are there any risks if join the study?  
No. The needle used to test your blood can hurt.  Sometimes the needle can leave a 
bruise on the skin.  We can put a cream on your skin before we take blood.  This cream 
would help so it won’t hurt as much.   
 
You can say ‘no’ to what we ask you to do for the research at any time and we will stop. 
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Could the research help me? 
This research may not help you immediately.  We do hope to learn something from this 
research though.  And someday we hope it will help other kids who have similar 
problems like you do. 
 
 
What else should I know about this research? 
If you don’t want to be in the study, you don’t have to be. 
It is also OK to say yes and change your mind later.  You can stop being in the research 
at any time.  If you want to stop, please tell the research doctors. 
 
 
 
 
 
Thank You for reading this. Please ask us if you have any questions. 
 
. 
 
 
  
 
 
 
 
 
Version 2.0, 15.10.2015 
Whole Exome Sequencing in rare Endocrine Disorders  
   
 
PATIENT INFORMATION 
SHEET FOR YOUNG 
PEOPLE AGED 13-15 YEARS 
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You are invited to join a research project. Ask your mum and dad 
or the doctors if you have any questions. 
 
Why have I been asked to take part?  
 
Hormones are special chemicals your body makes to help it do certain things - like 
growing up. They are important and keep us healthy and strong. There are different 
hormones in our body, each of which has a specific role of action. We are doing this 
research to find out more about your hormone problem and to see if it the problem is 
caused by some of your genes that don't work right. 
 
 
Why are we doing this research? 
 
Genes are information passed on by your Mum and Dad. They decide everything about 
you and how your body works. So, if you have a genetic problem, it might be because 
certain genes don't work properly. There are over 30,000 genes on each chromosome 
which act as special carrier for your genes. Genes are made of DNA. DNA contains four 
chemicals (adenine, thymine, cytosine, and guanine — called A, T, C, and G for short) 
and different patterns of A, T, G, and C code for the instructions for making things your 
body needs to function (like the enzymes to digest food or the specific action of a 
particular hormone).Imagine, if there is a problem in giving a right instruction code(like a 
spelling mistake in the DNA) then it may result in a particular problem or illness. We are 
doing this research to find out if there is a genetic reason for the hormonal problem. 
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What would happen if I join this research? 
 
If you decide to be in the research, we will need to take a small amount of your blood 
(about one teaspoon). We will try to get blood at the same time when you are having 
blood test in the clinic  
We will look at your health records and use information about your care. 
 
What will you do with my blood? 
We will use your blood sample to get DNA from your cells and also to run tests to find 
out if there are any problems in the instructions code(sequence) of the DNA that make 
up your genes. 
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Could the research help me? 
This research may not help you immediately.  We do hope to learn something from this 
research though.  And someday we hope it will help other kids who have similar 
problems like you do. 
 
Do I have to take part? 
If you and your parents talk about it and together you decide not to take part, that’s OK. 
If there are things that you are worried about it, talk to the research team about how you 
feel. Tell your parents and the doctors and nurses if you don’t want to join. It’s OK if you 
decide to be in the Project and then change your mind. 
 
Is there any risk involved? 
  
No risk is involved. The needle used  to test your blood can hurt.  Sometimes the needle 
can leave a bruise on the skin.  We can put a numbing cream on your skin before we 
take blood.  This cream would help so it won’t hurt as much.  You can say ‘no’ to what 
we ask you to do for the research at any time and we will stop. 
 
 
What else should I know about this research? 
 
If you don’t want to be in the study, you don’t have to be. It is also OK to say yes and 
change your mind later.  You can stop being in the research at any time.  If you want to 
stop, please tell the research doctors. If you stop taking part, won’t be affected. 
 
 
Thank You for reading this. Please ask if you 
have any questions. 
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PATIENT/PARTICIPANT CONSENT FORM                  
Title of Project:     Whole Exome Sequencing in rare Endocrine disorders. 
Research Team: 
Dr Senthil Senniappan, Consultant Paediatric Endocrinologist & Honorary Senior Lecturer & 
Dr Dinesh Giri, Clinical Research Fellow, Paediatric Endocrinology 
Please tick the boxes as appropriate 
I have read and understood the Information Sheet for parents of participating children dated 
__ /__ /__ (version__). I have had the opportunity to consider this information, ask questions 
and I have had these answered satisfactorily.  
                    
I understand that my child’s participation in this study is my decision and that I am free to 
withdraw at any time without giving any reason.  If I do withdraw consent now or later, I don’t 
need to give any reason and my child’s present or future medical care or legal rights will not 
be affected. 
                                                                                                                            
I understand that sections of any of my child’s medical notes may be looked at by research 
team, where it is relevant to my child taking part in research.  I give permission for these 
individuals to have access to the records                                                                                      
 
I understand information on my child will be stored on a computer database for the purposes 
of research only.  I give permission for information to be stored on the database                            
 
I understand that this research project will involve collecting blood sample from my child. I 
agree for the blood sample to be collected from my child for this purpose. 
  
I understand that it is not possible to guarantee that any genetic results of significance for 
my child will be found through this project and I also understand that the results may not be 
able to provide a clinical diagnosis.  
 
I agree for my child’s blood samples to be stored at the end of this project for future research 
after obtaining further informed consent.        
                   
Secondary Findings 
 
I choose to receive results about genetic disorders that that are not related to my or my 
child’s current signs and symptoms. 
 
I choose not to receive results about genetic disorders that are not related to my or my 
child’s current signs and symptoms. I understand that I will not have access to these results 
later 
 
Name of the Child       Date of Birth 
 
 
Name of Patient/Parent                Date                                        Signature                
 
Name of Person taking Consent                Date                                        Signature  
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PARENT CONSENT FORM                  
Title of Project:     Whole Exome Sequencing in rare Endocrine disorders. 
Research Team: 
Dr Senthil Senniappan, Consultant Paediatric Endocrinologist & Honorary Senior Lecturer & 
Dr Dinesh Giri, Clinical Research Fellow, Paediatric Endocrinology 
Please tick the boxes as appropriate 
I have read and understood the Information Sheet for parents of participating children dated 
__ /__ /__ (version__). I have had the opportunity to consider this information, ask questions 
and I have had these answered satisfactorily.  
                    
I understand that my participation in this study is my decision and that I am free to withdraw 
at any time without giving any reason.  If I do withdraw consent now or later, I don’t need to 
give any reason and my present or future medical care or legal rights will not be affected. 
                                                                                                                            
 
I agree to give a sample of blood for the purpose of this research study. 
 
 
I understand that samples, DNA sequence, and information from my health records from 
hospital/GP and any other information will be looked into by research team. 
 
 
I understand that by giving my blood sample, my DNA sequence will be compared to that of 
my affected child’s DNA sequence.               
 
 
I understand my health information will be stored on a computer database for the purposes 
of research only.  I give permission for information to be stored on the database                            
 
 
Name of Parent                                                         Date                                                                         
Signature            
Relationship to the child:                  Mum/Dad 
 
 
 Name of the Child                                          Date of Birth 
 
Name of Person taking Consent                               Date                                                       
Signature  
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Novel Splicing Mutation in B3GAT3 associated with Short Stature, GH deficiency, 
Hypoglycaemia, Developmental delay and Multiple Congenital Anomalies 
 
Samuel Bloor, Dinesh Giri, Mohammed Didi, Senthil Senniappan 
 
Introduction 
B3GAT3, encoding β-1,3-glucuronyltransferase 3, has an important role in proteoglycan 
biosynthesis. Homozygous B3GAT3 mutations have been associated with short stature, 
skeletal deformities and congenital heart defects. We describe for the first time, a novel 
heterozygous splice site mutation in B3GAT3 contributing to severe short stature, growth 
hormone (GH) deficiency, recurrent ketotic hypoglycaemia, facial dysmorphism and 
congenital heart defects.  
 
Patient and Methods 
A female infant, born at 34 weeks gestation to non-consanguineous Caucasian parents with 
a birth weight of 1.9kg was noted to have cloacal abnormality, ventricular septal defect and 
pulmonary stenosis and congenital sensorineural deafness. She also had recurrent 
hypoglycaemic episodes and the results were consistent with severe ketotic hypoglycaemia. 
At 4 years of age, she was diagnosed with GH deficiency due to her short stature 
(height<2.5SD) and commenced on GH therapy. MRI of the pituitary gland revealed small 
anterior pituitary. She has multiple dysmorphic features: anteverted nares, small upturned 
nose, hypertelorism, slight frontal bossing, short proximal bones, hypermobile joints and down 
slanting palpebral fissures. There is a history of short stature and dysmorphism in father and 
a stillborn previous sibling with multiple dysmorphic features, congenital heart defects and 
short bones. Targeted exome sequencing of genes associated with ketogenesis, ketolysis, 
carbohydrate metabolism and fatty acid oxidation was negative for pathogenic mutations. 
Whole exome sequencing (WES) was performed on the genomic DNA from the patient but 
the DNA samples from biological parents were unavailable.  
 
Results 
A heterozygous B3GAT3 mutation (c.888+262T>G) in the invariant “GT” splice donor site was 
identified. This variant is considered to be pathogenic as it decreases the splicing efficiency in 
the mRNA as predicted by a MaxEntScan score decrease of 100% (from 11.01 to -0.14) 
thereby creating an alternative splice site resulting in a frame shift and truncation of the protein 
through misfolding. 
 
Conclusion 
B3GAT3 is involved in glycosaminoglycan (GAG) biosynthesis, which provides structural 
support within the extracellular matrix surrounding the cells. Genetic defects can thus lead to 
multi-system disorders. We report a novel splice site mutation in B3GAT3 associated with 
short stature, GH deficiency and multiple congenital anomalies.  
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Abstract
Congenital hypopituitarism (CH) is characterized by the deficiency of one or more pituitary hormones and can present alone
or in association with complex disorders. Congenital hyperinsulinism (CHI) is a disorder of unregulated insulin secretion
despite hypoglycaemia that can occur in isolation or as part of a wider syndrome. Molecular diagnosis is unknown in many
cases of CH and CHI. The underlying genetic etiology causing the complex phenotype of CH and CHI is unknown. In this
study, we identified a de novo heterozygous mutation in the developmental transcription factor, forkhead box A2, FOXA2
(c.505T>C, p.S169P) in a child with CHI and CH with craniofacial dysmorphic features, choroidal coloboma and endoderm-
derived organ malformations in liver, lung and gastrointestinal tract by whole exome sequencing. The mutation is at a highly
conserved residue within the DNA binding domain. We demonstrated strong expression of Foxa2mRNA in the developing
hypothalamus, pituitary, pancreas, lungs and oesophagus of mouse embryos using in situ hybridization. Expression profiling
on human embryos by immunohistochemistry showed strong expression of hFOXA2 in the neural tube, third ventricle,
diencephalon and pancreas. Transient transfection of HEK293T cells with Wt (Wild type) hFOXA2 or mutant hFOXA2 showed
an impairment in transcriptional reporter activity by the mutant hFOXA2. Further analyses using western blot assays showed
that the FOXA2 p.(S169P) variant is pathogenic resulting in lower expression levels when compared with Wt hFOXA2. Our
results show, for the first time, the causative role of FOXA2 in a complex congenital syndrome with hypopituitarism,
hyperinsulinism and endoderm-derived organ abnormalities.
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Introduction
The pituitary gland is a master regulator of vital physiological
functions such as growth, puberty, lactation, metabolism, stress
response and reproduction. The development of the pituitary
gland is tightly controlled by signalling molecules and tran-
scription factors that dictate pituitary cell lineage specification,
cell proliferation and terminal differentiation into hormone-
producing cells (1,2). Abnormal pituitary development can lead
to congenital hypopituitarism (CH) resulting in deficiency in one
or more pituitary hormones. CH comprises of a spectrum of dis-
orders with variable phenotypes that can range in severity,
from isolated hormone deficiency [isolated growth hormone
deficiency being the most common] to combined pituitary hor-
mone deficiency (CPHD) when two or more pituitary hormones
are deficient. CH may present as part of a syndrome with abnor-
malities in structures that share a common embryological ori-
gin with the pituitary gland, such as the forebrain and eyes,
leading to septo-optic dysplasia (SOD) or holoprosencephaly
(HPE) (1). SOD is a rare condition with a prevalence of 1:10 000 (3)
live births and comprises the following features: optic nerve
hypoplasia, midline forebrain defects and hypopituitarism (4,5).
Mutations in transcription factors such as HESX1 (6), PROP1 (7),
POU1F1 (8), LHX3 (9), LHX4 (10), PITX1, PITX2 (11), OTX2 (12), SOX2
(13) and SOX3 (14,15) have been associated with CH in mouse
and humans. However, these mutations account only for a
small proportion of CH patients with the majority of patients
having an unknown genetic cause for their symptoms.
Congenital hyperinsulinism (CHI) is a rare condition with an
estimated prevalence of 1 in 50000 live births, characterized by an
inappropriate secretion of insulin from the b-cells of the pancreas
during hypoglycemia (16). CHI is themost common cause of severe
and persistent hypoglycaemia in the neonatal period. The identifi-
cation and appropriate management of this condition is very
important to avoid hypoglycaemic episodes and prevent the
consequent neurological impairment. Mutations in genes ABCC8
(17–21), KCNJ11 (17–21), GLUD1 (22), GCK (23), HADH (24), UCP2 (25),
HNF4A (26), HNF1A (26), MCT1 (27), HK1 (28) and PGM1 (29) have
been associated with genetic forms of CHI (30). However, the
genetic cause for many CHI patients remains elusive.
FOXA2 (formerly hepatocyte nuclear factor-3b, HNF-3b)
belongs to the family of the forkhead class of transcription factors
that has an essential role in embryogenesis during the formation
of the node, notochord and floorplate (31,32), which are important
for the development of the vertebrate body axis. Thus, Foxa2 null
mice embryos die during early gestation, at embryonic day 9.5,
and fail to form axial mesoderm (31). Later during organogenesis,
Foxa2 co-operates with Foxa1 and are required for the formation
of endoderm-derived organs such as the liver (33), lung (34), pan-
creas (35) and gastrointestinal tract (36). Foxa2 has been shown to
be important in the development of anterior forebrain structures,
which have the same embryonic origin as the pituitary gland
(37). Data from murine genetic studies have shown a genetic
interaction between Foxa2 and Sonic Hedgehog (Shh) signalling
pathway with overlapping expression pattern of Foxa2 and Shh in
the notochord and floor plate at e8.5. Foxa2 can modulate Shh
signalling, contributing to the specification of ventral motor
neuron progenitor identity (38). The secretion of Shh by the
notochord and floor plate is an important morphogenetic signal
that is required for the development of central nervous system
including the pituitary gland (39). In the islet cells of mature pan-
creas, Foxa2 has been shown to activate components of insulin
secretion, such as sulfonylurea receptor1 [sur1], (40) and the
inward rectifier potassium channel member 6.2 [kir 6.2] (40). In
humans, mutations in ABCC8 [encoding SUR1] and KCNJ11
[encoding Kir 6.2] (17–21) are the most common causes of genetic
forms of CHI. Notably, tissue-specific deletion of Foxa2 from the
pancreatic b-cells (Foxa2loxp/loxp; Ins:Cre) has been shown to the
development of CHI in mouse (41).
Thus, FOXA2 is an important developmental transcription
factor required for the formation of ventral midline structures
such as the floorplate and forebrain, as well as endoderm-
derived organs including the pancreas, and regulating glucose
homeostasis in mature pancreatic b-cells. To date, mutations in
FOXA2 causing disorders of glucose homeostasis, endoderm
abnormalities and CH have not been described in humans. In
this study, we report for the first time, a ‘de novo’ heterozygous
mutation in FOXA2 in a patient with unique clinical phenotype
of CH, persistent CHI, craniofacial dysmorphism, abnormalities
in the liver, heart, lung and the gastrointestinal tract. This finding
brings a new insight into the underlying molecular cause of a
complex clinical phenotype that will serve as a tool to elucidate
the pathogenesis of these congenital malformations and to
better understand the development and function of the pituitary
gland and the pancreas.
Results
Clinical findings
Our patient, a 5-year-old girl, was born to non-consanguineous
Caucasian British parents at 42weeks’ gestation with a birth
weight of 4.185 kg (þ1.72 SDS). The pregnancy was normal and
the 20-week antenatal scan showed polyhydramnios. The deliv-
ery was complicated by shoulder dystocia, needing resuscita-
tion. She was found to be persistently hypoglycaemic (blood
glucose< 2.5mmol/l) requiring a total glucose load of 25mg/kg/
min (normal: 4–6mg/kg/min) to maintain normoglycaemia
(blood glucose> 3.5mmol/l). She had low free thyroxine (FT4)
(5.3 pmol/l) and suppressed thyroid-stimulating hormone (TSH)
(<0.03mu/l) that persisted even after the phase of acute severe
illness. She also had an undetectable adrenocorticotropic hor-
mone (ACTH) (<1.1 pmol/l) with no cortisol response to syn-
acthen stimulation (peak cortisol to synacthen<50nmol/l).
Hydrocortisone replacement (10mg/m2/day) was commenced
followed by levothyroxine therapy. The MRI scan of the brain
showed a hypoplastic anterior pituitary, absent posterior pitui-
tary, interrupted pituitary stalk and a thin corpus callosum
(Fig. 1B). The hypoglycaemia persisted and further investiga-
tions showed an inappropriately high plasma insulin (200pmol/l)
and c-peptide (1500pmol/l) with suppressed plasma free fatty
acid (<100mmol/l) and beta hydroxyl butyrate (<100mmol/l) dur-
ing hypoglycaemia (blood glucose: 1.2mmol/l) confirming the di-
agnosis of CHI. The Growth hormone (GH) was undetectable at
the time of hypoglycaemia [<0.05mg/l]. A trial of diazoxide (5mg/
kg/day) was commenced along with chlorothiazide (7mg/kg/day).
However, the patient suffered from significant fluid retention
leading to discontinuation of diazoxide. Commencement of
octreotide (10mcg/kg/day) caused a derangement of liver
enzymes and therefore had to be discontinued after which
the liver enzymes returned to normal levels. She developed
significant feed intolerance due to severe gastroesophageal
reflux which persisted despite maximum medical treatment.
A gastro-jejonostomy tube was inserted to support feeding.
Normoglycaemia was maintained by continuous feed via the
gastro-jejonostomy tube. Genetic analysis was negative for ABCC8,
KCNJ11, HNF4A and GCKmutations. The 18F-DOPA PET-CT scan of
the pancreas suggested a diffuse uptake.
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The facial dysmorphic features comprise of a single median
maxillary central (SMMC) incisor (Fig. 1A), congenital nasal pyri-
form aperture stenosis (CNPAS), which was conservatively
managed, and a left choroidal coloboma. She does not have any
vision abnormalities. The cardiac echocardiogram revealed pul-
monary stenosis which required balloon dilatation. She had a
persistent oxygen requirement (0.5–1 l via nasal cannulae) of
unknown etiology [negative for respiratory infections, normal
chest imaging (CT) and bronchoscopy] from birth. At 1.5 years of
age she was diagnosed with GH deficiency [height < -3 SDS,
IGF1< 3.3 nmol/l and a peak GH of 1.1 mg/l (normal> 7 mg/l) to
arginine stimulation] and was commenced on rGH (recombinant
GH) therapy. She demonstrated a good response to treatment
with rGH (25mcg/kg/day) with an improvement in the height
velocity (Fig. 1C). She developed persistently elevated liver
transaminases when she was 3years old, with a negative auto-
immune hepatitis and infection screen. The liver biopsy showed
dense chronic inflammation with portal-portal bridging fibrosis.
The clinical features are summarized in Table 1.
She is currently 5 years old, with persistent CHI, motor,
speech and developmental delay and continues to be on rGH,
levothyroxine and hydrocortisone replacements. There are no
symptoms suggestive of diabetes insipidus and the biochemis-
try has been completely normal. She has shown response to the
reintroduction of diazoxide (5mg/kg/day) and chlorothiazide
without any features of fluid retention, which has enabled her
to come off continuous feeds for 6h.
Mutation analysis
A novel heterozygous FOXA2 mutation (c.505T>C, p.S169P) was
identified in the affected child but not in the parents by whole
exome sequencing. To further validate our results, the mutation
was confirmed by Sanger sequencing (Fig. 1D). The variant is
not present in control databases (ExAc, dbSNP, 1000 genome).
Multiple sequence alignment shows that the serine residue at
position 169 is highly conserved across different species, from
drosophila, human, mouse, chicken to frog (Fig. 1E), suggesting
that this residue is functionally important and has been main-
tained throughout evolution in different species. The FOXA2
mutation (c.505T>C, p.S169P) lies at the DNA binding domain of
the transcription factor. In silico analysis using SIFT, PolyPhen,
Mutation Taster predict this aminoacid substitution to have
deleterious impact on the protein function.
Figure 1. Picture of the patient’s face showing single central incisor tooth (A, arrowhead). (B) Sagittal view of the MRI scan of the brain: The normal pituitary gland can-
not be identified, the sella turcica is shallow and poorly defined with possibly a very hypoplastic anterior pituitary gland (arrowhead). Also, there is no evidence of the
normal high signal of the posterior pituitary. There is a very short and thin pituitary stalk in its superior third (arrow) which is suggestive of an interrupted pituitary
stalk. The corpus callosum is also noted to be thin (arrowhead). (C) The patient’s linear growth curve compared with British contemporary references. Recombinant GH
was started at 1.5 years of age when the linear height was -3SDS. A good response to GH treatment is seen subsequently with an improvement in the height SDS.
(D) Electropherograms show the wild type (Wt FOXA2) and the presence of the missense mutation (thymine to cytosine) in the patient at the nucleotide position 505.
(E) The evolutionary conservation of the amino acid residue serine at position 169 is shown across different species such as drosophila, human, mouse, chicken and
frog. Abbreviations: standard deviation score, SDS; wild-type, Wt; growth hormone, GH; drosophila, DROME; frog, XENTR.
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Functional analysis
To further characterize the possible role of FOXA2 in the observed
clinical phenotype, we studied the expression of Foxa2 at the
mRNA level during mouse embryonic development. Foxa2 mRNA
transcripts were detected in the midbrain, ventral forebrain, ven-
tral hindbrain, epithelial structures lining the main bronchus,
lungs and the esophagus from embryonic day (e)11.5 (Fig. 2).
Importantly, the expression of Foxa2 mRNA was detected in the
pituitary gland from e13.5 (Fig. 2C–C0) in the anterior lobe. From
e15.5, Foxa2 mRNA expression was stronger with robust expres-
sion in the ventral diencephalon, and anterior lobe of the pitui-
tary gland (Fig. 2D–D0). At embryonic day e18.5, Foxa2 mRNA
transcripts were localized in the hypothalamic-pituitary axis,
with transcripts strongly expressed in the ventral hypothalamus
and anterior pituitary (Fig. 2E–E0). Analysis of hFOXA2 expression
in human embryos by immunohistochemistry revealed expres-
sion of hFOXA2 in the ventral neural tube (Fig. 3A0) and in the
diencephalon (Fig. 3A00) at six weeks (Carnegie stage 16), and
around the third ventricle at 8weeks (Carnegie stage 23) (Fig. 3B0).
hFOXA2 was specifically localized in the cytoplasm of cells
scattered in the pancreatic parenchyma at 13weeks of gestation
(Fig. 3C–C0–C00). In summary, our expression analysis shows
expression of Foxa2 mRNA in hypothalamic-pituitary axis and
lungs during mice embryonic development. hFOXA2 expression
was detected in midline neural tube and pancreas.
FOXA2 has been previously shown to bind and activate the
human glucose transporter type 2 (GLUT2) (42). To determine
the pathogenic effect of FOXA2 p.S169P variant, we performed
transcriptional activation assays using the GLUT2 promoter
coupled to luciferase (phGT2-294-promoter-luc). We used tran-
siently transfected HEK293T cells with equal quantities of Wt
hFOXA2 or mutant hFOXA2 p.S169P and demonstrated that the
hFOXA2 p.S169P significantly impairs the transcriptional activa-
tion of the GLUT2 luciferase reporter (Fig. 4A). We also per-
formed quantification of protein expression using western blot
and showed that the mutant hFOXA2 p.S169P results in signifi-
cantly reduced protein expression levels compared to the Wt
hFOXA2 (Fig. 4B). Using double immunofluorescence on tran-
siently transfected HEK293T cells, we demonstrated that both
the Wt hFOXA2 and mutant hFOXA2 are expressed in the
nucleus and the mutation did not result in changes to cellular
localization (Fig. 5). Together the results indicate that the
hFOXA2 p.S169P variant results in lower transcriptional activity
due to an effect of the mutation on the FOXA2 protein levels.
Discussion
We have characterized a ‘de novo’ heterozygous mutation in the
developmental transcription factor FOXA2 that causes a rare
and unique clinical phenotype of hypopituitarism, CHI, dysmor-
phic features, liver, pancreas, heart and gastrointestinal abnor-
malities. The c.505T>C, p.S169P genetic variant occurs at the
conserved forkhead DNA binding domain of the FOXA2. This
region binds to the DNA and may provide tissue-specific gene
regulation important for the development of multiple organs.
Our data has confirmed that the mutation impairs the tran-
scriptional activation of FOXA2. Importantly, FOXA2 is localized
at the cytogenetic location 20p11.2 and some studies have
linked chromosomal deletions within this region with the clini-
cal phenotype of hypopituitarism, central nervous system (CNS)
defects, hypoglycaemia, facial dysmorphic features and congen-
ital abnormalities of the heart, liver and gastrointestinal tract
(43–47). Chromosomal deletions of the 20p11.2 are rare (46) and
recent studies have mapped the minimal critical region which
contains 20 genes (43), including FOXA2. All the patients
reported to have the 20p11.2 chromosomal deletion have hypo-
pituitarism, CNS abnormalities and facial dysmorphic features
as shared features, strongly indicating that a gene or multiple
genes within this chromosome region have a key role in CNS,
pituitary and facial development. We have identified the gene
responsible for the clinical phenotype of hypopituitarism at the
20p11.2 region as FOXA2 and confirmed the causative role with
functional analysis.
In our study, we show that FOXA2 mutation causes the
clinical phenotype of hypopituitarism, CHI and facial dysmor-
phic features that overlaps with the clinical data published in
patients with 20p11.2 deletions (43–47). The mutation in
hFOXA2 p.S169P is pathogenic, as it results in impaired tran-
scriptional activation of the phGT2-294-promoter-luc reporter
and significant reduction in the protein expression compared
to wild type hFOXA2. Interestingly, FOXA2 has been shown to
regulate key signalling pathways important in ventral midline,
pituitary and CNS development such as Shh signaling (38).
Data from in vivo studies using Wnt1:Cre; Foxa2flox/flox embryos
showed that Foxa2 has an early role in the initiation of Shh
expression. Foxa2, in combination with Foxa1, downregulates
the expression of intracellular transducers and downstream
targets of shh signalling such as Ptch1, Gli1 and Gli2, which
regulate the patterning of the ventral midbrain (38). Hence, we
hypothesize that hFOXA2 could mediate its role in pituitary
development by regulating Shh expression. Moreover, the
midline anomalies in our patient including SMMC, CNPAS
are often associated with pituitary abnormalities, as described
in an extensive literature review by Lo et al. (48), where
hypopituitarism or growth hormone deficiency were identified
in 43–48% of patients with CNPAS or SMMC. This is consistent
with the clinical presentation of our patient, who has hypopi-
tuitarism along with hypoplastic pituitary, thin corpus
callosum and thin pituitary stalk on the MRI.
Table 1. Summary of clinical features
Face Single median maxillary central incisor, congenital nasal pyriform aperture stenosis
Eye Left choroidal coloboma
Heart Supra-valvular pulmonary stenosis
Gastrointestinal Feed intolerance, severe gastro-esophageal reflux disease requiring gastro-jejonostomy feeding
Liver Portal-portal bridging fibrosis, elevated transaminases
Lung Persistent oxygen requirement of unknown etiology
Pancreas Persistent form of hyperinsulinism
Pituitary ACTH, GH and TSH deficiencies
Thin pituitary stalk, hypoplastic anterior pituitary
Thin corpus callosum
Neuro-developmental Speech and motor developmental delay
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Figure 2. mRNA expression of Foxa2 during mouse embryonic development. A–D represent sagittal sections, with anterior to the left side, and E is a coronal section.
A0 , C0 , D0, E0 show higher-magnification views of the boxed areas in A, C, D, E, respectively. At embryonic day e11.5 (A) Foxa2 mRNA transcripts were expressed within
the midbrain (MB) and ventral hindbrain (HB) (arrowheads) and also in a few cells localized in the forebrain (asterisk) (FB). At this stage of development no transcripts
were detected in the primordium of the anterior pituitary gland, the Rathke’s pouch (RP dotted line in A and A0), or in the infundibulum (Inf). A0 shows an enlarged
image of the squared area in A, confirming undetectable expression of Foxa2 at this stage in the RP and Inf. At e12.5 (B and B0) Foxa2mRNA transcripts were detected in
the epithelial structures lining the main bronchus (MBr) (B, arrowhead) and in the epithelium lining the lung (Lu) and oesophagus (OE) (B0 , arrowheads). By e13.5,
expression of Foxa2 appears localized in the ventral side of the anterior lobe of the developing pituitary gland (AL, arrow) with transcripts localized in the ventral
marginal zone (arrowheads in C0). Foxa2 mRNA expression become stronger at e15.5 (D) with robust expression in the ventral diencephalon (VD, asterisk), posterior
lobe (PL) and anterior lobe (AL, arrowheads in D0) of the pituitary gland. At embryonic day e18.5 (E), expression was found widely spread in the central nervous system,
with strong expression in the lumen surrounding the lateral ventricles (LV, arrowheads) and the third ventricle (TV, asterisks). Enlarged image of the boxed area in E
shows mRNA expression localized in the hypothalamic area (Hyp) (E0 , arroheads) with distinct pattern in the luminal area where the hypothalamic precursors
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The detection of Foxa2 mRNA transcripts from the early
stages of mouse pituitary and brain embryonic development
suggests a potential role in the development of these structures.
Furthermore, the detection of hFOXA2 by immunohistochemis-
try in human embryos at various developmental stages, along
with the biochemical experiments demonstrating that the vari-
ant p.S169P mutation in FOXA2 impairs transcriptional activa-
tion and protein expression levels, strongly indicate that FOXA2
has a pivotal role in hypothalamic-pituitary axis formation in
humans.
The co-existence of hypopituitarism along with a persistent
form of hyperinsulinism, as encountered in our patient, is
extremely uncommon. Hypoglycaemia in CHI is caused by
unregulated insulin secretion while in hypopituitarism it is due
to the lack of counter-regulatory hormonal response due to the
deficiency of ACTH and GH. Diagnosis can often be challenging,
as the hallmark of CHI is detectable insulin in the presence of
hypoketotic hypoglycaemia while hypopituitarism causes ke-
totic hypoglycaemia. Almost half of the patients with persistent
CHI do not have mutations in the already recognized genes
known to cause CHI. Genetic diagnosis is important as it will
inform the prognosis, recurrence risk and guide the medical
management besides providing valuable insight into b-cell
physiology. The negative mutations in the known CHI genes in
our patient together with strong biochemical evidence of CHI,
makes it highly likely that the CHI in our patient is due to a
novel genetic aetiology (FOXA2). We have further confirmed this
by demonstrating the expression of hFOXA2 in the developing
human pancreas.
Glucose-stimulated insulin secretion occurs by the closure
of ATP dependent KATP channels situated on the b-cell mem-
brane with the resultant depolarization of the membrane caus-
ing the exocytosis of the insulin granules (16,30). KATP
channels consist of 2 subunits, SUR1 and Kir6.2, encoded by
ABCC8 and KCNJ11 respectively, the mutations of which cause
defects in the channels resulting in the most common form of
genetic CHI (16,30). Lantz et al. demonstrated that when SUR1 or
Kir6.2 promoter/luciferase reporter was transfected with Foxa2
tanycytes reside (arrowheads in E0). mRNA transcripts were also localized in both the posterior (PL) and anterior (AL) lobes of the pituitary gland (arrows in E0).
Abbreviations: midbrain, MB; hindbrain, HB; forebrain, FB; Rathke’s pouch, RP; infundibulum, Inf; main bronchus, MBr; lung, Lu; oesophagus, OE; ventral diencephalon,
VD; pituitary gland posterior lobe, PL; pituitary gland anterior lobe, AL; lateral ventricles, LV; third ventricle, TV; hypothalamus, Hyp. Scale bars represent: 50 lm (A0 , B,
C0 , D0); 100lm (B0), 250 lm (A, C, D, E0); 500 lm (E).
Figure 3. Immunohistochemical analysis of human FOXA2 expression during human embryonic development. A–C represent coronal sections of human embryos at
6weeks (Carnegie stage 16), 8weeks (Carnegie stage 23) and 13weeks of gestation, respectively. A0–C00 show higher-magnification views of the boxed areas in A, B, C, re-
spectively. At 6weeks of gestation (A) Foxa2 expression was observed in the developing neural tube (NT) (A0) and diencephalon (Dc) (arrowheads in A00). At 8weeks of
gestation (B) its expression was localized in the epithelium surrounding the third ventricle (TV) (B0) and in the cells lining the diencephalon (Dc) (arrowheads in B00). No
expression of Foxa2 was detected in the primordium of the pituitary gland (Rathke’s pouch, RP) at CS16 (A0 00) nor in the developing pituitary gland at CS23 (B0 00). In the
pancreas at 13weeks of gestation (C) Foxa2 was specifically localized in the cytoplasm of cells scattered in the pancreatic parenchyma (cells pointed by arrowheads in
C0 and C00). Abbreviations: neural tube, NT; diencephalon, Dc; Rathke’s pouch, RP; pituitary gland, P; third ventricle, TV. Scale bars represent: 50lm (A0 , A00 , A0 00 , B0, C00);
100 lm (B00 , B0 00), 250 lm (C0).
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expression plasmids, Foxa2-Sur1 and Foxa2-Kir6.2 promoter
constructs showed 6-fold and 4-fold activation respectively
demonstrating a vital role of Foxa2 in the transcriptional activa-
tion of the KATP subunits (40). Hence, a FOXA2 mutation could
potentially alter the expression of SUR1 and/or Kir6.2 leading to
hyperinsulinism although the precise mechanism is yet to be
explored. The other possible mechanism could be linked to
HADH that encodes L-3-Hydroxyacyl-CoA-dehydrogenase
(HADH), an enzyme involved in the penultimate step of the
beta-oxidation pathway (8). Mutations in HADH cause CHI in
humans. It has been demonstrated in mice that Foxa2 directly
targets HADH causing its transcriptional activation (49). Sund
et al. demonstrated that Foxa2 knocked out from the b-cells in
mice resulted in a 3-fold downregulation of Hadh mRNA leading
to severe hyperinsulinaemic hypoglycaemia (41,42). The third
possibility could be linked to GLUT2, which is expressed in the
plasma membrane of the pancreatic b-cells, liver, kidney and
intestine to facilitate insulin secretion by transporting the
glucose across the cell membrane (29). Wang et al. showed that
GLUT2 plays an important role in the insulin secretion from the
b-cells as its mRNA level is influenced by the plasma concentra-
tions of glucose and insulin (50). Cha et al. demonstrated that
GLUT2 has binding sites for FOXA2 and showed that the pro-
moter activity of GLUT2 is synergistically activated by FOXA2 in
NIH3T3 cells (42). FOXA2 also plays a critical role in the tissue
specific expression of GLUT2 (42). The reduction in the tran-
scriptional activation of the GLUT2 reporter (phGT2-294-pro-
moter-luc) activity by the mutant hFOXA2 (p.S169P) shown in
our transcriptional assay experiment, could imply that the
GLUT2 tissue expression is reduced in the pancreatic b-cells of
patients with FOXA2 mutation. However, the precise mecha-
nism by which this leads to hyperinsulinaemic hypoglycaemia
is not yet understood.
It is also plausible that Foxa2 plays a role in the development
of the pancreas. Foxa2 has been shown to regulate Pdx1, a
homeobox gene essential for pancreatic development (49).
Foxa2 has also been linked to regulating the mRNA levels of
pancreatic transcription factors such as Hnf4a and Hnf1a, muta-
tions of which can cause monogenic forms of diabetes mellitus.
However, some studies contradict that Foxa2 is an upstream
regulator of Pdx1, Hnf4a and Hnf1a (50). While it has been
shown that b-cell-specific deletion of Foxa2 in mice causes a
phenotype of hypoglycaemia (41), it also has been demon-
strated that it can cause downregulation of Pdx1 mRNA causing
the reduction of PDX-1 protein levels in the pancreatic islets (51)
and a targeted b-cell-specific deletion of Pdx1 results in diabetes
in transgenic mice (52). Thus, FOXA2 is a crucial transcription
factor that controls the expression of multiple genes involved
both in glucose sensing and glucose homeostasis and therefore
has a potential role in diseases involving insulin secretion and
glucose homeostasis.
Diazoxide is used as an effective treatment in majority of
patients with CHI except in those with mutations abolishing the
KATP channel activity (ABCC8 or KCNJ11) or activating muta-
tions in GCK. Our patient has shown response to diazoxide
treatment which could potentially imply that the variant
p.S169P has not completely abolished the KATP channel activity
or increased the GCK expression.
Whilst it is difficult to speculate the progression of abnor-
malities in glucose homeostasis in patients with FOXA2 muta-
tion, screening more patients with similar phenotype will give
further insights into the role of this transcription factor in the
insulin secretion and in related diseases like neonatal diabetes
mellitus and maturity onset diabetes of the young (MODY). The
main limitation of our study is the lack of more patients with
similar phenotype. As the combination of the phenotype
comprising CHI and hypopituitarism is extremely rare, we were
unable to recruit more patients for this study. However we are
hopeful that the dissemination of the findings from this study
will alert the researchers from across the world to screen for
FOXA2 mutations in patients with similar phenotype, thereby
enabling a better understanding of genotype-phenotype
correlations.
Figure 4. The serine to proline change in position 169 of hFOXA2 results in
decreased protein expression levels leading to impairment of transcriptional
activation of the human GT2 promoter. Dual luciferase assay (A) in HEK293T
cells transiently transfected with 50ng or 75ng of Wt hFOXA2 or mutant
hFOXA2 p.S169P indicates that Wt hFOXA2 is able to transactivate the human
GT2 reporter, whilst the hFOXA2 p.S169P transcriptional activation is impaired
(graph represents 4 independent experiments performed in triplicate, *P<0.05,
one-way ANOVA). 3 independent western blots (B) show that the levels of the
variant hFOXA2 p.S169P protein are reduced compared to the Wt hFOXA2,
indicating that the mutation is functional and affects protein levels. Graph of
the quantification of the western blots (B0) as percentage of Wt hFOXA2 and
hFOXA2 p.S169P normalized to GAPDH indicates that hFOXA2 p.S169P variant
results in half of the protein expression levels compared to Wt hFOXA2 (results
from 6 independent experiments; ****P <0.0001, one-way ANOVA). Abbreviation:
NT, non-transfected; Wt, wild-type.
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In conclusion, we have identified the first disease-causing
mutation in FOXA2 in an individual with an extremely rare
complex phenotype of CHI, cranio-facial dysmorphic features,
CH, cardiac, liver and gastrointestinal abnormalities.
Identification of the genetic cause contributing to such a unique
clinical phenotype will help medical management and provide
valuable insights into molecular mechanisms underlying pitui-
tary development and b-cell physiology.
Materials and Methods
Patient enrolment
The patient was recruited to the ‘Whole exome sequencing for
rare endocrine disorders’ study following written consent from
the parents. The study was given favorable ethical opinion by
the North West – Liverpool Central Research Ethics Committee
(REC Reference: 15/NW/0758) and site study approval was
granted by the Clinical Research Business Unit at Alder Hey
Children’s NHS Foundation Trust, Liverpool, UK.
DNA extraction
DNA was obtained from blood samples of the child and both the
biological parents (trio) using the QIAmp DNA blood Midi Kit
(Qiagen, Hilden, Germany) as per the manufacturer’s instruc-
tions and subjected to whole exome sequencing. The quality
and the quantity of the genomic DNA were assessed using
the Qubit (ThermoFisher Scientific) and the NanoDrop
(ThermoFisher Scientific).
Library preparation, exon capture and sequencing
The samples (3 mg/sample) were sheared with the Picoruptor to
a size of approximately 150–200 bp. The samples were cleaned
with 1.8" AMPure beads (Agencourt) and end repaired at 20 #C
for 30min. The products were A tailed by incubation at 37 #C for
30min, cleaned with AMPure beads again and ligated to index
adapters at 30 #C for 10min to make a pre-capture library using
the Agilent Sureselect XT target enrichment system for
Illumina. Enrichment was achieved by five rounds of PCR using
Herculase II fusion DNA polymerase. The libraries were checked
on an Agilent HS Bioanalyser chip and quantified by Qubit
Assay. 750ng of pre-capture library was used for the hybridiza-
tion. Samples were lyophilized to attain the required volume.
Libraries were then mixed with hybridization buffer, baits from
the Human All Exon 5 kit and incubated overnight (24h) at
65 #C. The samples were then mixed with washed streptavidin
beads (Dynabeads MyOne Streptavidin T10) and the captured
products were washed and pooled. The quantity and quality of
the pool was assessed by Bioanalyzer and subsequently by
qPCR using the Illumina Library Quantification Kit from Kapa on
a Roche Light Cycler LC480II, according to manufacturer’s
instructions. The template DNA was denatured according to the
protocol described in the Illumina cBot user guide and loaded at
300pM concentration. Sequencing was carried out on one lane
of an Illumina HiSeq4000 at 2 " 150bp paired-end sequencing
with v1 chemistry.
Bioinformatics
The sequence data were aligned to the reference genome
(GRCh37/hg19). Reads were mapped to the reference sequences
using BWA mem version 0.7.5a (53) with default parameters.
The mean depth of the coverage was 100". In order to retain
only confidently aligned reads, alignments were filtered to
remove reads with a mapping quality lower than 10. The mapped
reads were locally re-aligned to improve the alignments around
small insertions/deletions (indels) using the Genome Analysis
Tool Kit (GATK) version 2.1.13 (54). Base quality scores were
Figure 5. The S169P mutation in hFOXA2 does not result in changes in cellular localization of the protein. Double-immunofluorescence using anti-FOXA2 antibody (red
A, B) and anti-PHALLOIDIN (green A0 , B0) performed in HEK293 cells transiently transfected with either 200ng of Wt hFOXA2 (A–A0 00) or mutant hFOXA2 p.S169P (B–B0 00)
shows nuclear expression of both Wt and mutant FOXA2 (A, B) which overlaps with the nuclear DNAmarker DAPI staining (A00 , B00) but not with the cytoskeletal marker
phalloidin. Abbreviation: DAPI, 40 ,6-diamidino-2-phenylindole. Scale bars in A and B represent 10 mm.
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recalibrated using GATK Base Quality Score Recalibrator (BQSR).
BQSR is a module of GATK to create more accurate base
qualities, which in turn improves the accuracy of our variant
calls. The variants identified were annotated using SnpEff. The
variants present in at least 1% minor allele frequency in 1000
Genomes Project, Exome aggregation consortium (ExAC),
dbSNP142 and NHLBI ESP exomes were excluded. The predicted
deleterious variants included non-synonymous coding, splice
site, frameshift and stop gain variants. The analysis of variants
was performed using the ingenuity variant analysis (Qiagen bio-
informatics) software. The identified potential variant segregat-
ing with the patient’s phenotype was subsequently confirmed
by Sanger sequencing.
Mice
All mice were housed with a 12h light/12h dark cycle in a tem-
perature- and humidity-controlled room (21 #C, 55% humidity)
with constant access to food and water. Timed pregnancies
were achieved by mating females and males overnight and, the
presence of vaginal plug the following morning, was considered
as embryonic day (e) 0.5. All experiments were conducted under
the regulations, licenses and local ethical review of the UK
Animals (Scientific Procedures) Act 1986.
Immunohistochemistry
Paraffin-embedded human tissue samples at 6, 8 and 13weeks
of gestation were obtained from the Human Developmental
Biology Resource (Institute of Genetic Medicine, Newcastle
and Institute of Child Health, London; www.hdbr.org).
Immunohistochemistry was performed by deparaffinization of
the sections followed by rehydration through decreasing etha-
nol dilutions. Heat-induced antigen retrieval was performed
with a microwave in 10mM sodium citrate buffer (pH 6).
Samples were left to cool down at room temperature before
incubating them for 1h in blocking buffer [1" PBS, 0.1% Triton
X-100, 5% Normal Goat Serum (Vector Laboratories)].
Endogenous hFOXA2 was detected with a primary rabbit mono-
clonal antibody against hFOXA2 (Thermo Fisher Scientific;
701698; 1:250) followed by a secondary biotinylated goat anti-
rabbit antibody (Vector Laboratories; BA-1000; 1:300). Staining
was achieved using DAB Peroxidase Substrate Kit (Vector
Laboratories; SK-4100). The colorimetric reaction was stopped
with washes in water and the sections were counterstained
using Haematoxylin (Sigma-Aldrich). Images were acquired
using a Leica microscope and figures were done with Adobe
Photoshop CS6.
In situ hybridization
Wild type mouse embryos were collected at different embryonic
stages of mouse development (e11.5, e12.5, e13.5, e15.5 and
e18.5), fixed with 4% paraformaldehyde (PFA) and washed in
PBS before proceeding with paraffin embedding. Paraffin-
embedded mouse embryos were sectioned at 7 lm thickness for
histochemical evaluation. In situ hybridization was performed
by processing the slides with a pre-hybridization treatment.
Sections were deparaffinised, rehydrated through decreasing
ethanol dilutions, fixed with 4% PFA, incubated with proteinase
K, fixed again with 4% PFA and finally incubated with 0.1M trie-
thanolamine, 0.1% acetic anhydride. The mouse Foxa2 gene
fragment (1567 bp) plasmid was kindly provided by www.hdbr.
org. The digoxigenin-labeled anti-sense probe for mFoxa2 was
generated by in vitro transcription using T3 RNA polymerase
(Roche). Hybridization with 100ng of the digoxigenin-labeled
probe was carried out overnight at 65 #C. Sections were washed
in 0.1M Tris-HCl Buffer (pH¼ 7.5, 0.15M Sodium) followed by
1h blocking at room temperature and overnight incubation
at 4 #Cwith anti-Dig antibody (Sigma-Aldrich). Detection ofmurine
Foxa2 was achieved by colorimetric reaction using 4-Nitro
blue tetrazolium chloride solution (NBT, Sigma-Aldrich) and
5-Bromo-4-chloro-3-indolyl phosphate disodium salt (BCIP,
Sigma-Aldrich). Images were acquired using a Leica microscope
and figures were done using Adobe Photoshop CS6.
Plasmids and site-direct mutagenesis
Full length cDNA of human FOXA2 (GENE Bank RefSeq NM
021784.4) was cloned in ORF mammalian expression vector
pCMV3 (pCMV3-hFOXA2, Sino Biological Inc). E. coli DH5a
competent cells were transformed with hFOXA2 (cDNA size:
1392bp). The detected mutation was introduced by site-directed
mutagenesis using QuikChange II XL Site-Directed Mutagenesis
Kit (Agilent Technologies) according to the manufacturer’s
instructions (primers used, Forward strand: 50-CAAAGCCGCCC
TACCCGTACATCTCGCTC-30. Reverse strand: 50-GAGCGAGATG
TACGGGTAGGGCGGCTTTG-30). Sanger sequencing confirmed
the point mutation.
Cell culture and luciferase assays
HEK293T cells were grown in Dulbecco’s Modified Eagle Medium
(DMEM) supplemented with 10% FBS. 2.5 x 105 cells/well were
seeded in 24-well plates. 200ng of phGT2-294-promoter-luc
reporter (kindly provided by Professor Yong-Ho Ahn) and 100ng
of Renilla SV-40 were transiently co-transfected with either i)
equal amounts (50 and 75ng) of Wt or mutant p.S169P hFOXA2
expression plasmids or ii) both Wt and mutant p.S169P hFOXA2
expression plasmid (25 or 37.5ng of each plasmid) using
Lipofectamine 2000 (Life Technologies) according to the manu-
facturer’s instructions. The total amount of DNA transfected
was kept constant at 500ng by adding pBluescript plasmid. The
cells were harvested 24h after transfection and the luciferase
activity was measured using the Dual-Luciferase Reporter
Assay System (Promega) in a BMG LABTECH Microplate reader
(Omega, Germany) according to manufacturer’s instructions.
Firefly luciferase activity was normalized to the Renilla lucifer-
ase expression from pRL-SV40 (Promega). The experiments
were independently repeated four times in triplicates and
statistical analysis was performed using one-way ANOVA.
Western blotting
1.75 " 105 cells/well were seeded in 24-well plates and tran-
siently transfected with equal amounts (200ng) of Wt or mutant
p.S169P hFOXA2 expression plasmids using Lipofectamine 2000
according to the manufacturer’s instructions. 300ng of
pBluescript plasmid were added to each transfection mix to
maintain the total amount of DNA constant at 500ng. The cells
were harvested 24h after the transfection in a lysis buffer con-
taining 50mM Tris-Base (pH 7.6), 150mM NaCl, 1% Triton X-100,
protease inhibitor cocktail (Complete Mini, EDTA-free tablets,
Roche) at a 1:6 ratio and 1% phosphatase inhibitor Cocktail3
(Sigma-Aldrich). Samples containing 20 mg of total proteins were
loaded on 12% polyacrylamide gel. The proteins were
9Human Molecular Genetics, 2017, Vol. 00, No. 00 |
Downloaded from https://academic.oup.com/hmg/article-abstract/doi/10.1093/hmg/ddx318/4093718/Novel-FOXA2-mutation-causes-Hyperinsulinism
by University of Manchester user
on 17 September 2017
transferred on a nitrocellulose membrane and nonspecific bind-
ing sites were blocked for 1h with 5% dried skimmed milk in
PBS-T (1" PBS, 0.1% Tween 20). The membrane was incubated
overnight at 4 #C with the primary antibody (rabbit anti-FOXA2;
Thermo Fisher Scientific; 701698, 1:5000 dilution in 5% dried
skimmed milk in PBS-T), followed by one hour incubation with
IRDye 800CW Donkey anti-rabbit antibody (LI-COR Biosciences;
1:5000). Anti-GAPDH (Santa Cruz; 1:5000, rabbit polyclonal) lev-
els were used to normalize the total level of protein. Blots
were analyzed using Odyssey 2.1 Imaging System (LI-COR
Biosciences). The experiments were independently repeated six
times and the statistical analysis was performed using one-way
ANOVA.
Immunofluorescence
1 " 105 cells/well were seeded in 4-well cell culture slide
(Millipore, Fisher Scientific) and transiently transfected with
200ng of Wt or mutant p.S169P hFOXA2 expression plasmids
and 300ng of pBluescript plasmid using Lipofectamine 2000
according to the manufacturer’s instructions. 24h after trans-
fection, the cells were fixed in 2% PFA in 1" PBS for 10min and
washed with 1" PBS three times. Samples were permeabilized
with 0.1% Triton X-100 in 1" PBS for 30min and blocked
with blocking buffer (5% Normal Goat Serum in 1" PBS) for
30min. The staining was performed by incubating the samples
with a-FOXA2 antibody (Thermo Fisher Scientific; 701698,
2 lg/ml) in blocking buffer for 1h, followed by a 30min incuba-
tion with goat a-rabbit Alexa fluor 594 (ThermoFisher
Scientific; 1:250) and a-PHALLOIDIN Alexa fluor 488 (Molecular
Probes; 1:1000) antibodies. The cell nuclei were stained with
DAPI (40,6-diamidino-2-phenylindole). Images were acquired
using a fluorescence microscope (Leica microsystem,
Germany) and processed using Adobe Photoshop CS6.
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Novel compound heterozygous ASXL3
mutation causing Bainbridge-ropers like
syndrome and primary IGF1 deficiency
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Abstract
Background: De novo truncating and splicing mutations in the additional sex combs-like 3 (ASXL3) gene have
been implicated in the development of Bainbridge-Ropers syndrome (BRPS) characterised by severe developmental
delay, feeding problems, short stature and characteristic facial features.
Case presentation: We describe, for the first time, a patient with severe short stature, learning difficulties, feeding
difficulties and dysmorphic features with a novel compound heterozygous mutation in ASXL3.Additionally the
patient also has primary insulin like growth factor-1 (IGF1) deficiency. The mutations occur in exon 11 and proximal
part of exon 12 and are strongly conserved at the protein level across various species. In-silico analyses using
PolyPhen-2 and SIFT predict the amino acid substitutions to be potentially deleterious to the protein function.
Detailed bioinformatics analysis show that the molecular defects caused by the two compound heterozygous
mutations synergistically impact on two points of the molecular interaction network of ASXL3.
Conclusion: We hypothesise that ASXL3 potentially has a role in transcriptional activation of IGF1 involved in
signalling pathways that regulate cell proliferation and growth, which could be contributing to short stature
encountered in these patients.
Keywords: ASXL3, Bainbridge-Ropers syndrome, IGF-1 deficiency
Background
The use of next generation sequencing in children with
undiagnosed or unidentified syndromic disorders is
becoming more popular in recent years, increasing the
diagnostic ability and discovery of novel genes and
mutations contributing to novel clinical phenotypes.
Bainbridge-Ropers syndrome (BRPS: OMIM #615485)
was described for the first time by Bainbridge and his col-
leagues in the year 2013 [1]. BRPS is caused by de-novo
truncating mutations in the additional sex combs-like 3
(ASXL3) gene giving rise to characteristic phenotypic
features such as short stature, severe intellectual deficit,
feeding difficulties, failure to thrive and cranio-facial
features. BRPS has been reported in 27 patients in the
literature so far [1–4]. The majority of the patients had
frameshift or truncating mutations in ASXL3. One patient
has been reported to have a splicing mutation in ASXL3
resulting in BRPS [3].
Bohring-Opitz syndrome (BOS: OMIM#605039) is a de-
velopmental syndrome characterised by a severe intellectual
deficit, distinct posture and cranio-facial abnormalities,
feeding problems and failure to thrive [5]. BOS is caused by
de novo truncating mutations in ASXL1, which belongs to
the same family as ASXL3 [5]. BOS and BRPS have been
found to have some overlap of their clinical phenotypes.
We describe, for the first time, a patient, with severe
short stature secondary to IGF1 (Insulin Growth Factor 1)
deficiency, developmental delay, intellectual deficit, cranio-
facial abnormalities due to a novel compound heterozygous
mutation in ASXL3 identified by whole exome sequencing.
Case presentation
The patient is a 16-year-old Caucasian British boy born
at full term following an induction of labour to non-
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consanguineous Caucasian healthy British parents. The
antenatal scans were normal and the birth weight was
4.1 kg (1.84 SDS). He was admitted to the neonatal unit
due to respiratory distress. Whilst in the neonatal unit, he
had persistent feeding difficulties and required tube feeding.
He was noted to have scaphocephaly that required surgical
fixation at 4 months of age. He also developed severe con-
stipation from 5 weeks of age requiring daily bowel wash-
outs from 18 months of age and colostomy at 3 years. He
had bilateral undescended testes requiring orchidopexy. He
has global developmental delay and complex learning diffi-
culties requiring additional support at school. He also has
been diagnosed with autism. At 7 years of age, he was re-
ferred to endocrinology for assessment of his severe short
stature (−4.11 SDS for height, mid parental height: −1.1
SDS, weight: -2.30 SDS). He has dysmorphic features in-
cluding prominent long nasal bridge and forehead, small
lower jaw, thin lips, low set cupped ears, strabismus and
down-slanting palpebral fissures (Fig. 1). He was found to
have a normal growth hormone (GH) response (peak GH
11.7 μg/L) (Normal:>6.7 μg/L) to an arginine stimulation
test. He had a bone age delay of 3 years and the IGF1 was
persistently low at 4.9 nmol/L (−3.2 SDS). TSH (Thyroid
stimulating hormone), Free T4 (thyroxine), ACTH (Adreno
corticotrophic hormone), prolactin and cortisol concentra-
tions were all within the normal range. A trial of rhGH
(recombinant human growth hormone) (50 μg/kg/day) for
a period of 1 year was ineffective in improving height
velocity (Fig. 2a). An IGF1 (insulin growth factor-1) gener-
ation test after 33 μg/kg of rhGH did not produce any re-
sponse. Subsequently, recombinant IGF1 (rIGF1) therapy
(mecasermin) was commenced at 12.5 years which resulted
in improvement of height velocity to -3SDS (Fig. 2a). He
has a normal muscle tone and normal deep tendon reflexes.
His cranial MRI scan of brain and spine were normal. The
hearing has been normal. The echocardiogram and renal
ultrasound did not identify any abnormalities. The plasma
amino acids, urine organic acids, pyruvic acid analysis were
within the normal limits. CGH microarray did not reveal
any copy number changes. Targeted sequencing of IGF1,
IGF1R and GHR did not reveal any mutations. Currently,
the patient continues to require rIGF1 therapy to support
growth. The weight gain continues to be suboptimal (Fig.
2b).
Material and methods
This study was given favourable ethical opinion by the
North West - Liverpool Central Research Ethics Commit-
tee (REC Reference: 15/NW/0758) and site study approval
was granted by the Clinical Research Business Unit at
Alder Hey Children’s NHS Foundation Trust, Liverpool,
UK. Informed and written consent was obtained from the
parents. DNA was extracted from blood samples of the
child and both the biological parents (trio). Exons were
captured using SureSelect XT Human All Exon V5 cap-
ture library and DNA sequencing was carried out using
the Illumina HiSeq4000 at 2 × 150 bp paired-end sequen-
cer. The sequence data were aligned to the reference
genome (GRCh37/hg19). The variants present in at least
1% minor allele frequency in 1000 Genomes Project,
dbSNP142, and NHLBI ESP exomes were excluded. The
predicted deleterious variants included non-synonymous
coding, splice site, frameshift, stop gain variants.
Results
Two novel heterozygous mutations in ASXL3 [NM_0
30632.1]: c.2965C > G, p.R989G inherited from the
mother and c.3078G > C, p.K1026 N, inherited from the
father were found in the patient. The mutations were sub-
sequently confirmed by Sanger sequencing (Fig. 3). The
mutations occur in exon 11 and proximal part of exon
12(Fig. 4). Multiple sequence alignment visualisation using
the UCSC Genome Browser showed that both mutated
positions are strongly conserved at the protein level across
vertebrates as diverse as lemur, bat, fish and frog, implying
that mutation could potentially affect the protein structure
or function. In silico analyses using PolyPhen-2 and SIFT
predict the amino acid substitutions to be potentially
deleterious to the protein function.
Discussion
Loss of function mutations in ASXL3 in the form of de-
novo truncating dominant mutations and splicing muta-
tion have been implicated in BRPS. Here we report for the
first time, a compound heterozygous ASXL3 mutation in a
patient with BRPS-like features and associated with pri-
mary IGF1 deficiency. Pathogenic mutations in ASXL3
have been reported to occur predominantly in exon 11
and proximal part of exon 12. All the described mutations
retain the ASXN and ASXH domains. The compound
heterozygous mutations in our patient also lie on exon 11
and proximal exon 12, retaining the ASXN and ASXH do-
mains similar to previously described mutations (Fig. 4).
Fig. 1 Dysmorphic features: prominent long nasal bridge and
forehead, small lower jaw, thin lips, strabismus, down slanting
palpebral fissures and low set cupped ears
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Fig. 2 a Height and its response to GH and IGF1 treatment. b Weight
Fig. 3 Electropherograms showing the compound heterozygous mutations
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Both these mutations occur on the conserved ASXM1
domain in ASXL3 (Fig. 4). Both the variants are extremely
rare and have a population frequency < 0.01, as indicated
from the ExAC browser. The synergistic effect of both of
these rare mutations potentially contributes to the loss of
function of the protein contributing to the BRPS like
phenotype. Our patient has multiple dysmorphic features
that overlap with those described in previous reported
cases of BRPS such as short stature, failure to thrive, feed-
ing difficulties, cranio-facial features, developmental delay
and learning difficulties (Table 1).
ASXL3 belongs to the gene family of ASXL genes, the
mammalian homologues of Drosophila Asx. ASXL includes
three orthologues: ASXL1, ASXL2 and ASXL3 that encode
the Putative Polycomb group (PcG) protein that has a role
in regulating the homeotic genes (Hox) [6]. PcG proteins
can act either as transcriptional repressors or activators of
Hox genes [6]. The genes in the ASXL family share a com-
mon domain architecture consisting of ASXN, ASXH,
ASXM1, ASXM2 domains and a PHD finger, and act by
forming complexes with other proteins via methylation of
histones [4, 6, 7]. ASXL3 has been implicated in the deubi-
quitination of histone H2A lysine 119(H2AK119Ub1), a
component of the polycomb repressive deubiquitination
(PR-DUB) complex [4]. The formation of PR-DUB complex
is critical for normal function. ASXL3 interacts with BAP1,
a ubiquitin terminal hydroxylase and removes the mono-
ubiquitin (Ub1) from the H2AK119Ub1 [8]. Patients with
BRPS have been found to have a significant increase in the
H2AK119Ub1 in their fibroblasts because of the impaired
deubiquitination [4]. ASXL3 has a similar expression pat-
tern in human tissues as ASXL1 but at a relatively lesser
levels, which may explain the overlap of some phenotypic
features seen in BRPS and BOS [9]. Within the human
brain, ASXL3 expression has been found within the white
matter, insula, cingulate gyrus and amygdala [10]. The
spinal cord, kidney, bone marrow and liver also express
ASXL3, but at a lower level when compared to ASXL1 [9].
Detailed bioinformatics analysis suggests a possible mo-
lecular mechanism by which the first of the mutations
R989G would lead to a functional defect. A scan against
the ELM(Eukaryotic Linear Motif) database shows a stretch
of amino-acid residues from the position 989 to 997 within
the wild-type ASXL3 that matches with an interaction
motif (LIG_14–3-3_CanoR_1; Accession ELME000417)
that describes canonical phosphopeptide binding motif of
14–3-3 group of proteins. 14–3-3 proteins are important
cell regulators [11], best known for their role in cell cycle
control. The mutated Arginine at position 989 together
with a phosphorylated Serine residue, 3–5 residues down-
stream are the main determinants of interaction with 14–3-
3 proteins. These proteins are also characterised as histone
modification readers [12]. This links suggestively to the
recently determined role of ASXL3 in histone deubiquitina-
tion [4]. According to this hypothesis, mutation of R989 to
glycine would prevent the interaction of ASXL3 with an as-
yet unidentified 14–3-3 protein, thereby damaging function
through impairing its ability to scaffold epigenetic protein
complexes [6]. Although the molecular mechanism of the
second mutation K1026 N, is unclear it is possible that this
mutation affects phosphorylation of ASXL3 through its
location within recognition motifs for kinases (PIKK group,
motif from 1024 to 1030 or GSK3, motif from 1024 to
1031); The molecular defects caused by the two mutations
would specify the disorder additively or synergistically by
simultaneously impacting on two points of the molecular
interaction network of ASXL3 contributing to its loss of
function.
The association of primary IGF1 deficiency in BRPS has
not been described before. IGF-1 is a 70-amino acid pep-
tide hormone and growth factor that is structurally hom-
ologous to proinsulin [13]. In normal individuals, IGF-1
circulates as part of a ternary complex with a molecular
weight of 150 kDa. The complex consists of IGF-1, an
acid-labile subunit (ALS), and a protein that binds IGF-1
(IGFBP-3). Primary IGF1 deficiency is defined as basal
Fig. 4 ASXL3 gene with domains. 1–12 represents the exon numbers. Some of the previously reported mutations (frameshift and truncating) and
splice site mutations have been shown. Compound heterozygous mutations in our patient have been highlighted in bold
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IGF-1 and height of ≤ -3 SDS with normal or elevated
levels of GH [13]. The primary action of IGF1 is mediated
by binding to its specific receptor, the insulin-like growth
factor 1 receptor (IGF1R), which is present in many
tissues. IGF1R is a receptor tyrosine kinase and binding of
IGF1 to IGF1R initiates intracellular signalling. IGF-1 is
Table 1 Phenotypic comparison between our patient and other reported patients with BRPS
Phenotype Our Patient Bainbridge et al. [1].
4 patients
Dinwiddie et al. [2].
1 patient
Srivastava et al. [4].
3 patients
Hori et al. [3].
1 patient
Balasubramanian
et al. [17]. 12 patients
Kuechler et al.
[18]. 6 patients
Clinical
Feeding
problems
+ + + + + 9/12 6/6
Failure to thrive + + + + + 3/6
Short stature + + ND + 2/12 2/6
IUGR − 3/4 + 2/3 + −
Craniofacial
Trigonocephaly − 1/4 + 1/3 + ND ND
Microcephaly − 2/4 + − + + 1/6
Scaphocephaly + − − − − + ND
Palate High arched 1/4 ND ND ND High arched (9/12) High arched
(5/6)
Prominent
forehead
+ 2/4 ND 1/3 ND + 5/6
Prominent eyes − − + − ND ND ND
Palpebral
fissures
downslanting upslanting downslanting
(2/3)
− downslanting-10/12
Upslanting-2/12
downslanting
Nasal bridge long − depressed Broad (1/3) depressed long, prominent 6/6 (prominent
columella)
Low set ears + 1/4 NA 1/3 − + ND
Posteriorly
rotated ears
Cupped ears 2/4 + + − + ND
Anteverted
nares
− + + 1/3 − ND 5/6
Small chin + ND ND 2/3 + + ND
Ophthalmic
Strabismus + ND ND 1/3 + 7/12 5/6
Astgmatism myopia ND Myopia (1/3) Hyperopia (1/3) myopia ND
Neurological
Developmental
delay
+ + + + + 12/12 6/6
Intellectual
deficit
+ + + 2/3 + 12/12 5/6
Seizures − − + 1/3 3/12 2/6
Autism + NA NA NA + 9/12 not formally
diagnosed
Other Features
large
fontanelle
+ 1/4 ND ND ND ND ND
Undescended
testes
+ 1/4 ND ND ND ND ND
Chronic
constipation
+ ND ND 1/3 ND ND ND
ND: not described. +: present. -: absent
Giri et al. International Journal of Pediatric Endocrinology  (2017) 2017:8 Page 5 of 6
one of the most potent natural activators of the Akt sig-
nalling pathway, which stimulates cellular growth and pro-
liferation [14].
Transcriptome analysis of ASXL3 fibroblasts from patients
with BRPS examining the differentially expressed genes
(DEGs) has shown that the genes regulating the cellular pro-
liferation are downregulated [4]. IGF1 plays a vital role in ac-
tivating the Akt signalling pathway, a potent stimulator for
cell proliferation and growth [15]. We therefore hypothesise
that ASXL3 potentially has a role in transcriptional activa-
tion of IGF1 involved in this pathway potentially via epigen-
etic mechanisms [16], which could be contributing to short
stature encountered in these patients.
Conclusions
The compound heterozygous mutations potentially contrib-
ute to the loss of function in ASXL3, causing a phenotype
similar to BRPS. Although with our current knowledge, the
molecular interaction between ASXL3 and IGF1 is unclear,
it may important to look for IGF1 deficiency in the patients
with ASXL3mutation.
Consent
Written informed consent was obtained from the patient’s
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available for review by the Editor-in-Chief of this journal.
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